CA2517386A1 - 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis - Google Patents
4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis Download PDFInfo
- Publication number
- CA2517386A1 CA2517386A1 CA002517386A CA2517386A CA2517386A1 CA 2517386 A1 CA2517386 A1 CA 2517386A1 CA 002517386 A CA002517386 A CA 002517386A CA 2517386 A CA2517386 A CA 2517386A CA 2517386 A1 CA2517386 A1 CA 2517386A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- methyl
- ylmethoxy
- cyclohexyloxy
- oxazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 178
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 6
- 239000002253 acid Substances 0.000 title abstract description 17
- 201000001320 Atherosclerosis Diseases 0.000 title description 6
- LWMPJXQIKZEVCH-UHFFFAOYSA-N 4-[(3-butoxycyclohexyl)oxymethyl]-2-phenyl-1,3-oxazole Chemical compound C1(=CC=CC=C1)C=1OC=C(N=1)COC1CC(CCC1)OCCCC LWMPJXQIKZEVCH-UHFFFAOYSA-N 0.000 title 1
- 101150014691 PPARA gene Proteins 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 77
- -1 (C1-C3)-alkyl-phenyl Chemical group 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000003178 anti-diabetic effect Effects 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 230000004129 fatty acid metabolism Effects 0.000 claims description 3
- 230000002349 favourable effect Effects 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229930192474 thiophene Chemical group 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 29
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 13
- 102000004877 Insulin Human genes 0.000 abstract description 8
- 108090001061 Insulin Proteins 0.000 abstract description 8
- 229940125396 insulin Drugs 0.000 abstract description 6
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 4
- 229930195729 fatty acid Natural products 0.000 abstract description 4
- 239000000194 fatty acid Substances 0.000 abstract description 4
- 150000004665 fatty acids Chemical class 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 230
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 153
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- 235000019260 propionic acid Nutrition 0.000 description 118
- 238000006243 chemical reaction Methods 0.000 description 97
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 59
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 37
- 239000002904 solvent Substances 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 32
- 238000003786 synthesis reaction Methods 0.000 description 32
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 31
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 229910000104 sodium hydride Inorganic materials 0.000 description 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 26
- 239000000556 agonist Substances 0.000 description 26
- 239000004480 active ingredient Substances 0.000 description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 24
- 102000023984 PPAR alpha Human genes 0.000 description 23
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 23
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 23
- 230000008569 process Effects 0.000 description 23
- BNCNAQNTIYCMGB-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-5-phenyl-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=C(C=2C=CC=CC=2)O1 BNCNAQNTIYCMGB-UHFFFAOYSA-N 0.000 description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 238000007792 addition Methods 0.000 description 20
- 239000012230 colorless oil Substances 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 108060001084 Luciferase Proteins 0.000 description 17
- FSEUPUDHEBLWJY-HWKANZROSA-N diacetylmonoxime Chemical compound CC(=O)C(\C)=N\O FSEUPUDHEBLWJY-HWKANZROSA-N 0.000 description 17
- 108010016731 PPAR gamma Proteins 0.000 description 16
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 15
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 15
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 15
- 239000012312 sodium hydride Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000004146 Propane-1,2-diol Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 229960004063 propylene glycol Drugs 0.000 description 14
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 235000013772 propylene glycol Nutrition 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- XJHCXCQVJFPJIK-UHFFFAOYSA-M cesium fluoride Substances [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 10
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 102100039556 Galectin-4 Human genes 0.000 description 9
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000012285 osmium tetroxide Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 239000012973 diazabicyclooctane Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- XWACKBMPGJMLFJ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(3-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 XWACKBMPGJMLFJ-UHFFFAOYSA-N 0.000 description 5
- AONKVWHDUVHQSZ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(4-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 AONKVWHDUVHQSZ-UHFFFAOYSA-N 0.000 description 5
- LAKXJTRDJPBSAS-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 LAKXJTRDJPBSAS-UHFFFAOYSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229940100389 Sulfonylurea Drugs 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 108010084455 Zeocin Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 4
- NTMNMWBNRDKKEE-UHFFFAOYSA-N 2-(2,4-dimethylphenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC(C)=CC=2)C)=N1 NTMNMWBNRDKKEE-UHFFFAOYSA-N 0.000 description 4
- ZVJBPHMCBRHVEV-UHFFFAOYSA-N 2-hydroxyiminopentan-3-one Chemical compound CCC(=O)C(C)=NO ZVJBPHMCBRHVEV-UHFFFAOYSA-N 0.000 description 4
- JEMQSYWUSRUZQU-UHFFFAOYSA-N 3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexan-1-ol Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(O)C1 JEMQSYWUSRUZQU-UHFFFAOYSA-N 0.000 description 4
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 4
- WEWPHAAWLKAJKC-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-5-phenyl-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=C(C=2C=CC=CC=2)O1 WEWPHAAWLKAJKC-UHFFFAOYSA-N 0.000 description 4
- DQFNFCZJCTWYGP-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazole Chemical compound ICC1=C(C(C)C)OC(C=2C=CC(C)=CC=2)=N1 DQFNFCZJCTWYGP-UHFFFAOYSA-N 0.000 description 4
- QGKGLJHQIRRWES-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CI)=C(C)O1 QGKGLJHQIRRWES-UHFFFAOYSA-N 0.000 description 4
- ACMFBGDVEITOFZ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 ACMFBGDVEITOFZ-UHFFFAOYSA-N 0.000 description 4
- WZOMSQRBEXCMRP-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(3-methoxyphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=C(OC)C=CC=2)=N1 WZOMSQRBEXCMRP-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- DGHNORVAQRVHDN-UHFFFAOYSA-N ethyl 2-amino-4-methyl-3-oxopentanoate Chemical compound CCOC(=O)C(N)C(=O)C(C)C DGHNORVAQRVHDN-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- FDBGURXQLIASAR-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-methyl-4-[(3-prop-2-enoxycyclohexyl)oxymethyl]-1,3-oxazole Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(OCC=C)C1 FDBGURXQLIASAR-UHFFFAOYSA-N 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 3
- XJKVVHCZKAADFP-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-methyl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(C)=C(CI)N=2)=C1 XJKVVHCZKAADFP-UHFFFAOYSA-N 0.000 description 3
- OJSUKGKXAPQITL-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 OJSUKGKXAPQITL-UHFFFAOYSA-N 0.000 description 3
- SLYIGTWFTNDINH-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 SLYIGTWFTNDINH-UHFFFAOYSA-N 0.000 description 3
- XFLMZIVSUSURBJ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-naphthalen-2-yl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C3C=CC=CC3=CC=2)=N1 XFLMZIVSUSURBJ-UHFFFAOYSA-N 0.000 description 3
- HSJYZRUAFNGACR-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 HSJYZRUAFNGACR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000001126 Keratosis Diseases 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 241000713333 Mouse mammary tumor virus Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 229910003849 O-Si Inorganic materials 0.000 description 3
- 229910003872 O—Si Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 241000254064 Photinus pyralis Species 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 229910018557 Si O Inorganic materials 0.000 description 3
- HQTZHHDTBSHTDM-CVEARBPZSA-N [(1s,3r)-3-prop-2-enoxycyclohexyl]oxymethylbenzene Chemical compound C1[C@H](OCC=C)CCC[C@@H]1OCC1=CC=CC=C1 HQTZHHDTBSHTDM-CVEARBPZSA-N 0.000 description 3
- QJHAWRGKDNXWIY-UHFFFAOYSA-N [2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazol-4-yl]methanol Chemical compound OCC1=C(C(C)C)OC(C=2C=CC(C)=CC=2)=N1 QJHAWRGKDNXWIY-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 3
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010931 ester hydrolysis Methods 0.000 description 3
- XWKOSAYDZJXYQO-UHFFFAOYSA-N ethyl 2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazole-4-carboxylate Chemical compound O1C(C(C)C)=C(C(=O)OCC)N=C1C1=CC=C(C)C=C1 XWKOSAYDZJXYQO-UHFFFAOYSA-N 0.000 description 3
- SMAOVIHJZYGLNT-UHFFFAOYSA-N ethyl 2-hydroxyimino-4-methyl-3-oxopentanoate Chemical compound CCOC(=O)C(=NO)C(=O)C(C)C SMAOVIHJZYGLNT-UHFFFAOYSA-N 0.000 description 3
- OCJKUQIPRNZDTK-UHFFFAOYSA-N ethyl 4,4,4-trifluoro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)C(F)(F)F OCJKUQIPRNZDTK-UHFFFAOYSA-N 0.000 description 3
- HDTDHYKMFULBIB-UHFFFAOYSA-N ethyl 4-methyl-2-[(4-methylbenzoyl)amino]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)C(C)C)NC(=O)C1=CC=C(C)C=C1 HDTDHYKMFULBIB-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 3
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- YPINLRNGSGGJJT-JXMROGBWSA-N (2e)-2-hydroxyimino-1-phenylpropan-1-one Chemical compound O\N=C(/C)C(=O)C1=CC=CC=C1 YPINLRNGSGGJJT-JXMROGBWSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- KQDQZEZWWRPNQH-UHFFFAOYSA-N 1,3-diazabicyclo[2.2.2]octane Chemical compound C1CC2CCN1CN2 KQDQZEZWWRPNQH-UHFFFAOYSA-N 0.000 description 2
- AKMNUCBQGHFICM-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea Chemical compound C1=CN=C2C(NC(=O)NC3=CC=C4N=C(OC4=C3)C)=CC=NC2=C1 AKMNUCBQGHFICM-UHFFFAOYSA-N 0.000 description 2
- PFFCLJDVINXVNR-RBUKOAKNSA-N 1-[[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]cyclopropane-1-carboxylic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC1(C(O)=O)CC1 PFFCLJDVINXVNR-RBUKOAKNSA-N 0.000 description 2
- DEFNUDNHTUZJAL-UHFFFAOYSA-N 1-bromo-2-methylprop-1-ene Chemical compound CC(C)=CBr DEFNUDNHTUZJAL-UHFFFAOYSA-N 0.000 description 2
- GIYZJSLQVOWCAR-UHFFFAOYSA-N 1-cyclohexyl-2-hydroxyiminopropan-1-one Chemical compound ON=C(C)C(=O)C1CCCCC1 GIYZJSLQVOWCAR-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 description 2
- ARNCUSIEBKDVTJ-UHFFFAOYSA-N 2-(2,6-dimethylphenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC=CC=2C)C)=N1 ARNCUSIEBKDVTJ-UHFFFAOYSA-N 0.000 description 2
- NGBNUEIXIRLOQR-UHFFFAOYSA-N 2-(2,6-dimethylphenyl)-5-ethyl-4-(iodomethyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C(=CC=CC=2C)C)=N1 NGBNUEIXIRLOQR-UHFFFAOYSA-N 0.000 description 2
- UEJHHKGNCWUBHD-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 UEJHHKGNCWUBHD-UHFFFAOYSA-N 0.000 description 2
- ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 2
- VNLHFRIFAMCIHY-UHFFFAOYSA-N 2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]acetaldehyde Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(CC=O)C1 VNLHFRIFAMCIHY-UHFFFAOYSA-N 0.000 description 2
- MFDBEIHCSIVRCN-UXHICEINSA-N 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybut-2-enoic acid Chemical compound C1[C@H](OCC=C(CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 MFDBEIHCSIVRCN-UXHICEINSA-N 0.000 description 2
- CMINROMQYDFVKZ-OHAXFNJZSA-N 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybutanoic acid Chemical compound C1[C@H](OCCC(CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 CMINROMQYDFVKZ-OHAXFNJZSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VCTKYTBWZTZPHF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-2-phenyl-1,3-oxazole Chemical compound ClCC1=C(C)OC(C=2C=CC=CC=2)=N1 VCTKYTBWZTZPHF-UHFFFAOYSA-N 0.000 description 2
- DOSVJMCCPCFNCO-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC=C(CI)N=2)=C1 DOSVJMCCPCFNCO-UHFFFAOYSA-N 0.000 description 2
- VBEYNUQRWAKFMV-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=CO1 VBEYNUQRWAKFMV-UHFFFAOYSA-N 0.000 description 2
- OHVWIGRETNBHOI-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CI)=CO1 OHVWIGRETNBHOI-UHFFFAOYSA-N 0.000 description 2
- SREYTZRPAWGRQQ-UHFFFAOYSA-N 4-(iodomethyl)-2-[3-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound FC(F)(F)C1=CC=CC(C=2OC=C(CI)N=2)=C1 SREYTZRPAWGRQQ-UHFFFAOYSA-N 0.000 description 2
- RIPPLGSFZLWCCG-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 RIPPLGSFZLWCCG-UHFFFAOYSA-N 0.000 description 2
- MLRCAXSQHSXLRA-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-phenyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC=CC=2)=N1 MLRCAXSQHSXLRA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- NIVGNNIVMXYXFG-UHFFFAOYSA-N 4-methyl-2-(4-methylphenyl)-3-oxido-5-phenyl-1,3-oxazol-3-ium Chemical compound [O-][N+]=1C(C)=C(C=2C=CC=CC=2)OC=1C1=CC=C(C)C=C1 NIVGNNIVMXYXFG-UHFFFAOYSA-N 0.000 description 2
- KBIHBGYYYFRDEA-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(4-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=CC(C)=CC=2)=N1 KBIHBGYYYFRDEA-UHFFFAOYSA-N 0.000 description 2
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000003810 Jones reagent Substances 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010015181 PPAR delta Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 102000005630 Urocortins Human genes 0.000 description 2
- 108010059705 Urocortins Proteins 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000001351 alkyl iodides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- RLMGYIOTPQVQJR-UHFFFAOYSA-N cyclohexane-1,3-diol Chemical compound OC1CCCC(O)C1 RLMGYIOTPQVQJR-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- MTCMFVTVXAOHNQ-UHFFFAOYSA-N ethyl 2-(bromomethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CBr MTCMFVTVXAOHNQ-UHFFFAOYSA-N 0.000 description 2
- MVHIIPHBVXIUCL-YADHBBJMSA-N ethyl 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybut-2-enoate Chemical compound C1[C@H](OCC=C(CC)C(=O)OCC)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 MVHIIPHBVXIUCL-YADHBBJMSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 150000003385 sodium Chemical class 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 description 2
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000000777 urocortin Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- OMXRTIUYSHDUTH-UHFFFAOYSA-N 1-(3-ethyl-1-benzofuran-7-yl)piperazine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2C(CC)=COC2=C1N1CCNCC1 OMXRTIUYSHDUTH-UHFFFAOYSA-N 0.000 description 1
- TXVVVEUSVBLDED-UHFFFAOYSA-N 1-(bromomethyl)-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1CBr TXVVVEUSVBLDED-UHFFFAOYSA-N 0.000 description 1
- MYYYZNVAUZVXBO-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CBr)=C1 MYYYZNVAUZVXBO-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- QZNQSIHCDAGZIA-UHFFFAOYSA-N 1-(bromomethyl)-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(CBr)C=C1 QZNQSIHCDAGZIA-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- MHCKTCPQIUFRLF-UHFFFAOYSA-N 1-azaniumyl-1,2,3,4-tetrahydronaphthalene-2-carboxylate Chemical compound C1=CC=C2C(N)C(C(O)=O)CCC2=C1 MHCKTCPQIUFRLF-UHFFFAOYSA-N 0.000 description 1
- NNMBNYHMJRJUBC-UHFFFAOYSA-N 1-bromo-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(Br)=C1 NNMBNYHMJRJUBC-UHFFFAOYSA-N 0.000 description 1
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 1
- VDHGRVFJBGRHMD-UHFFFAOYSA-N 1-bromopent-2-yne Chemical compound CCC#CCBr VDHGRVFJBGRHMD-UHFFFAOYSA-N 0.000 description 1
- DYQIYXDSKUUZRI-UHFFFAOYSA-N 1-fluoro-4-iodo-2-methylbenzene Chemical compound CC1=CC(I)=CC=C1F DYQIYXDSKUUZRI-UHFFFAOYSA-N 0.000 description 1
- GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 1
- GISVICWQYMUPJF-UHFFFAOYSA-N 2,4-Dimethylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(C)=C1 GISVICWQYMUPJF-UHFFFAOYSA-N 0.000 description 1
- DHJPEGRMZQBUMM-UHFFFAOYSA-N 2-(bromomethyl)-1,4-dimethylbenzene Chemical compound CC1=CC=C(C)C(CBr)=C1 DHJPEGRMZQBUMM-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- CKKXBBNLSRIAOY-VEPNZUSMSA-N 2-[(2,5-dimethylphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC(C)=CC=C1C CKKXBBNLSRIAOY-VEPNZUSMSA-N 0.000 description 1
- WAYZWXLEBGEFKA-ZDCXKQOISA-N 2-[(4-tert-butylphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(C(C)(C)C)C=C1 WAYZWXLEBGEFKA-ZDCXKQOISA-N 0.000 description 1
- DKDSZOOZDBVUAH-UHFFFAOYSA-N 2-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxyethyl]pentanoic acid Chemical compound C1C(OCCC(CCC)C(O)=O)CCCC1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 DKDSZOOZDBVUAH-UHFFFAOYSA-N 0.000 description 1
- FAUGURYODQJLOV-UHFFFAOYSA-N 2-[4-(iodomethyl)-5-methylnaphthalen-2-yl]-1,3-oxazole Chemical compound C=1C(CI)=C2C(C)=CC=CC2=CC=1C1=NC=CO1 FAUGURYODQJLOV-UHFFFAOYSA-N 0.000 description 1
- NROPYOPQAVMCJC-MOPGFXCFSA-N 2-[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]prop-2-enoic acid Chemical compound CC=1OC(C=2C=C(C)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(=C)C(O)=O)C1 NROPYOPQAVMCJC-MOPGFXCFSA-N 0.000 description 1
- MQTKXCOGYOYAMW-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)thiophene Chemical compound ClCC1=CC=C(Cl)S1 MQTKXCOGYOYAMW-UHFFFAOYSA-N 0.000 description 1
- IBIMXAAZWOQNDX-UHFFFAOYSA-N 2-ethyl-3-(iodomethyl)-5-(4-methylphenyl)-1h-pyrrole Chemical compound ICC1=C(CC)NC(C=2C=CC(C)=CC=2)=C1 IBIMXAAZWOQNDX-UHFFFAOYSA-N 0.000 description 1
- YCOXJFAUNLRWPU-UHFFFAOYSA-N 2-methyl-n,n-dipropyl-9-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indol-4-amine Chemical compound C12=CC=CC=C2C=2C(N(CCC)CCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C YCOXJFAUNLRWPU-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- LCRCBXLHWTVPEQ-UHFFFAOYSA-N 2-phenylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CC=C1 LCRCBXLHWTVPEQ-UHFFFAOYSA-N 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- FQEVHRCPXFKJHF-UHFFFAOYSA-N 3-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=CC(C=O)=C1 FQEVHRCPXFKJHF-UHFFFAOYSA-N 0.000 description 1
- NMTUHPSKJJYGML-UHFFFAOYSA-N 3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1 NMTUHPSKJJYGML-UHFFFAOYSA-N 0.000 description 1
- YTAGWZUNCHKJNH-KTVLMBSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 YTAGWZUNCHKJNH-KTVLMBSMSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RUROFEVDCUGKHD-UHFFFAOYSA-N 3-bromoprop-1-enylbenzene Chemical compound BrCC=CC1=CC=CC=C1 RUROFEVDCUGKHD-UHFFFAOYSA-N 0.000 description 1
- TWJQZBXURHWBPV-UHFFFAOYSA-N 3-cyclohexyl-1-(4,4-dimethyl-6,7-dihydro-1h-imidazo[4,5-c]pyridin-5-yl)propan-1-one;oxalic acid Chemical compound OC(=O)C(O)=O.C1CC=2NC=NC=2C(C)(C)N1C(=O)CCC1CCCCC1 TWJQZBXURHWBPV-UHFFFAOYSA-N 0.000 description 1
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
- MVUPNMYSPWFTJE-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-(trifluoromethyl)-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C(F)(F)F)=C1 MVUPNMYSPWFTJE-UHFFFAOYSA-N 0.000 description 1
- OKHGLMQXLUEZMI-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-phenyl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C=2C=CC=CC=2)=C1 OKHGLMQXLUEZMI-UHFFFAOYSA-N 0.000 description 1
- UUOZIINDOMFDBE-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-propan-2-yl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C(C)C)=C1 UUOZIINDOMFDBE-UHFFFAOYSA-N 0.000 description 1
- CUPROPFTDOKVRM-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methoxyphenyl)-5-methyl-1,3-oxazole Chemical compound C1=CC(OC)=CC=C1C1=NC(CI)=C(C)O1 CUPROPFTDOKVRM-UHFFFAOYSA-N 0.000 description 1
- OSXBFDMJBHFWDS-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-5-(trifluoromethyl)-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=C(C(F)(F)F)O1 OSXBFDMJBHFWDS-UHFFFAOYSA-N 0.000 description 1
- XHVLHNBJYTXNHA-UHFFFAOYSA-N 4-(iodomethyl)-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound FC(F)(F)C1=CC=CC=C1C1=NC(CI)=CO1 XHVLHNBJYTXNHA-UHFFFAOYSA-N 0.000 description 1
- MRSKWSKTUZNPPK-UHFFFAOYSA-N 4-(iodomethyl)-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=NC(CI)=CO1 MRSKWSKTUZNPPK-UHFFFAOYSA-N 0.000 description 1
- NYFYEHIGJXMWHU-UHFFFAOYSA-N 4-(iodomethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC(CI)=CO1 NYFYEHIGJXMWHU-UHFFFAOYSA-N 0.000 description 1
- CMZCJQHKTKCTFG-UHFFFAOYSA-N 4-(iodomethyl)-2-naphthalen-2-yl-1,3-oxazole Chemical compound ICC1=COC(C=2C=C3C=CC=CC3=CC=2)=N1 CMZCJQHKTKCTFG-UHFFFAOYSA-N 0.000 description 1
- SOINZDZUVFPFLV-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(5-methylfuran-2-yl)-1,3-oxazole Chemical compound O1C(C)=CC=C1C1=NC(CI)=C(C)O1 SOINZDZUVFPFLV-UHFFFAOYSA-N 0.000 description 1
- URSQQDZMMODUMK-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-thiophen-2-yl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2SC=CC=2)=N1 URSQQDZMMODUMK-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- MSZHFMAFAHIHRC-UHFFFAOYSA-N 4-[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxybutanoic acid Chemical class C1C(OCCCC(=O)O)CCCC1OCC1=COC(C=2C=CC=CC=2)=N1 MSZHFMAFAHIHRC-UHFFFAOYSA-N 0.000 description 1
- DXRXMOWGZRJUQO-UHFFFAOYSA-N 4-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methylbutanoic acid Chemical compound C1C(OCCC(C)C(O)=O)CCCC1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 DXRXMOWGZRJUQO-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- HNYDEEDKJQQHRT-UHFFFAOYSA-N 5-cyclohexyl-4-(iodomethyl)-2-(3-methoxyphenyl)-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C2CCCCC2)=C1 HNYDEEDKJQQHRT-UHFFFAOYSA-N 0.000 description 1
- HFKMMKOEOOHUFA-UHFFFAOYSA-N 5-cyclohexyl-4-(iodomethyl)-2-(4-methylphenyl)-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=C(C2CCCCC2)O1 HFKMMKOEOOHUFA-UHFFFAOYSA-N 0.000 description 1
- PBFCTVPSJFFZSU-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=CC(=CC=2)C(C)C)=N1 PBFCTVPSJFFZSU-UHFFFAOYSA-N 0.000 description 1
- QZRROGXWZYTYFV-UHFFFAOYSA-N 5-methylcyclohexa-2,4-dien-1-one Chemical compound CC1=CC=CC(=O)C1 QZRROGXWZYTYFV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 206010008528 Chillblains Diseases 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 241001151024 Giulia Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 229940122014 Lyase inhibitor Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124757 MC-4 agonist Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- UULIGRNKXHCLQN-UHFFFAOYSA-N N-[[4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- DQJWAUDLUKISHH-NEPJUHHUSA-N [(1s,3r)-3-hydroxycyclohexyl] benzoate Chemical compound C1[C@H](O)CCC[C@@H]1OC(=O)C1=CC=CC=C1 DQJWAUDLUKISHH-NEPJUHHUSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 229940112930 apidra Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- BMWITAUNXBHIPO-OZZZDHQUSA-N benzenesulfonic acid;(2s,4s)-4-fluoro-1-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OS(=O)(=O)C1=CC=CC=C1.OCC(C)(C)NCC(=O)N1C[C@@H](F)C[C@H]1C#N BMWITAUNXBHIPO-OZZZDHQUSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- GYUCVQSNZFRDRL-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylbutanoate Chemical compound CCOC(=O)C(CC)P(=O)(OCC)OCC GYUCVQSNZFRDRL-UHFFFAOYSA-N 0.000 description 1
- BUPVIVDUPRDDFI-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpentanoate Chemical compound CCOC(=O)C(CCC)P(=O)(OCC)OCC BUPVIVDUPRDDFI-UHFFFAOYSA-N 0.000 description 1
- BVSRWCMAJISCTD-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpropanoate Chemical compound CCOC(=O)C(C)P(=O)(OCC)OCC BVSRWCMAJISCTD-UHFFFAOYSA-N 0.000 description 1
- XCLDSQRVMMXWMS-UHFFFAOYSA-N ethyl 4-methyl-3-oxopentanoate Chemical compound CCOC(=O)CC(=O)C(C)C XCLDSQRVMMXWMS-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000054223 human PPARA Human genes 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229950005809 implitapide Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- YDCVQGAUCOROHB-UHFFFAOYSA-N oxadiazolidine-4,5-dione Chemical class O=C1NNOC1=O YDCVQGAUCOROHB-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 1
- 229950005482 pamaqueside Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- JIWDQJYCCQFDAF-UHFFFAOYSA-N potassium;2-methylpropan-2-olate;oxolane Chemical compound [K+].CC(C)(C)[O-].C1CCOC1 JIWDQJYCCQFDAF-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 102220106802 rs139353014 Human genes 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 108091008012 small dense LDL Proteins 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZAOPBCHLHBOUPR-UHFFFAOYSA-N tert-butyl 1-[2-[di(propan-2-yl)amino]ethylcarbamoyl]-6-phenylmethoxy-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C2C(C(=O)NCCN(C(C)C)C(C)C)N(C(=O)OC(C)(C)C)CCC2=CC=1OCC1=CC=CC=C1 ZAOPBCHLHBOUPR-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 229950004437 tiqueside Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention relates to aryl-cycloalkyl substituted alkane acid derivatives and the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to compounds of formula (I), wherein the radicals have the above-mentioned meanings, in addition to the physiologically compatible salts thereof and a method for the production thereof. Said compounds can be used for example, in the treatment and/or prevention of disorders in the metabolism of fatty acids and disorders related to the use of glucose, in addition to insulin-related disorders.
Description
4-(3-(2-PHENYLOXAZOL-4-YLMETHOXY)CYCLOHEXYLOXY)-BUTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS
ATHEROSCLEROSiS
Description Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives.
Compounds of a similar structure have already been described in the prior art for the treatment of hyperlipidemia and diabetes (WO 2000164876).
It was an object of the invention to provide compounds which permit a therapeutically exploitable modulation of the lipid and/or carbohydrate metabolism and are thus suitable for the prevention andlor treatment of disorders such as type 2 diabetes and atherosclerosis and their multifarious sequelae.
Surprisingly, we have found a number of compounds which modulate the activity of PPAR receptors. The compounds are particularly suitable for activating PPARalpha and PPARgamma, where the extent of the relative activation may vary, depending on the compounds.
The invention thus relates to compounds of the formula i R1 W ~ R3 R2~~ ~ ~ Ring A R4 R6 ( )o N Y I 0 Y' zy ~n ~R8 in which:
ATHEROSCLEROSiS
Description Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives.
Compounds of a similar structure have already been described in the prior art for the treatment of hyperlipidemia and diabetes (WO 2000164876).
It was an object of the invention to provide compounds which permit a therapeutically exploitable modulation of the lipid and/or carbohydrate metabolism and are thus suitable for the prevention andlor treatment of disorders such as type 2 diabetes and atherosclerosis and their multifarious sequelae.
Surprisingly, we have found a number of compounds which modulate the activity of PPAR receptors. The compounds are particularly suitable for activating PPARalpha and PPARgamma, where the extent of the relative activation may vary, depending on the compounds.
The invention thus relates to compounds of the formula i R1 W ~ R3 R2~~ ~ ~ Ring A R4 R6 ( )o N Y I 0 Y' zy ~n ~R8 in which:
Ring A is (C3-C8)cycloalkanediyl or (C3-C8)cycloalkenediyl, where in the cycloalkanediyl or cycloalkenediyl rings one or more carbon atoms may be replaced by oxygen atoms;
R1, R2 independently of one another are H, F, CI, Br, CF3, OCF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, SCF3, SFS, OCF2-CHF2, (C6-C10)-aryl, (C6-C10)-aryloxy, OH, N02; or R1 and R2 together with the phenyl, pyridine, 1 H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C6-C10)-aryl, (C5-C11)-heteroaryl;
R3 is H, (C1-C6)-alkyl, (C3-C8)cycloalkyl, (C1-C3)-alkyl-(C3-C8)cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl, (C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl or (C1-C3)-alkyl which is fully or partially substituted by F;
W is CHorNifo=1;
W is O, S or NR9 if o = 0;
X is (C1-C6)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;
Y1 is O;
Y2 is CR12R13, SO, S02;
n is 0-2;
R4 is H, F, (C1-C6)-alkyl;
R5 is H, F, (C1-C6)-alkyl;
R6 is H, (C1-C6)-alkyl; or F if n is not 0;
R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl, O-(C3-C8)cycloalkyl, O-phenyl, which may be substituted by OH, NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)cycloalkyl, O-phenyl, O-(C5-G11)-heteroaryl, and where (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, CI, Br, J, OH, NR10R11, CO-(C1-C6)-alkyl, CO-(C6-C10)-aryl, CO-(C1-C6)-alkyl-(C6-C10)-aryl, CO-(C5-C11)-heteroaryl, C(O)-O-(C1-C6)-alkyl, C(O)-O-(C1-C6)-alkyl-(C6-C10)-aryl, C(O)-O-(C6-C10)-aryl, C(O)-O-(C5-C11)-heteroaryl, S02-(C1-C6)-alkyl, S02-(C1-C6)-alkyl-(C6-C10)-aryl, S02-(C1-C6)-alkyl-S02-(C1-C6)-alkyl, S02-(C6-C10)-aryl, S02-(C5-C11)-heteroaryl;
R6 and R7 together with the carbon atom that carries them are (C3-C8)cycloalkyl;
R8 is H, (C1-C6)-alkyl;
R9 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R10 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R11 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R12 is H, (C1-C6)-alkyl;
R13 is H, (C1-C6)-alkyl;
and their physiologically acceptable salts.
R1, R2 independently of one another are H, F, CI, Br, CF3, OCF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, SCF3, SFS, OCF2-CHF2, (C6-C10)-aryl, (C6-C10)-aryloxy, OH, N02; or R1 and R2 together with the phenyl, pyridine, 1 H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C6-C10)-aryl, (C5-C11)-heteroaryl;
R3 is H, (C1-C6)-alkyl, (C3-C8)cycloalkyl, (C1-C3)-alkyl-(C3-C8)cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl, (C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl or (C1-C3)-alkyl which is fully or partially substituted by F;
W is CHorNifo=1;
W is O, S or NR9 if o = 0;
X is (C1-C6)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;
Y1 is O;
Y2 is CR12R13, SO, S02;
n is 0-2;
R4 is H, F, (C1-C6)-alkyl;
R5 is H, F, (C1-C6)-alkyl;
R6 is H, (C1-C6)-alkyl; or F if n is not 0;
R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl, O-(C3-C8)cycloalkyl, O-phenyl, which may be substituted by OH, NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)cycloalkyl, O-phenyl, O-(C5-G11)-heteroaryl, and where (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, CI, Br, J, OH, NR10R11, CO-(C1-C6)-alkyl, CO-(C6-C10)-aryl, CO-(C1-C6)-alkyl-(C6-C10)-aryl, CO-(C5-C11)-heteroaryl, C(O)-O-(C1-C6)-alkyl, C(O)-O-(C1-C6)-alkyl-(C6-C10)-aryl, C(O)-O-(C6-C10)-aryl, C(O)-O-(C5-C11)-heteroaryl, S02-(C1-C6)-alkyl, S02-(C1-C6)-alkyl-(C6-C10)-aryl, S02-(C1-C6)-alkyl-S02-(C1-C6)-alkyl, S02-(C6-C10)-aryl, S02-(C5-C11)-heteroaryl;
R6 and R7 together with the carbon atom that carries them are (C3-C8)cycloalkyl;
R8 is H, (C1-C6)-alkyl;
R9 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R10 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R11 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R12 is H, (C1-C6)-alkyl;
R13 is H, (C1-C6)-alkyl;
and their physiologically acceptable salts.
Preference is given to compounds of the formula I in which Ring A is (C3-C8)cycloalkanediyl or (C3-Ca)cycloalkenediyl, where in the cycloalkanediyl or cycloalkenediyl rings one carbon atom may be replaced by an oxygen atom;
X is (C1-C6)-alkanediyl, where in the alkanediyl group the C1 or C2 carbon atom (to Ring A) may be replaced by an oxygen atom;
and their physiologically acceptable salts.
Particular preference is given to the compounds of the formula I in which one or more radicals are as defined below:
Ring A is cyclohexane-1,3-diyl; or R1 is F, Br, CF3, OCF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, phenyl; or R1 and R2 together with the phenyl ring = naphthyl; or such in which the substituent R1 is in the meta- or in the para-position; or R2 is hydrogen; or R3 is H, (C1-C6)-alkyl, (C3-C8)cycloalkyl, (C1-C3)-alkyl-(C5 C6)cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl; or W is CHifo=1; or X is CH2-O or CH2-O-CH2; or n is 0; or R6 is H, (C1-C6)-alkyl; or R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)cycloalkyl, phenyl, O-(C3-C8)cycloalkyl, O-phenyl, (C5-5 C11)-heteroaryl, which may be substituted by OH, NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)cycloalkyl, O-phenyl, O-(C5-C11)-heteroaryl, and where (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, CI, Br, J, OH, NR10R11; or R6 and R7 together with the carbon atom that carries them are (C3-C6)cycloalkyl, in particular cyclopentyl; or R10 and R11 are H, (C1-C6)-alkyl; or R12 and R13 are hydrogen.
Particular preference is furthermore given to the compounds of the formula I in which R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)cycloalkyl, phenyl, (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl, which may be substituted by NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)cycloalkyl, O-phenyl, O-(C5-C11)-heteroaryl, and where phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, CI, NR10R11;
and their physiologically acceptable salts.
Very particular preference is given to the compounds of the formula I
X is (C1-C6)-alkanediyl, where in the alkanediyl group the C1 or C2 carbon atom (to Ring A) may be replaced by an oxygen atom;
and their physiologically acceptable salts.
Particular preference is given to the compounds of the formula I in which one or more radicals are as defined below:
Ring A is cyclohexane-1,3-diyl; or R1 is F, Br, CF3, OCF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, phenyl; or R1 and R2 together with the phenyl ring = naphthyl; or such in which the substituent R1 is in the meta- or in the para-position; or R2 is hydrogen; or R3 is H, (C1-C6)-alkyl, (C3-C8)cycloalkyl, (C1-C3)-alkyl-(C5 C6)cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl; or W is CHifo=1; or X is CH2-O or CH2-O-CH2; or n is 0; or R6 is H, (C1-C6)-alkyl; or R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)cycloalkyl, phenyl, O-(C3-C8)cycloalkyl, O-phenyl, (C5-5 C11)-heteroaryl, which may be substituted by OH, NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)cycloalkyl, O-phenyl, O-(C5-C11)-heteroaryl, and where (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, CI, Br, J, OH, NR10R11; or R6 and R7 together with the carbon atom that carries them are (C3-C6)cycloalkyl, in particular cyclopentyl; or R10 and R11 are H, (C1-C6)-alkyl; or R12 and R13 are hydrogen.
Particular preference is furthermore given to the compounds of the formula I in which R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)cycloalkyl, phenyl, (C3-C8)cycloalkyl, phenyl, (C5-C11)-heteroaryl, which may be substituted by NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)cycloalkyl, O-phenyl, O-(C5-C11)-heteroaryl, and where phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, CI, NR10R11;
and their physiologically acceptable salts.
Very particular preference is given to the compounds of the formula I
in which Ring A is cis-cyclohexane-1,3-diyl R1, R2 independently of one another are H, F, CF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, phenyl, or R1 and R2 together with the phenyl ring = naphthyl;
R3 is (C1-C6)-alkyl;
W is CHifo=1;
X is (CH2)O, CH2-O-CH2;
Y1 is O;
Y2 is CH2;
n is 0, 1;
R4 is H;
R5 is H;
R6 is H;
R7 is H, (C1-C6)-alkyl, O-(C1-C6)-alkyl, (C1-C6)-alkyl-O-(C1-C6)-alkyl, O-(C2-C6)-aikenyl, O-(C2-C6)-alkynyl, CH2NR10R11, where alkyl, O-alkyl and alkenyl may be substituted by phenyl or (C5-C6)-heteroaryl, which in turn may be substituted by (C1 C6)-alkyl, O-(C1-C6)-alkyl, CF3;
R6 and R7 together with the carbon atom that carries them are (C3-C6)cycloalkyl;
R8 is H;
R 10 is (C 1-C6)-alkyl;
R11 is (C1-C6)-alkyl which is substituted by phenyl;
and their physiologically acceptable salts.
The alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5 , R6, R7, R8, R9, R10, R11, R12 and R13 may be either straight-chain or branched.
Aryl means an aromatic carbocyclic mono- or bicyclic ring system which comprises 6 to 10 atoms in the ring or rings.
Heteroaryl is a mono- or bicyclic aromatic ring system having 4 to 11 ring members, in which at least one atom in the ring system is a heteroatom from the series N, O and S.
The compounds of the formula I comprise at least two centers of asymmetry and may comprise more in addition. The compounds of the formula I may therefore exist in the form of their racemates, racemic mixtures, pure enantiomers, diastereomers and mixtures of diastereomers.
The present invention encompasses all these isomeric forms of the compounds of the formula I. These isomeric forms can be obtained by known methods even if not specifically described in some cases.
Pharmaceutically acceptable salts are, because their solubility in water is greater than that of the initial or basic compounds, particularly suitable for medical applications. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloroic acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid, and of organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, malefic, malic, methanesulfonic, succinic, p-toluenesulfonic and tartaric acid. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as magnesium and calcium salts), and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediof), diethanolamine, lysine or ethyfenediamine.
Salts with a pharmaceutically unacceptable anion such as, for example, trifluoroacetate likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.
The term "physiologically functional derivative" used herein refers to any physiologically tolerated derivative of a compound of the formula I of the invention, for example an ester, which on administration to a mammal such as, for example, a human is able to form (directly or indirectly) a compound of the formula I or an active metabolite thereof.
Physiologically functional derivatives also include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be active or not.
The compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.
All references to "compound(s) of formula l" hereinafter refer to compounds) of the formula I as described above, and their salts, solvates and physiologically functional derivatives as described herein.
Use This invention relates further to the use of compounds of the formula I and their pharmaceutical compositions as PPAR ligands. The PPAR ligands of the invention are suitable as modulators of PPAR activity.
Peroxisome proliferator-activated receptors (PPAR) are transcription factors which can be activated by ligands and belong to the class of nuclear hormone receptors. There are three PPAR isoforms, PPARalpha, PPARgamma and PPARdelta, which are encoded by different genes (Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions: Motojima K, Cell Struct Funct. 1993 Oct; 18(5): 267-77).
Two variants of PPARgamma exist, PPARgamma~ and gamma2, which are the result of alternative use of promoters and differential mRNA splicing (Vidal-Puig et al. J. Clin. Invest., 97:2553-2561, 1996). Different PPARs have different tissue distribution and modulate different physiological functions. The PPARs play a key role in various aspects of the regulation of a large number of genes, the products of which genes are directly or indirectly crucially involved in lipid and carbohydrate metabolism. Thus, for example, PPARalpha receptors play an important part in the regulation of fatty acid catabolism or lipoprotein metabolism in the liver, while PPARgamma is crucially involved for example in regulating adipose cell differentiation. In addition, however, PPARs are also involved in the regulation of many other physiological processes, including those which are not directly connected with carbohydrate or lipid metabolism. The activity of different PPARs can be modulated by various fatty acids, fatty acid derivatives and synthetic compounds to varying extents. For relevant reviews about functions, physiological effect and pathophysiology, see:
Joel Berger et al., Annu. Rev. Med. 2002, 53, 409 - 435; Timothy Wilson et al. J. Med. Chem., 2000, Vol. 43, No. 4, 527-550; Steven Kliewer et al., Recent Prog Horm Res. 2001; 56: 239-63.
The present invention relates to compounds of the formula I suitable for modulating the activity of PPARs, especially the activity of PPARalpha and PPARgamma. Depending on the modulation profile, the compounds of the formula I are suitable for the treatment, control and prophylaxis of the indications described hereinafter, and for a number of other pharmaceutical applications connected thereto (see, for example, Joel Berger et al., Annu.
Rev. Med. 2002, 53, 409 - 435; Timothy Wilson et al. J. Med. Chem., 2000, Vol. 43, No. 4, 527-550; Steven Kliewer et al., Recent Prog Horm Res.
2001; 56: 239-63; Jean-Charles Fruchart, Bart Staels and Patrick Duriez:
PPARS, Metabolic Disease and Arteriosclerosis, Pharmacological Research, Vol. 44, No. 5, 345-52; 2001; Sander Kersten, Beatrice Desvergne & Walter Wahli: Roles of PPARs in health and disease, NATURE, VOL 405, 25 MAY 2000; 421-4; Ines Pineda Torra, Giulia 5 Chinetti, Caroline Duval, Jean-Charles Fruchart and Bart Staels:
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice, Curr Opin Lipidol 12: 2001, 245-254).
Compounds of this type are particularly suitable for the treatment and/or prevention of 10 1. - disorders of fatty acid metabolism and glucose utilization disorders - disorders in which insulin resistance is involved 2. Diabetes mellitus, especially type 2 diabetes, including the prevention of the sequelae associated therewith.
Particular aspects in this connection are - hyperglycemia, - improvement in insulin resistance, - improvement in glucose tolerance, - protection of the pancreatic 13 cells - prevention of macro- and microvascular disorders 3. Dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders etc, especially those (but not restricted thereto) which are characterized by one or more of the following factors:
- high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, - low HDL cholesterol concentrations - low ApoA lipoprotein concentrations - high LDL cholesterol concentrations - small dense LDL cholesterol particles high ApoB lipoprotein concentrations 4. Various other conditions which may be associated with the metabolic syndrome, such as:
- obesity (excess weight), including central obesity - thromboses, hypercoagulable and prothrombotic states (arterial and venous) - high blood pressure - heart failure such as, for example (but not restricted thereto), following myocardial infarction, hypertensive heart disease or cardiomyopathy 5. Other disorders or conditions in which inflammatory reactions or cell differentiation may for example be involved are:
- atherosclerosis such as, for example (but not restricted thereto), coronary sclerosis including angina pectoris or myocardial infarction, stroke vascular restenosis or reocclusion - chronic inflammatory bowel diseases such as, for example, Crohn's disease and ulcerative colitis - pancreatitis - other inflammatory states - retinopathy - adipose cell tumors - lipomatous carcinomas such as, for example, liposarcomas - solid tumors and neoplasms such as, for example (but not restricted thereto), carcinomas of the gastrointestinal tract, of the liver, of the biliary tract and of the pancreas, endocrine tumors, carcinomas of the lungs, of the kidneys and the urinary tract, of the genital tract, prostate carcinomas etc - acute and chronic myeloproliferative disorders and lymphomas angiogenesis - neurodegenerative disorders - Alzheimer's disease - multiple sclerosis - Parkinson's disease - erythemato-squamous dermatoses such as, for example, psoriasis - acne vulgaris - other skin disorders and dermatological conditions which are modulated by PPAR
- eczemas and neurodermitis - dermatitis such as, for example, seborrheic dermatitis or photodermatitis - keratitis and keratoses such as, for example, seborrheic keratoses, senile keratoses, actinic keratosis, photo-induced keratoses or keratosis follicularis - keloids and keloid prophylaxis - warts, including condylomata or condylomata acuminata human papilloma viral (HP~ infections such as, for example, venereal papillomata, viral warts such as, for example, molluscum contagiosum, leukoplakia - papular dermatoses such as, for example, Lichen planus - skin cancer such as, for example, basal-cell carcinomas, melanomas or cutaneous T-cell lymphomas - localized benign epidermal tumors such as, for example, keratoderma, epidermal naevi - chilblains - high blood pressure - syndrome X
- polycystic ovary syndrome (PCOS) - asthma - osteoarthritis - lupus erythematosus (LE) or inflammatory rheumatic disorders such as, for example, rheumatoid arthritis - vasculitis - wasting (cachexia) - gout - ischemia/reperfusion syndrome - acute respiratory distress syndrome CARDS) Formulations The amount of a compound of formula 1 necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. The daily dose is generally in the range from 0.001 mg to 100 mg (typically from 0.01 mg to 50 mg) per day and per kilogram of bodyweight, for example 0.1-10 mglkg/day. An intravenous dose may be, for example, in the range from 0.001 mg to 1.0 mglkg, which can suitably be administered as infusion of 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Thus, ampules for injections may contain, for example, from 1 mg to 100 mg, and single-dose formulations which can be administered orally, such as, for example, capsules or tablets, may contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg. For the therapy of the abovementioned conditions, the compounds of formula I may be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not harmful for the patient's health.
The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient. Other pharmaceutically active substances may likewise be present, including other compounds of formula I. The pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which essentially consist of mixing the ingredients with pharmacologically acceptable carriers andlor excipients.
Pharmaceutical compositions of the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula I used in each case. Coated formulations and coated slow-release formulations also belong within the framework of the invention. Preference is given to acid- and gastric juice-resistant formulations. Suitable coatings resistant to gastric juice comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
Suitable pharmaceutical preparations for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contain a defined amount of the compound of formula J; as powders or granules, as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. The compositions are generally produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients.
Compressed tablets can be produced by tableting the compound in free-flowing form such as, for example, a powder or granules, where appropriate mixed with a binder, glidant, inert diluent and/or one (or more) surface-active/dispersing agents) in a suitable machine. Molded tablets can be produced by molding the compound, which is in powder form and is moistened with an inert liquid diluent, in a suitable machine.
Pharmaceutical compositions which are suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula I with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
Pharmaceutical compositions suitable for parenteral administration comprise preferably sterile aqueous preparations of a compound of formula 1, which are preferably isotonic with the blood of the intended recipient.
These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from 0.1 to 5% by weight of the active compound.
Pharmaceutical compositions suitable for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing a compound of the formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
Pharmaceutical compositions suitable for topical use on the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances.
The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an aqueous solution which is buffered where appropriate, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 5 1 % to 35%, preferably about 3% to 15%. A particular possibility is for the active ingredient to be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
The compounds of the formula I are distinguished by favorable effects on 10 metabolic disorders. They beneficially influence lipid and sugar metabolism, in particular they lower the triglyceride level and are suitable for the prevention and treatment of type II diabetes and arteriosclerosis and the diverse sequalae thereof.
15 Combinations with other medicaments The compounds of the invention can be administered alone or in combination with one or more further pharmacologically active substances which have, for example, favorable effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are 1. medicaments which lower blood glucose, antidiabetics, 2. active ingredients for the treatment of dyslipidemias, 3. antiatherosclerotic medicaments, 4. antiobesity agents, 5. antiinflammatory active ingredients 6. active ingredients for the treatment of malignant tumors 7. antithrombotic active ingredients 8. active ingredients for the treatment of high blood pressure 9. active ingredients for the treatment of heart failure and 10. active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.
They can be combined with the compounds of the invention of the formula I
in particular for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
Examples which may be mentioned are:
Antidiabetics Suitable antidiabetics are disclosed for example in the Rote Liste 2001, chapter 12 or in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001. Antidiabetics include all insulins and insulin derivatives such as, for example, Lantus~ (see www.lantus.com) or Apidra~, and other fast-acting insulins (see US 6,221,633), GLP-1 receptor modulators as described in WO 01/04146 or else, for example, those disclosed in WO 98108871 of Novo Nordisk A/S.
The orally effective hypoglycemic active ingredients include, preferably, sulfonylureas, biguanides, meglitinides, oxadiazolidinediones', thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, DPP-IV inhibitors, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO 99/03861, insulin sensitizers, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds which alter lipid metabolism and lead to a change in the blood lipid composition, compounds which reduce food intake, PPAR and PXR
modulators and active ingredients which act on the ATP-dependent potassium channel of the beta cells.
In one embodiment of the invention, the compounds of the formula I are administered in combination with insulin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with substances which influence hepatic glucose production such as, for example, glycogen phosphorylase inhibitors (see: WO 01194300, WO 02/096864, WO 03/084923, WO
03/084922, WO 03/104188).
In one embodiment, the compounds of the formula I are administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
In one embodiment, the compounds of the formula I are administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a biguanide such as, for example, metformin.
In a further embodiment, the compounds of the formula I are administered in combination with a meglitinide such as, for example, repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione such as, for example, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
In one embodiment, the compounds of the formula I are administered in combination with a DPPIV inhibitor as described, for example, in W098/19998, W099/61431, W099/67278, W099/67279, W001 /72290, WO 02/38541, W003/040174, in particular P 93/01 (1-cyclopentyl-3-methyl-1-oxo-2-pentanammonium chloroide), P-31/98, LAF237 (1-[2-[3-hydroxyadamant-1-ylamino)acetyl]pyrrolidine-2-(S)-carbonitrile), TS021 ((2S, 4S)-4-fluoro-1-[[(2-hydroxy-1,1-dimethylethyl)amino]-acetyl]pyrrolidine-2-carbonitrile monobenzenesulfonate).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARgamma agonist such as, for example, rosiglitazone, pioglitazone.
In one embodiment, the compounds of the formula I are administered in combination with compounds with an inhibitory effect on SGLT-1 and/or 2, as disclosed directly or indirectly for example in PCT/EP03/06841, PCTIEP03/13454 and PCT/EP03/13455.
In one embodiment, the compounds of the formula I are administered in combination with an o-glucosidase inhibitor such as, for example, miglitol or acarbose.
In one embodiment, the compounds of the formula I are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
Lipid modulators In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as lovastatin, fluvastatin, pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid reabsorption inhibitor (see, for example, US 6,245,744, US 6,221,897, US 6,277,831, EP 0683 773, EP
0683 774).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine, colesevelam.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor as described for example in WO 0250027, or ezetimibe, tiqueside, pamaqueside.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an LDL receptor inducer (see, for example, US 6,342,512).
In one embodiment, the compounds of the formula I are administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, carob/Caromax~ (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES 1N THERAPY (2001 Sep-Oct), 18(5), 230-6.) Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, (ndustriepark Hoechst, 65926 Frankfurt/Main)). Combination with Caromax~ is possible in one preparation or by separate administration of compounds of the formula I and Caromax~. Caromax~ can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARalpha agonist.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a mixed PPAR alpha/gamma agonist such as, for example, AZ 242 (Tesaglitazar, (S)-3-(4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl)-2-ethoxypropionic acid), BMS
298585 (N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine) or as described in WO 99/62872, WO 99/62871, WO 01 /40171, WO 01 /40169, W096/38428, WO 01 /81327, WO 01 /21602, WO 03/020269, WO 00/64888 or WO 00/64876.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate such as, for example, fenofibrate, gemfibrozil, clofibrate, bezafibrate.
In one embodiment of the invention, the compounds of the formula I are administered in combination with nicotinic acid or niacin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, e.g. CP- 529, 414 (torcetrapib).
In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor such as, for example, implitapide.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP citrate lyase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a iipoprotein(a) antagonist.
Antiobesity agents In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor such as, for example, orlistat.
10 In one embodiment, the further active ingredient is fenfluramine or dexfentluramine.
In another embodiment, the further active ingredient is sibutramine.
In a further embodiment, the compounds of the formula I are administered 15 in combination with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A, et al., M.: Hormone and Metabolic Research (2001 ), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1-sulfonic acid {4-[(4-aminoquinazolin-2-ylamino)methyl]-20 cyclohexylmethyl}amide hydrochloroide (CGP 71683A)), MC4 agonists (e.g. 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4, 3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-amide; (WO 01/91752)), orexin antagonists (e.g. 1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea hydrochloroide (SB-334867-A)), H3 agonists (3-cyclohexyl-1-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropylamine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), urocortin agonists, (33 agonists (e.g. 1-(4-chloro-3-methanesulfonylmethy!phenyl)-2-[2-(2,3-dimethyl-1 H-indol-6-yloxy)ethylamino]-ethanol hydrochloroide (WO 01 /83451 )), MSH
(melanocyte-stimulating hormone) agonists, CCK-A agonists (e.g. ~2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525)), serotonin reuptake inhibitors (e.g. dexfenfluramine), mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01 /09111 ), bombesin agonists, galanin antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing compounds (6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1 H-isoquinoline-2-carboxylic acid tertiary butyl ester (WO 01/85695)), TRH agonists (see, for example, EP 0 462 884), uncoupling protein 2 or 3 modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001 ), 26(9), 873-881 ), DA
agonists (bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO
00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or TR-~i agonists.
In one embodiment of the invention, the further active ingredient is leptin.
In one embodiment, the further active ingredient is dexamphetamine, amphetamine, mazindole or phentermine.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having effects on the coronary circulation and the vascular system, such as, for example, ACE inhibitors (e.g.
ramipril), medicaments which act on the angiotensin-renine system, calcium antagonists, beta blockers etc.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having an antiinflammatory effect.
In one embodiment, the compounds of the formula I are administered in combination with medicaments which are employed for cancer therapy and cancer prevention.
It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is regarded as falling within the protection conferred by the present invention.
The activity of the compounds was tested as follows:
Determination of EC50 values of PPAR agonists in the cellular PPARalpha assay Principle The potency of substances which bind to human PPAR~ and activate in an agonistic manner is analyzed using a stably transfected HEK cell line (HEK= human embryo kidney} which is referred to here as PPARalpha reporter cell line. It contains two genetic elements, a luciferase reporter element (pOM-GAL4-Luc-Zeo) and a PPARalpha fusion protein (GR-GAL4-humanPPARo-LBD) which mediates expression of the luciferase reporter element depending on a PPARalpha ligand. The stably and constitutively expressed fusion protein GR-GAL4-humanPPARalpha-LBD binds in the cell nucleus of the PPARalpha reporter cell line via the GAL4 protein portion to the GAL4 DNA binding motifs 5'-upstream of the luciferase reporter element which is integrated in the genome of the cell line. There is only little expression of the luciferase reporter gene without addition of a PPARalpha ligand if fatty acid-depleted fetal calf serum (cs-FCS) is used in the assay. PPARD ligands bind and activate the PPAR~ fusion protein and thereby bring about expression of the luciferase reporter gene. The luciferase which is formed can be detected by means of chemiluminescence via an appropriate substrate.
Construction of the cell line The PPARalpha reporter cell line was prepared in 2 stages. Firstly, the luciferase reporter element was constructed and stably transfected into HEK cells. For this purpose, five binding sites of the yeast transcription factor GAL4 (each .5'-CGGAGTACTGTCCTCCGAG-3') were cloned in 5'-upstream of a 68 bp-long minimal MMTV promoter (Genbank Accession #
V01175). The minimal MMTV promoter section contains a CCAAT box and a TATA element in order to enable efficient transcription by RNA
polymerase I1. The cloning and sequencing of the GAL4-MMTV construct took place in analogy to the description of Sambraok J. et. al. (Molecular cloning, Cold Spring Harbor Laboratory Press, 1989). Then the complete Photinus pyralis gene (Genbank Accession # M15077) was cloned in 3'-downstream of the GAL4-MMTV element. After sequencing, the luceriferase reporter element consisting of five GAL4 binding sites, MMTV
promoter and luciferase gene was recloned into a plasmid which confers zeocin resistance in order to obtain the plasmid pOM-GAL4-Luc-Zeo. This vector was transfected into HEK cells in accordance with the statements in Ausubel, F.M. et al. (Current protocols in molecular biology, Vol. 1-3, John Wiley & Sons, Inc., 1995). Then zeocin-containing medium (0.5 mg/ml) was used to select a suitable stable cell clone which showed very low basal expression of the luceriferase gene.
In a second step, the PPARalpha fusion protein (GR-GAL4-humanPPARalpha-LBD was introduced into the stable cell clone described.
For this purpose, initially the cDNA coding for the N-terminal 76 amino acids of the glucocorticoid receptor (Genbank Accession # P04150) was linked to the cDNA section coding for amino acids 1-147 of the yeast transcription factor GAL4 (Genbank Accession # P04386). The cDNA of the ligand-binding domain of the human PPARalpha receptor (amino acids S167-Y468; Genbank Accession # S74349) was cloned in at the 3'-end of this GR-GAL4 construct. The fusion construct prepared in this way (GR-GAL4-humanPPARalpha-LBD) was recloned into the plasmid pcDNA3 (from Invitrogen) in order to enable constitutive expression therein by the cytomegalovirus promoter. This plasmid was linearized with a restriction endonuclease and stably transfected into the previously described cell clone containing the luciferase reporter element. The finished PPARalpha reporter cell line which contains a luciferase reporter element and constitutively expresses the PPARalpha fusion protein (GR-GAL4-human PPARalpha-LBD) was isolated by selection with zeocin (0.5 mg/ml) and 6418 (0.5 mglml).
Assay procedure The activity of PPARalpha agonists is determined in a 3-day assay which is described below:
Day 1 The PPAR~reporter cell line is cultivated to 80% confluence in DMEM
(# 41965-039, Invitrogen) which is mixed with the following additions: 10%
cs-FCS (fetal calf serum; #SH-30068.03, Hyclone), 0.5 mg/ml zeocin (#R250-01, Invitrogen), 0.5 mg/ml 6418 (#10131-027, Invitrogen), 1%
penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen). The cultivation takes place in standard cell culture bottles (# 353112, Becton Dickinson) in a cell culture incubator at 37°C in the presence of 5% C02. The 80%-confluent cells are washed once with 15 ml of PBS (#14190-094, Invitrogen), treated with 3 ml of trypsin solution (#25300-054, Invitrogen) at 37°C for 2 min, taken up in 5 ml of the DMEM described and counted in a cell counter. After dilution to 500.000 cells/ml, 35,000 cells are seeded in each well of a 96 well microtiter plate with a clear plastic base (#3610, Corning Costar). The plates are incubated in the cell culture incubator at 37°C and 5% C02 for 24 h.
Day 2 PPARalpha agonists to be tested are dissolved in DMSO in a concentration of 10 mM. This stock solution is diluted in DMEM (#41965-039, Invitrogen) which is mixed with 5% cs-FCS (#SH-30068.03, Hyclone), 2 mM L-glutamine (#25030-024, Invitrogen) and the previously described antibiotics (zeocin, 6418, penicillin and streptomycin).
Test substances are tested in 11 different concentrations in the range from 10 NM to 100 pM. More potent compounds are tested in concentration ranges from 1 NM to 10 pM or between 100 nM and 1 pM.
The medium of the PPARaipha reporter cell line seeded on day 1 is completely removed by aspiration, and the test substances diluted in medium are immediately added to the cells. The dilution and addition of the substances is carried out by a robot (Beckman FX). The final volume of the test substances diluted in medium is 100 NI per well of a 96 well microtiter plate. The DMSO concentration in the assay is less than 0.1 % v/v in order to avoid cytotoxic effects of the solvent.
Each plate was charged with a standard PPARalpha agonist, which was likewise diluted in 11 different concentrations, in order to demonstrate the functioning of the assay in each individual plate. The assay plates are incubated in an incubator at 37°C and 5% C02 for 24 h.
Day 3 The PPARalpha reporter cells treated with the test substances are removed from the incubator, and the medium is aspirated off. The cells are lyzed by pipetting 50 pl of Bright Glo reagent (from Promega) into each well of a 96 well microtiter plate. After incubation at room temperature in the dark for 10 minutes, the microtiter plates are measured in the luminometer (Trilux from Wallac). The measuring time for each well of a microtiter plate is 1 sec.
Evaluation The raw data from the luminometer are transferred into a Microsoft Excel file. Dose-effect plots and EC50 values of PPAR agonists are calculated using the XL.Fit program as specified by the manufacturer (IDBS).
The PPARalpha EC50 values for the compounds of Examples 1 to 91 in this assay are in the range from 0.6 nM to >10 NM.
5 The results for the activity of some compounds of the invention of the formula I are indicated in Table I below:
T~F,Ic 1 Example No. EC50 PPARalpha [nM~
18 1.5 25 6.2 47 0.8 81 0.6 10 It is evident from Table I that the compounds of the invention of the formula I activate the PPARalpha receptor and thus bring about for example in analogy to fibrates in clinical use a lowering of triglycerides in the body (see, for example, J.-Ch. Fruchard et al.: PPARS, Metabolic Disease and Atherosclerosis, Pharmacological Research, Vol. 44, No. 5, 345-52, 2001;
15 S. Kersten et al.: Roles of PPARs in health and disease, NATURE, VOL
405, 25 MAY 2000, 421-4; I. Pineda et al.: Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice, Curr Opin Lipidol 12: 2001, 245-254).
Determination of EC50 values of PPAR agonists in the cellular PPARgamma assay Principle A transient transfection system is employed to determine the cellular PPARgamma activity of PPAR agonists. It is based on the use of a luciferase reporter plasmid (pGL3basic-SxGAL4-TK} and of a PPARgamma expression plasmid (pcDNA3-GAL4-humanPPARgammaLBD). Both plasmids are transiently transfected into human embryonic kidney cells (HEK cells). There is then expression in these cells of the fusion protein GAL4-humanPPARgammaLBD which binds to the GAL4 binding sites of the reporter plasmid. In the presence of a PPARgamma-active ligand, the activated fusion protein GAL4-humanPPARgammaLBD induces expression of the luciferase reporter gene, which can be detected in the form of a chemiluminescence signal after addition of a luciferase substrate. As a difference from the stably transfected PPARalpha reporter cell line, in the cellular PPARy assay the two components (luciferase reporter plasmid and PPARgamma expression plasmid) are transiently transfected into HEK
cells because stable and permanent expression of the PPARgamma fusion protein is cytotoxic.
Construction of the plasmids The luciferase reporter plasmid pGL3basic-SxGAL4-TK is based on the vector pGL3basic from Promega. The reporter plasmid is prepared by cloning five binding sites of the yeast transcription factor GAL4 (each binding site with the sequence 5'-CTCGGAGGACAGTACTCCG-3'), together with a 160 bp-long thymidine kinase promoter section (Genbank Accession # AF027128) 5'-upstream into pGL3basic. 3'-downstream of the thymidine kinase promoter is the complete luciferase gene from Photinus pyralis (Genbank Accession # M15077) which is already a constituent of the plasmid pGL3basic used. The cloning and sequencing of the reporter plasmid pGL3basic-5xGAL4-TK took place in analogy to the description in Sambrook J. ef. al. (Molecular cloning, Cold Spring Harbor Laboratory Press, 1989).
The PPARgamma expression plasmid pcDNA3-GAL4-humanPPARyLBD
was prepared by first cloning the cDNA coding for amino acids 1-147 of the yeast transcription factor GAL4 (Genbank Accession # P04386) into the plasmid pcDNA3 (from Invitrogen) 3'-downstream of the cytomegalovirus promoter. Subsequently, the cDNA of the ligand-binding domain (LBD) of the human PPARy receptor (amino acids 1152-Y475; Accession #
81480099) 3'-downstream of the GAL4 DNA binding domain. Cloning and sequencing of the PPARgamma expression plasmid pcDNA3-GAL4-humanPPARgammaLBD again took place in analogy to the description in Sambrook J. et. al. (Molecular cloning, Cold Spring Harbor Laboratory Press, 1989). Besides the luciferase reporter plasmid pGL3basic-SxGAL4-TK and the PPARy expression plasmid pcDNA3-GAL4-humanPPARgammaLBD, also used for the cellular PPARgamma assay are the reference plasmid pRL-CMV (from Promega) and the plasmid pBluescript SK(+) from Stratagene. All four plasmids were prepared using a plasmid preparation kit from Qiagen, which ensured a plasmid quality with a minimal endotoxin content, before transfection into HEK cells.
Assay procedure The activity of PPARgamma agonists is determined in a 4-day assay which is described below. Before the transfection, HEK cells are cultivated in DMEM (# 41965-039, Invitrogen) which is mixed with the following additions: 10% FCS (#16000-044, Invitrogen), 1 % penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen).
Day 1 Firstly, solution A, a transfection mixture which contains all four plasmids previously described in addition to DMEM, is prepared. The following amounts are used to make up 3 ml of solution A for each 96 well microtiter plate for an assay: 2622 Nl of antibiotic- and serum-free DMEM (# 41965 039, Invitrogen), 100 NI of reference plasmid pRL-CMV (1 ng/NI), 100 NI of luciferase reporter plasmid pGL3basic-SxGAL4-TK (10 ng/Nl), 100 NI of PPARy expression plasmid pcDNA3-GAL4-humanPPARyLBD (100 ngJtrl) and 78 NI of plasmid pBluescript SK(+) (500 ng/Nl). Then 2 ml of solution B
are prepared by mixing 1.9 ml of DMEM (# 41965-039, Invitrogen) with 100 pl of PolyFect transfection reagent (from Qiagen) for each 96 well microtiter plate. Subsequently, 3 ml of solution A are mixed with 2 m! of solution B to give 5 ml of solution C, which is thoroughly mixed by multiple pipetting and incubated at room temperature for 10 min.
80°lo-confluent HEK cells from a cell culture bottle with a capacity of cm2 are washed once with 15 ml of PBS (#14190-094, Invitrogen) and treated with 3 ml of trypsin solution (#25300-054, Invitrogen) at 37°C
for 2 min. The cells are then taken up in 15 ml of DMEM (# 41965-039, Invitrogen) which is mixed with 10% FCS (# 16000-044, Invitrogen), 1%
penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM L
glutamine (#25030-024, lnvitrogen). After the cell suspension has been counted in a cell counter, the suspension is diluted to 250,000 cells/ml. 15 ml of this cell suspension are mixed with 5 ml of solution C for one microtiter plate. 200 NI of the suspension are seeded in each well of a 96 well microtiter plate with a clear plastic base (#3610, Corning Costar). The plates are incubated in a cell culture incubator at 37°C and 5% C02 for h.
Day 2 PPAR agonists to be tested are dissolved in DMSO in a concentration of 10 mM. This stock solution is diluted in DMEM (# 41965-039, Invitrogen) which is mixed with 2% Ultroser (#12039-012, Biosepra), 1 % penicillin streptomycin solution (#15140-122, Invitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen). Test substances are tested in a total of 11 different concentrations in the range from 10 pM to 100 pM. More potent compounds are tested in concentration ranges from 1 NM to 10 pM.
The medium of the HEK cells transfected and seeded on day 1 is completely removed by aspiration, and the test substances diluted in medium are immediately added to the cells. The dilution and addition of the substances is carried out by a robot (Beckman FX). The final volume of the test substances diluted in medium is 100 NI per well of a 96 well microtiter plate. Each plate is charged with a standard PPARy agonist, which is likewise diluted in 11 different concentrations, in order to demonstrate the functioning of the assay in each individual plate. The assay plates are incubated in an incubator at 37°C and 5% C02.
Day 4 After removal of the medium by aspiration, 50 NI of Dual-GIoT"" reagent (Dual-GIoT"" Luciferase Assay System; Promega) are added to each well in accordance with the manufacturer's instructions in order to lyze the cells and provide the substrate for the firefly luciferase (Photinus pyralis) formed in the cells. After incubation at room temperature in the dark for 10 minutes, the firefly luciferase-mediated chemiluminescence is measured in a measuring instrument (measuring timelwell 1 sec; Trilux from Wallac).
Then 50 NI of the Dual-GIoT"" Stop & Glo reagent (Dual-GIoT"" Luciferase Assay System; Promega) is added to each well in order to stop the activity of the firefly luciferase and provide the substrate for the Renilla luciferase expressed by the reference plasmid pRL-CMV. After incubation at room temperature in the dark for a further 10 minutes, a chemiluminescence mediated by the Renilla luciferase is again measured for 1 sec/well in the measuring instrument.
Evaluation The crude data from the luminometer are transferred into a Microsoft Excel file. The firefly/Renilla luciferase activity ratio is determined for each measurement derived from one well of the microtiter plate. The dose-effect plots and EC50 values of PPAR agonists are calculated from the ratios by the XL.Fit program as specified by the manufacturer (IDBS).
PPARgamma EC50 values in the range from 6 nM to >10 NM were measured for the PPAR agonists described in this application.
i _ i i ~ I i ~I
G ; ; ~i ~" II il ~I iC ~~ I~ I1 i I II
I i , i ~ id ~ i~
' ~ 0.I ~
e Z
Z
I
I
I
U
U
I
U
~I iT_ ~2 ._ , I
O
Z I C C~ O O
il I
i t w oo n -i / ~ ~ iI S II I I ~I I
o II (U U U U U .U U
° ~ ~ ~ r 10 0 .0 0 ~0 !0 0 c 'c_ ' ~
U j X 0 0 0 0~0~0~0 ao ~ n U U I I 2 tI (I
c>s ~ ~ UUUUIU
i ., o M
~ i ; I
I II II I ~I tI 'I
I!
O L I
° / Z >, t r IlL iL ~~ ~~ ~~
°' ~ ~ ~ !~ i~ ~' i~ ~~i c~ m v I I ~
- i~ ~ Q i ~ t i X W i N c7 E d' ~'7 ;p I;~
a~ ~ ~ v '~ ~ ; ~ I I ~ ! ~ , I
z I I j , I I
i i i I ~ i I ~ I
! j , 1 1 ~ I i I ~ i ~ I I ~ I ' ! I i i I I
I~ ~ , ' ~ I
i _ i I I I i I I
f I ~ t ; I ~ , ~ ! I 1 i l;l ;
i ' .I I I ' f I .o . , i ;
~o o o ~N I~ o ~o o . i i I ~= Z j= I= j= = IT T ~ ':
I N U U IU ~V fo U U UU I O ;
L~ .=.. ~ .~ U ~ --, ' I j ~ U ~ O l,= p = _ ~~ ~a~ ~ _ = I
cQ c~ g I o cs~ cD
m / ~ (_) ~ U U U ~ U p U U
' ' ' ~ _ i tL >i ~- ~ ~ Z m ~ _ t,.~ U C? g , , U
I ~' d' !'~ ~.;~ N d' .t N ~
i I I
2 Z I2 I I = I = Z 2 Z I2 Z
i i I
f ( 0 0 0 ~ 0 0 o c o o to o . o I
CV ~ N N N N N N N N !N N N C' 2 2 Z Z 2 Z Z Z = 'Z 2 2 U ~-~ IU U U 'U U U iU IU U U
I I I
j 10 ~ O O O IO O O IO I O 10 10 O O
f I i ~0 0 0 0 !o 'o to 'o o ~0 0 0 0 x ~= z = z I= z I= z z I= z s z IU U U U IU U ~U U U U U U U
I
' c~ m m m m m m im m m m 'm 'm m 2 I Z I2 'Z = I= (_ _ = 2 Z j=
I~ I i ~ ; ~ i I
I
i m , v Im m m m ~a~ m m (m m Im I m ~ ~ , ~ ~ ~I~~~~~ ~ ~ ~ ~i~i ~ i ' , , ' , I , , ' , , ; , ' ;
M M r~ r7 ro ! c~7 I M M :~ M c~ ; c~
i ~ i !
I ~ jr~ ? ~ Q T IN M Ict L~ I :~ ~f~ M IG:
iT IT If Ir ~T IT I C~ T' IT : N
I I t I i I
__ i I ~ I I
i I I I 1 l I ~ i I, ~
I ~ i I I I
I I ! I
I
t i ~ 1 ~ I f I 1 I ~ ; ~ I
I I I i I I
I ~ ~ I I
I
' I i I
O p O
I ~ O O O O O
ry ~ i i ~' I
i Z T I Z Z I I ~T
.Z~ 2 Z
N ' = 0 0 o c ~ c o 0 o c o 0 Z = = I Z 1 Z = T
U U U U U U IU C? U U U
I
j O ~ O ~ O O O O 10O O
O O
I
' O O O O O O IO O O O O
N N N N N N N N N N _N
U U U U U U ~ lU U U U v U
I Z Z Z ~ I z = T 1=~ !_ l r .
l v ~ ~ a~ a~ a~ , t''~t'~7 M
I~ ~ = I c~
~ ~ M ~ M I U ' ~ fir;, ~
r N l L1J l N M V' 4~ ~U 1~ ~ i , M
N i N N ~ N CO ~ M
~N .N i i i I -j, f j , I ~ I ~ y ~ ~ s y i i i ~ r ~ ' i ' ~I
! I
I s ~ ! a I I I
I I 1 ' ' ~ ; ~ I
! I 1 ~ I,~ y 1 I ~ ~ I
. I ! ~
I
I ' ~ i n ' I ~ i I I
~ 1 I O O ~ ( O Q
! O o i I o a I O O O I
I ~ o ~
I I
~
i ! C I C C
i I ~ I 1 I
I ~ ~ T I I
; ~ ,=I i I I
~ , ! I ~ ~
I ~
j M I I
M
O C~ I0 0 1 O c o 0 0 0 0 l o ! ; I 0 I o ~
N N ,N N IN ~N N N N N ! N
I I N
I N I I INZ T Z Z Z Is.
I I Z
i U U U ,UU U U U U U U U U IU
, IO O O O ~O ~O O O IO~O ~OIO O O
I I I
~
O O !0 0 0 ! 0 0 0 ,0 ~OO LO O
~ ~
N N N N N N N N N j N N N N
x z z = z z ~= z ~ i=N z z ~ z z z U U ~ U U IU IU~U IUU U U i U
IU U
M m N i ~ ~ ' .......-.r. ~ N
N Q7 i t N
i I c~ = ~ ~~ ~= I I I ~ s Z .1.
g ~,~ ~ ~ !
~
I
~r I
y O- ~ M I
' ~ ~ 1 M
( ~~ ~
r ~~ ~ ~ ~ ~ ~ ~ U ~ -ri U O
Iv N N N N O '~ (VIN 1c~O I
I i f I
i i ; i N M I~t(l~rU t~ ~CJ''v7O ~ N M V
i C~ ('~ M I i c~7('~~ C"e- d'tt'd' I
I ~7M C'~ '~ I ~ ~
i ! 1 j ~ ~ ~ I ~ I ! , ~ ~
j ~ j f ~ I I i I ~ f ~ ~ t n !
I ! I ~ i ~ i ~ i , ~ ~ r ~ ~ ~ ~ s ~ : 1 ~ ~
~
j ~ ~ 1 1, ~ i ; 1 i ( t i i i ; ; ~ 1 ~ ~
i ~ ~ ~ ~ ~ ~ ~ ( I ~ i m y s y s s s y s n y s s ~ i c I ;
I ~ ~ I y i I
I I ' I ~ I i I i l ~ I I I
i i 0 0~ a t a.o 0 0 0 o o) 0 f I
i L L L 1 0 o L. L L.L L L ~I~ l , 4 a.a a a a il c~d 4. a W
~ , , ~ , ~ , ~ ~ n. u~u~
~
~
I
c c c c c c c ~ ~ G c ~ I
i j ~
I
I I ~ i I=iz z z z z ~z ~z z ~= z z z ~ = z . I ~ ~ ~ ~
I
M
o ~ 0 0 0 0 0 o Io c c c o . o , N N N N N N N N iNN N N N !NN
I S I i Z i= I z ~ ~_~ Z 2 2 IUCJ U ~U U (U~U C? U U I U I U IUU
U
"-' 0 0 0 0 0 0 0 0 0 0 O ~O~O O ~O
!
t I
to0 0 0 0 0 0 0 0 0 o io~ 0 0 0 N N N N N N N N N N N N N N N
z 2 Z z Z z 2 2 I Z z ~=f I Z z ~UU U U U U U U U U U IU~ U U U
I , M v fl7N N ~ a~m fr +.....r ~ N 47N
' W 'W !1J , I !
_ ~ I 4 , ~zI =
-r (~ I L (~'~ (~ ~ ~ ,~ (I~ ('~
r.. I C~ t j ~ f !L~ ~ LL ~ L ~ ~ M ~ (~'~, !1. U-, L1.
U ! lL~ U C L O , LL , i.Lo~ U ~ U
d'~ C.~, I s U ~,j~ U N U U ~ i J , V'I N N :~ CV :'~; O O
~ ~' I
~
I i I
~C ' I~.100~ I I N I ~tlt7cJ !~a? I I O
w COI~ ~ O O r~I~ c'~li~>n O
~~ !~ >n iL~ ~ ~ I f I t i I f ;
' ; i ~ ~ I i ' ~ I i f ~ I ~ , n ~ ~ i , I y y ! ' I I
~ I a i l I l n ~ I j I I I I ; I ; I ~ i I
I I i I
I ~ I I i I I ~ i ~ ~ ~ f i ~ I
I ~ I ! ~ I I ~ , y I i y ; I i ~ ; ; I ; I
i l I i ! ; n ~ ! i ~ I j i i ~ ~ i j I
I I i o ~ I
) ! i I ~ ; U
I I o j o o 0 0 o o 0 o , o 0 0 0 o.o ~
~ ' j i s ...... '' ~
.
,~ ..,w ~....~.,w.,. ~ ,~ w u~U! W uJ U
u~ uJU! u~W u~ u~uJ I
.
I
I ~ c~
L
C~1 I
I I
~D ~= I I I Z = Z = I Z Z =
I= I ~ 1 ~ G , I
r i i I j ~ t _ o 0 0 0 0 0 0 0 o 0 0 0 0 o I !
_ N N N N N N N N N N N N N N N N
i=~ = I I2= T = Z I
Z
~ ~= Z I Z I I= U U ~ U C.~ U ~ IU U
U U U U U IU U IU U
I I
~o '00 0 0 0 0 0 0 0 0 0 0 ~oo Io ~
i 'o ~oo ,00 0 0 0 0 0 0 ,o'o .00 0 N N I N N N iNN N N N N N N
X N 2 I Z 2 I Z 2 2 I 2 I Z I=
I I T U U U U i U U U U U U U !U
U U U U I ~
I
M Q? N av N .~-.-~.~.-. +.Q7 ~ N I ~
!lllIuJuJ~ W ~ ~ ~~N '~W ~~
uJ ~ ~
I I
I I
I I
1- t3~ m C ~ i I ~ ~ N
I
V ~ ~ ;~_; ,~~ .;z ~ p ~ I p ~
~ I I I
' N ~ ~ ~ ' IN d- M I~d' N
I 'NI N M M
I
I ~ ~
I I ~ I
' ' I
w i ! , d'lf7CO I 00 ! ~ r 1 , I ~ 'U
r N C~7 L I~ rnO N ('~~t i ~
,~ ~ I~ ~ ~ ~ ,~;~ ~ ,~ ~ i~~ ~ ~ ,~, i v 1 i ~ j ! I ~ 1 a i i ;
O I ~ ~ I ~ I i I
~ I I ;
I I
I I I I ~ 1 I ~ I I I
I I I f ~ i I ~ I
I I
1 ~ I I I i ~
I
' I
i ~ I i i , ~ ! 1 l I I I l ; i I ~ I
I I 1 I I 1 i i f i I
i NOON iONSON~ ~ ~~iON ~ I O
I I Z Z I I Z ~ ~ Z 2 IUU U U U U U U ~ U U
~
i ~ i v v a ~ v z z z z z z z ~ o o z z t U U U U U U U IU m m ~' U U
m m ~,r~r v v ~r w ~ ~r 'r 1 1 1 1 1 1 1 1 ~ I
I M
~ U V Cue.)I U ~ Cue) U C~.a U ~ d~ ~ U d~ ~ ~ I 1 ~t~t ~
'I~ Z _ ~_ _ ,2_ ~=I= = 2 Z I ~ Z
I I
M
I
= 0 0 o i r, r, o o 0 0 0 0 r-, 0 0 I .
I
N N N N N N ~ N N INN N N N
I I ~=i= N Z _ = 2 N I I 2 U U U U IU T ~ U U C> T U U
U U I Z
U
U
I
I
~ 'o o Io0 0 0 o '00 I o ~ o o l t 0 ~ 'o ' ( I X ce'. N i N N N N N ~ IO N O N
I Z N 2 N ~ I _ ~' = N N ON N
U T U 2 = I U U U Z 'N Z 'r I U U U ~ I U Z
U I
I U
U
i I ~ U
M v a7 N ~ N ~ N N 07~ ~ m m I N
i _ ~,= _ 'r= S Z I
I I
_ *.
C~c'~ y 0 N M M ~ M ~ L
I I U ~''U c~ ~ ~~ c'U U ~ U( 1 1 cr3O W N ~ O ~.~ ~ ~ ' I I ~ f ~ M ~I M , M
I i ;~ , ~ ~ I
i i i ~f i L h ~ ~ 00c0 b ~ ~ CO~ 0~0 ~ ~ O
I J ~ ; ~ I ~ I s ~ap0 ' C7 ~ ~ i I
I
a I
' i ~ l I
~
_ i I
I
i I
'N
1~
i i J
i I .
. ~r l Z
V
i I
~t C.~
i I
' ~ T
M
t r (_ ' t C' I
i I C'! =
'~
I T~ ~ s N
l t I U
i i 1 i ? x ~2 O
lU
c ( 'o a~
i a~
i N ~ U
i.T j ~
i .
I N
Q? I
i Y
!~
I
, i , I
X Ir i U
LLl v L
The,compounds of the formula I according to the invention can be obtained according to the reaction schemes below:
Process A:
This process serves for the synthesis of the building block A-A where R1, R2, W and R3 are as defined above.
NaN02 O O H2/Pd O O
R3 O~ R3~0~ ~ R3~'O~
O~N N HCI
X41 ~4 2 I~ 3 Ri\WYcoci O O R3 O \ O
t )o ~\
R2 _ W~N COzEt POCI3 WY 'N O LiAIH4 X44 R1~~ )o R1~t )o R2 R''~~2 X45 ~6 O ~ 12, PPh3, ImH O
w W
R1 W~N O R1 ~N I
~/~ )o ~7 ,4g The ester A-1 in which R3 is as defined above is reacted with sodium nitrite and hydrochloroic acid to give the oxime A-2 which is reduced by hydrogenation with hydrogen over palladium/carbon to give the amine A-3.
The compound A-3 is reacted with acid chloroides of the formula A-4 in which R1, W and R2 are as defined above and base (for example triethylamine) to give the compound A-5.
The compound A-5 is converted by heating in phosphoryl chloroide into the compound A-6.
The ester A-6 is reduced with lithium aluminum hydride in diethyl ether to give the alcohol A-7. This is converted with iodine, imidazole (ImH) and triphenylphosphine into the iodide A-8.
Process B:
This process serves for the synthesis of the building block A-8 in which R1, R2, W and R3 are as defined above.
W CHO HCI O~ pOCl3 O
W . _ ~R3 + R1~
O~N ( )o ~R2 R1 ~W p- R1 W N CI
( )o~R2 )o R2 Nal O
acetone ~W~ ~N I
R1~ , R2 The compound B-1 is reacted with the aldehyde B-2 in which R1, R2, W
and R3 are as defined above in ethanol with hydrogen chloroide to give the compound B-3.
The compound B-3 is heated to the boil in phosphoryl chloroide, which gives the compound B-4. This is heated with sodium iodide in acetone to the boil. This gives the compound A-8.
Process C:
O Bu2Sn0 R3 R3 O O
CsF ~O O Chirazyme L-2 vinyl acetate O ,N - O iN
O ~ W, W
O / N ~ R2 ~ R2 C-1 R1 "( )o C-2 Rl v( )~ C-$
W ~~
~( )o A-8 NaH
NaOH R3 ~ allyl bromide ~O O
O ~_ IN
W
~ R2 R1 "( )o C.d R.' C-5 O O~
Os04 R3 O p ~ R3 Na104 ~ R6 P(O)(OEt)Z ~_ O
O iN O iN
O O
W, _ ~ ~ R2 ~ ~ R2 R1 "( )o R1 "( )o R3 ~ H2 R3 NaOH 0,.,_ /10 O PdlC O~O O
~ i~N I / i~N
O O
R6 W ~ R6 ~~, R2 O ~ ~ R2 p R1~( )o R1 "( )o The compound C-1 is boiled with dibutyltin oxide in toluene under reflux on a water separator. After addition of dimethylformamide, cesium fluoride and 5 the compound A-8 (see process A), the suspension is stirred at room temperature. This gives the compound C-2. This is converted with Chirazyme L-2 in vinyl acetate into the enantiomerically enriched acetate C-3. Using sodium hydroxide in methanol, the acetate C-3 is converted into the alcohol C-4.
10 At room temperature, the compound C-4 is reacted with sodium hydride and allyl bromide and dimethylformamide to give the compound C-5.
The compound C-5 is reacted with osmium tetroxide and sodium periodate in diethyl ether to give the compound C-6. In a Horner-Emmons-Wadsworth reaction, this is converted with sodium hydride and the compound C-7 into the compound C-8.
The compound C-8 is hydrolyzed to the free acid by stirring for a number of hours with sodium hydroxide in methanol at room temperature. The resulting compound C-9 is hydrogenated with hydrogen over palladium/
carbon to give the compound C-10.
Using this process, it is possible to synthesize examples 1 to 4.
Process D:
NaH ~
--..~ _ O~O O
, ~_ O O
O I B~ O
~N ~N
,1 ~ o ,1 R1~( )o O y )o R2 C-2 R1' '~ D-1 Me3S01 NR10R11 aryl halide NaH Pd(0) R3 ~ ~ R3 ~
O~O p~0 ~O
O ~N O O O
W~ O O ~ R10~N
I ~ W , I
( )o ~( )o R11 R1 R2 R1 ~ R
D-2 D-3 (~,-~e)a"".",, , , ,., 3, .....,., ,Z D-4 NaOH NaOH H2 PdIC
NaOH
O ~N
W' l R1~( )o (C~-C6)alkoxy, F, CF;
The compound C-2 is reacted with sodium hydride and ethyl 2-bromo-methylacrylate in dimethylformamide at 0°C, to give the compound D-1.
The compound D-1 is then reacted either with trimethylsulfonium iodide and sodium hydride in dimethyl sulfoxide to give the compound D-2, or with a secondary amine NR10R11, where R10 and R11 are as defined above, to give the compound D-3, or with an aryl halide and a palladium(0) catalyst in a Heck reaction to give the compound D-4. The compound D-4 is then hydrogenated using hydrogen over palladium-on-carbon to give the compound D-5.
Using sodium hydroxide, the compounds D-2, D-3 and D-5 are converted into compounds of the formula D-6, where R6 and R7 are as defined above.
Using this process, it is possible to synthesize examples 5 to 9.
Process E:
Os04 ~ O v O TBDMSCI
---~ O / N HO -w~ HO
R~ - R1~'~)0 G5 ~1 R3 ~ NaH R3 o ~ alkyl-I TBAF
O HO ~ O~ R7 ~N
W~ O_Si~ W, ~ ~ R2 ~ R2 R1~~ )o R1~~ )°
&2 ~3 1. DMP
R3 2. NaCIOz R3 HzOz ~_ O O
O iN R7 ~ O ~N R7 W~~ W~ HO O
R1W )°
R1W )°
&4 ~5 Using osmium tetroxide, 1,5-diazabicyclo[2.2.2]octane (DABCO) and N-methylmorpholine-N-oxide, the compound C-5 is dihydroxylated to the compound E-1. The primary hydroxyl group is then protected as trialkylsilyl ether E-2 by stirring the compound E-1 with a trialkylchlorosilane (for example tert-butyldimethylsilyl chloroide) and imidazole as base in dimethylformamide at room temperature. The compound E-2 is then reacted with a strong base (for example sodium hydride or potassium tert-butoxide) and an alkyl halide to give the compound E-3 where R7 is as defined above. Using tetrabutylammonium fluoride in tetrahydrofuran, the silyl protective group is removed, giving the compound E-4.
The compound E-4 is stirred at room temperature with Dess-Martin Periodinane (DMP) in dichloromethane for a number of hours, worked up and then reacted with sodium chloroite and hydrogen peroxide in acetonitrile to give the compound E-5. Alternatively, E-5 can be synthesized from E-4 by direct oxidation of E-4 using a chromium(VI) compound (for example Cr03 in sulfuric acid).
Using this process, it is possible to synthesize examples 10 to 27.
Process F:
This process serves as an alternative preparation of intermediates E-3 (see process E) PG
Os04 p (Alk)3SiCl O
( )n p ( )n ( )n HO HO
F-1 ~ F-2 HO F-3 O-Sid base PG
alkyl O~ O~ O
halide ( ) H2, Pd/C for PG=Bn, n=0 ( )n K2C03, MeOH for PG=Bz, n=0 HCOOOH, MeOH for PG=Tr, n=1 /S~'O
base ( )n p O ~ N R7 I
W
O i N R2 O
o ~Si~
W, R1~
The racemic or enantiomerically pure compound F-1 in which PG is as defined in the scheme is dihydroxylated to the compound F-2 using osmium tetroxide, 1,5-diazabicyclo[2.2.2]octane (DABCO) and N-methyl-morpholine-N-oxide.
The primary hydroxyl group is then protected as trialkylsilyl ether F-3 by stirring the compound F-2 at room temperature with a trialkylchlorosilane (for example tert-butyldimethylsilyl chloroide) and imidazole as base in dimethylformamide. The compound F-3 is then reacted with a strong base (for example sodium hydride or potassium tert-butoxide) and an alkyl halide to give the compound F-4 in which R7 is as defined above. The benzyl protective group is removed hydrolytically using hydrogen over Pd (10% on carbon), the benzoyl protective group is cleaved using potassium carbonate in methanol and the trityl group is removed using formic acid in methanol, which gives the compound F-5.
The compound F-5 is reacted with the alkyl iodide A-8 in the presence of a strong base (for example sodium hydride or potassium tert-butoxide) in an inert solvent (for example MTBE, chlorobenzene) to give the compound E-3 in which R1, R2, R3, R7 and W are as defined above.
The subsequent conversions of E-3 to E-5 are carried out as described under process E.
Using this process, it is possible to synthesize examples 28 to 90.
Process G:
I Pt02 O R8-OH
O \ N HOAc N R8 O NH3CI
O p O
cis racemate cis racemate / I /
BnBr LiAIH4 = R8~0 N O N
O \
cis racemate cis racemate R3 ~ H2 ~O N
base ~O N PdIC O ~ ~N
O iN
R~ I \
I
/ ('' R2 O ~ N R2 R1~( )o cis racemate R1~( )o cis racemate ~ G-7 W i \ G-6 R~~~
O O
1. coupling Ra R6 2. if required R3 ~ R8 R7 ester hydrolysis ~p /'~~ N O
O ORB O ~ N
R4 R~ R7 w' cis racemate ~(- R2 HO O R1 V ( )~ G-9 The compound G-1 (3-aminobenzoic acid) is hydrogenated in acetic acid using hydrogen over platinum dioxide under elevated pressure, which gives 10 the compound G-2. Using thionyl chloroide in an alcohol R80H in which R8 is as defined above (except for R8 = H), this is converted into an ester, which gives the compound G-3. The compound G-3 is then reacted with benzyl bromide and potassium carbonate to give the dibenzylamine G-4.
Reduction of G-4 with LiAIH4 affords the alcohol G-5.
Using an alkyl iodide A-8, the compound G-5 is converted into the compound G-6 in which R1, R2, W and R3 are as defined above. The compound G-6 is hydrogenated using hydrogen over palladium to give the compound G-7 in which R1, R2, W and R3 are as defined above.
The compound G-7 is coupled with carboxylic acid derivatives G-8 in which R4, R5, R6 and R7 are as defined above. If dicarboxylic acid monoesters G-8 are used, the coupling is followed by ester hydrolysis (using, for example, LiOH in THF/methanol/water for R8 = methyl or ethyl). This gives the compound G-9 in which R1, R2, W, R3, R4, R5, R6 and R7 are as defined above.
Using this process, it is possible to synthesize examples 28 to 90.
The abbreviations used denote:
Ac Acetyl Bn Benzyl 'Bu Isobutyl tBu tert-Butyl BuLi n=Butyllithium Bz Benzoyl Cy Cyclohexyl TLC Thin-layer chromatography DCI Direct chemical ionization (in MS) DCM Dichloromethane DMAP 4-N,N-Dimethylaminopyridine DMF N, N-Dimethylformamide DMSO Dimethyl sulfoxide EA Ethyl acetate EDC N'-(3-Dimethylaminopropyl)-N-ethylcarbodiimide x HCI
EI Electron impact ionization (in MS) eq Equivalent ESI Electrospray ionization (in MS) Et Ethyl sat. Saturated h Hour HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HOBt 1-Hydroxy-1 H-benzotriazole x H20 HPLC High pressure, high performance liquid chromatography LC-MS Liquid chromatography-coupled mass spectroscopy Me Methyl MS Mass spectroscopy MsCI Methanesulfonyl chloroide NMR Nuclear magnetic resonance spectroscopy Pd/C Palladium on carbon 'Pr Isopropyl "Pr n-Propyl Rf Retention time (in TLC) RT Room temperature TBAF Tetrabutylammonium fluoride TBAI Tetrabutylammonium iodide TBDPSCI tert-Butyldiphenylsilyl chloroide TBDMSCI tert-Butyldimethylsilyl chloroide THF Tetrahydrofuran Tr Trityl It is possible to prepare other compounds by the processes mentioned above.
Building block synthesis according to process A:
O O NaN02 H2lPd O O
O~ --~ ( 0~ ---~. O
O'N N HCI
w coca I i O O POCI3 O ~ O LiAIH4 --.-w \ N COzEt I \ N O
/
12, PPh3. ImH
\ ~N 0 \ ~N
5 Ethyl2-hydroxyimino-4-methyl-3-oxopentanoate NaN02 o~ ~ I o~
,N
O
42.4 g of ethyl 4-methyl-3-oxopentanoate are dissolved in 100 ml of glacial 10 acetic acid, and 21 g of sodium nitrite, dissolved in 100 ml of water, are' added at 5°C. Over a period of one hour, the mixture is allowed to warm to room temperature, 100 ml of water are added and the mixture is stirred at room temperature for another hour. The mixture is extracted three times with in each case 150 ml of methyl tert-butyl ether, 200 ml of water are 15 added to the combined organic phases and the mixture is neutralized by addition of solid NaHC03. The organic phase is removed, washed with saturated NaCI solution and dried over MgS04, and the solvent is removed under reduced pressure. This gives 46 g of ethyl 2-hydroxyimino-4-methyl-3-oxopentanoate as an oil. C8H13N04 (187.20), MS (ESI) = 188 (M+H+).
Ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide o~ -.~ o~
HCI
10 g of HCI are introduced into 200 ml of ethanol. 46 g of ethyl 2-hydroxy-imino-4-methyl-3-oxopentanoate are dissolved in this mixture, 5 g of Pd (10% on carbon) are added and the mixture is stirred under atmosphere of hydrogen (5 bar) for 8 hours. The reaction mixture is filtered through Celite and the solvent is removed under reduced pressure. This gives 45 g of ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide as a white solid.
C8H15N03*HCI (209.5), MS(ESI) = 188 (M+H+) Ethyl 4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate Coct o N + ' ~ ~ N O
HCt 10 g of ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide and 7.4 g of 4-methylbenzoyl chloroide are dissolved in 250 ml of dichloromethane, and 13.3 ml of triethylamine are slowly added dropwise at 0°C. The mixture is stirred at room temperature for one hour and then washed with water, the organic phase is separated off and dried over MgS04 and the solvent is then removed under reduced pressure. This gives 13 g of ethyl 4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate as an oil.
C16H21 N04 (291.35), MS(ESI) = 292 (M+H+).
Ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate o~ o ~ o N O -' \ \N
O
13 g of ethyl 4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate in 80 ml of phosphorus oxychloroide are heated to the boil under reflux for 2 h. The phosphorus oxychloroide is removed under reduced pressure and the resulting residue is dissolved in 200 ml of dichloromethane, washed three times with saturated NaHC03 solution and dried over MgS04, and the solvent is then removed under reduced pressure. This gives 11 g of ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate as a brownish sold. C16H19N03 (273.33), MS(ESI) = 292 (M+H+), Rf(n-heptane:ethyl acetate) = 2:1 ) = 0.43.
(5-Isopropyl-2-p-tolyloxazol-4-yl)methanol 11 g of ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate are dissolved in 100 ml of tetrahydrofuran, and 40 ml of a 1 molar solution of lithium aluminum hydride in tetrahydrofuran are added at 0°C. After 30 min, 1 N
of HCI are added to the reaction mixture, and the mixture is extracted five times with ethyl acetate. The combined organic phases are dried over MgS04 and the solvent is then removed under reduced pressure. The residue is purified on silica gel using the mobile phase n-heptane:ethyl acetate = 6:1 => 1:1. This gives 4.3 g of (5-isopropyl-2-p-tolyloxazol-4-yl)methanol as a light-yellow solid.
C14H17N02 (231.30), MS(ESI) - 232 (M+H+), Rf(n-heptane:ethyl acetate) = 1:1 ) = 0.17.
4-lodomethyl-5-isopropyl-2-p-tolyloxazole 500 mg of (5-isopropyl-2-p-tolyloxazol-4-yl)methanol, together with 690 mg of triphenylphosphine and 600 mg of imidazole, are dissolved in 20 ml of toluene. 715 mg of iodine are added, and the mixture is stirred at room temperature for 1 hour. 10 ml of saturated sodium carbonate solution and 500 mg of iodine are then added. After 10 minutes, the organic phase is separated off, washed twice with saturated Na2S2O3 solution and dried over MgS04, and the solvents are then removed under reduced pressure.
The residue is purified on silica gel using the mobile phase n-heptane:ethyl acetate = 10:1. This gives 400 mg of 4-iodomethyl-5-isopropyl-2-p-tolyl-oxazole as a white solid. C14H161N0 (341.19), MS(ESI): 342 (M+H+), Rf(n-heptane:ethyl acetate = 1:1 ) = 0.75.
Analogously to the building block synthesis according to process K, ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide and 3-methoxybenzoyl chloroide gave 4-iodomethyl-2-(3-methoxyphenyl)-5-isopropyloxazole.
O
C14H161N02 (357.19), MS(ESI): 358 (M+H+), Rf(n-heptane:ethyl acetate =
1:1) = 0.60.
Analogously to the building block synthesis of 4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl 4,4,4-trifluoro-3-oxobutyrate and 3-methoxybenzoyl chloroide gave 4-iodomethyl-2-(3-methoxyphenyl)-5-trifluoromethyloxazole.
F F
F
O
I
,O
C12H9F31N02 (383.11), MS(ESI): 384 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl 4,4,4-trifluoro-3-oxobutyrate and 3-trifluoromethyl-benzoyl chloroide gave 4-iodomethyl-2-(3-trifluoromethylphenyl)-5-trifluoro-methyloxazole.
F
C12H6F61N0 (421.08), MS(ESI): 422 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl 4,4,4-trifluoro-3-oxobutyrate and 4-methylbenzoyl chloroide gave 4-iodomethyl-5-trifluoromethyl-2-p-tolyloxazole.
C12H9F31N0 (367.11), MS(ESI): 368 (M+H+).
Building block synthesis according to process B:
O --' \ + \ CHO~ O
~N J / ~ / \ wN+
O I 1_ / O
j POC13 Nal, acetone O
---~. O \ _---> w \ ~N \ N I
w CI ~ /
4-Methyl-5-phenyl-2-p-tolyloxazole 3-oxide CHO HC~ O
w.
o,N ~ ~ ~ ~ ~ ~ o_ 12.5 g of 1-phenyl-1,2-propanedione-2-oxime and 10 ml of p-tolualdehyde are added to 50 ml of glacial acetic acid, and HCI gas is introduced for 30 minutes, with ice-cooling. The product is precipitated as the hydrochloroide by addition of methyl tert-butyl ether and filtered off with suction, and the precipitate is washed with methyl tert-butyl ether. The precipitate is suspended in water and the pH is made alkaline using ammonia. The mixture is extracted three times with in each case 200 ml of dichloromethane, the combined organic phases are dried over MgS04 and the solvent is then removed under reduced pressure. This gives 6.4 g of 4-methyl-5-phenyl-2-p-tolyloxazole 3-oxide as a white solid. C17H15N02 (265.31), MS(ESI) = 266 (M+H+).
4-Chloromethyl-5-phenyl-2-p-tolyloxazole / \
/ \
O \ POCI3 O
O I ~ N CI
6.4 g of 4-methyl-5-phenyl-2-p-tolyloxazole 3-oxide are dissolved in 50 ml of chloroform, 2.4 ml of phosphorus oxychloroide are added and the mixture is, under reflux, heated at the boil for 30 minutes. The reaction mixture is cooled to 0°C, the pH is made slightly alkaline using ammonia and the mixture is extracted three times with in each case 100 ml of ethyl acetate. The combined organic phases are washed with water and dried over MgS04, and the solvent then removed under reduced pressure. This gives 5.4 g of 4-chloromethyl-5-phenyl-2-p-tolyloxazole as a yellow solid.
C17H14CIN0 (283.76), MS(ESI) = 284 (M+H+), Rf(n-heptane:ethyl acetate) = 7:1) = 0.41 4-lodomethyl-5-phenyl-2-p-tolyloxazole Together with 3 g of sodium iodide, 1.8 g of 4-chloromethyl-5-phenyl-2-p-tolyloxazole are, in 150 ml of acetone, heated at the boil under reflux for 2 hours. After cooling of the reaction mixture, 300 ml of methyl tert-butyl ether are added, the mixture is washed three times with saturated Na2S203 solution and dried over MgS04 and the solvents are then removed under reduced pressure. This gives 2.7 g of 4-iodomethyl-5-phenyl-2-p-tolyloxazole as a light-yellow solid.
C17H141N0 (375.21), MS(ESI): 376 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-phenyl-1,2-propanedione-2-oxime and m-anisaldehyde gave 4-iodomethyl-2-(3-methoxyphenyl)-5-phenyloxazole.
C17H141N02 (391.21), MS(ESI): 392 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and m-anisaldehyde gave 4-iodomethyl-5-ethyl-2-(3-methoxyphenyl)oxazole.
,O
C13H141N02 (343.17), MS(ESI): 344 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and p-tolualdehyde gave 4-iodomethyl-5-ethyl-2-p-tolylazole.
O
i i C13H141N0 (327.17), MS(ESI): 328 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and 2,6-dimethyl-benzaldehyde gave 4-iodomethyl-5-ethyl-2-(2,6-dimethylphenyl)oxazole.
O
N I
C14H161N0 (341.19), MS(ESI): 342 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and 2-trifluoromethyl-benzaldehyde gave 4-iodomethyl-5-ethyl-2-(2-trifluoromethylphenyl)-oxazole.
F F
FO
N I
C13H11F31N0 (381.14), MS(ESI): 382 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-cyclohexyl-1,2-propanedione-2-oxime and m-anis-aldehyde gave 4-iodomethyl-5-cyclohexyl-2-(3-methoxyphenyl)oxazole.
O
N I
,O
C17H201N02 (397.26), MS(ESI): 398 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-cyclohexyl-1,2-propanedione-2-oxime and p-toluene-aldehyde gave 4-iodomethyl-5-cyclohexyl-2-p-tolyloxazole.
O
w ~ N !
C17H201N0 (381.26), MS(ESI): 382 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and p-toluenealdehyde gave 4-iodo-methyl-5-methyl-2-p-tolyloxazole.
O
N I
C12H121N0 (313.14), MS(ES1): 314 (M+H+) Analogously to the building block synthesis of 4-chloromethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and benzaldehyde gave 4-chloro-methyl-5-methyl-2-phenyloxazole.
O
\ 'N CI
5 C11H101N0 (207.66), MS(ESI): 208 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-biphenyloxazole, diacetylmonoxime and p-biphenylcarbaldehyde gave 10 4-iodomethyl-5-methyl-2-p-biphenyloxazole.
O
\ N I
\ /
/
C12H121N0 (375.21), MS(ESI): 376 (M+H+) 15 Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2-naphthalenecarbaldehyde gave 4-iodomethyl-5-methyl-2-naphthyloxazole.
O
N I
C12H121N0 (349.17), MS(ESI): 350 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2,4-dimethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(2,4-dimethylphenyl)oxazole.
C13H141N0 (327.17), MS(ESI): 328 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2,6-dimethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(2,6-dimethylphenyl)oxazole.
O
I \ ,N I
C13H141N0 (327.17), MS(ESI): 328 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and m-anisaldehyde gave 4-iodo-methyl-2-(3-methoxyphenyl)-5-methyloxazole.
,O
C12H121N02 (329.14), MS(ESI): 330 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 3-trifluoromethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(3-trifluoromethylphenyl)oxazole.
O
w N I
F F
F
C12H9F31N0 (367.11), MS(ESI): 368 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 4-fluorobenzaldehyde gave 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole.
O
I
F
C11H9FIN0 (317.10), MS(ESI):318 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyfoxazole, diacetylmonoxime and 4-methoxybenzaldehyde gave 4-iodomethyl-2-(4-methoxyphenyl)-5-methyloxazole.
O
N I
O
C12H121N02 (329.14), MS(ESI):330 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 4-trifluoromethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole.
F
F
C12H9F31N0 (367.11), MS(ESI):368 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2-trifluoromethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(2-trifluoromethylphenyl)oxazole.
F F
F O
N I
C12H9F31N0 (367.11), MS(ESI):368 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl 2-p-tolyloxazole, diacetylmonoxime and m-toluenealdehyde gave 4-iodo methyl-5-methyl-2-m-tolyloxazole.
C12H121N0 (313.14), MS(ESI):314 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 3-trifluoromethoxybenzaldehyde gave 4-iodomethyl-5-methyl-2-(3-trifluoromethoxyphenyl)oxazole.
O
N I
F\ /O
~F
F
C12H9F31N02 (383.11), MS(ESI):384 (M+H+), Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 5-methylfuran-2-carbaldehyde gave 4-iodomethyl-5-methyl-2-(5-methylfuran-2-yl)oxazole.
O
O ~N
I
C10H101N02 (303.11), MS(ESl):304 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and thiophene-2-carbaldehyde gave 4-iodomethyl-5-methyl-2-thiophen-2-yloxazole.
O
S \N
I
C9H81NOS (305.14), MS(ESI):306 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 4-isopropylbenzaldehyde gave 4-iodomethyl-2-(4-isopropylphenyl)-5-methyloxazole.
O
N I
5 C14H161N0 (341.19), MS(ESI):342 (M+H+).
Example 1:
2-Ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyloxy}butanoic acid Bu2Sn0 1. Chirazy CsF O OH v'snyl acet<
HO OH ~ 2. NaOH
N~ O
N~
/
F F
Os04 allyl bromide O O~ Na104 O OHO
NaH
N' O~ N1 / O
F F
NaH / O~ NaOH
O O
/-- O
O
O-P=O N\ \
O
o f F
/ O H~/Pd(C;
O O
O
N\ y-F F
rac-3-(cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol a~zsno O
O~ CsF \
~ ~N ~~----~~ I + O ~O ~ I ~ \N O O
F~
F
cislracemate 21.7 g of 1,3-cyclohexanediol and 30.3 g of dibutyltin oxide are dissolved in 450 ml of toluene and, under reflux on a water separator, heated to the boil.
During the duration of the reaction, the reaction volume is reduced to half of the original volume. After 3 hours, the reaction mixture is cooled to room temperature, and 300 ml of dimethylformamide, 29 g of 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole and 23.5 g of cesium fluoride are added.
The mixture is stirred at room temperature for another 18 hours. The reaction mixture is diluted by addition of ethyl acetate and washed with saturated sodium chloroide solution. The organic phase is dried over magnesium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptanel ethyl acetate = 10:1 ~ 1:4). This gives 58 g of rac-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol as a yellowish solid which is recrystallized from n-heptane/ethyl acetate. C17H20FN03 (305.35), MS
(ESI): 306 (M + H+).
3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol O~ ~ Chirazyme L-2 \ O
O O vinyl acetate I ~N O O
N
F ~ F
cislracemate NaOH
MeOH
O
~N O O
F
g of rac-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol are dissolved in 320 ml of vinyl acetate, and 1.3 g of Chirazyme L-2 Lyo 25 (Boehringer Mannheim) are added. After about three hours of stirring at room temperature (LC-MS control for 40-45% conversion), the enzyme is filtered off and rinsed with ethyl acetate, and the solvent is removed under reduced pressure. The residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 3:1 ). This gives 8 g of the acetate as a colorless oil. C19H22FN04 (347.39), MS (ESI): 348 (M + H+). The acetate is taken up in 170 ml of methanol and, after addition of 27 ml of 2N NaOH, stirred at room temperature for one hour. Most of the solvent is removed under reduced pressure. After addition of in each case 150 ml of water and ethyl acetate, the organic phase is washed with sodium chloroide solution.
The organic phase is dried over magnesium sulfate and the solvent is removed under reduced pressure. This gives 6.7 g of 3-((1R,3S)-cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol as a yellowish solid. C17H20FN03 (305.35), MS (ESI): 306 (M + H+).
4-(3-Allyloxycyclohexyloxymethyl)-2-(4-fluorophenyl)-5-methyloxazole NaH, DMF
O '~ O O
O ~ O O Br ,N ~ 'N
F F
2 g of the 3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol are dissolved in 15 ml of dimethylformamide, and 0.3 g of sodium hydride is added. After 30 minutes, 2.4 g of allyl bromide are added dropwise. The mixture is stirred at room temperature for 5 hours. 15 ml of 1 N HCI are then added to the reaction mixture, and the mixture is washed three times with 15 ml of ethyl acetate. The organic phase is dried over magnesium sulfate, and the solvent is then removed under reduced pressure. The residue is purified by RP-HPLC. This gives 2.4 g of 4-(3-allyloxycyclohexyloxymethyl)-2-(4-fluorophenyl)-5-methyloxazole as a yellowish oil. C20H24FN03 (345.42) MS(ESI): 346 (M+H+) [3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl]acet-aldehyde Os04 Na104 O O~ ~ 0 ~ 0 O~O
~N ~N
F F
2.0 g of 4-(3-allyloxycyclohexyloxymethyl)-2-(4-fluorophenyl)-5-methyloxa-zole are dissolved in 50 ml of diethyl ether, and 3.8 g of sodium periodate, dissolved in 50 ml of water, are added. At 0°C, 1 ml of an osmium tetroxide solution (2.5% by weight in tert-butanol) is added, and the mixture is stirred vigorously at room temperature. After 8 h, 100 ml of methyl tent-butyl ether are added, and the mixture is washed with a saturated sodium thiosulfate solution. The organic phase is dried over magnesium sulfate and the solvent is removed under reduced pressure. The residue is purified on silica gel (n-heptane:ethyl acetate = 1:1 --~ 1:5). This gives 1.4 g of [3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl]acetaldehyde as a yellow-brown oil. C20H25N04 (343.42), MS(ESI): 344 (M+H+), Rf(n-heptane:ethyl acetate = 1:1 ) = 0.25.
Ethyl 2-ethyl=4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-cyclohexyloxy}but-2-enoate NaH
O O~O O 0 ~ O
O
N~ O O N~ O
O
i F F
0.58 g of ethyl 2-(diethoxyphosphoryl)butanoate is dissolved in tetrahydrofuran (20 ml), and 0.06 g of sodium hydride is added at 0°C.
The suspension is stirred at 0°C for 30 min and at room temperature for 30 min and then cooled to -70°C. After addition of 0.4 g of 2-((1 R,3S)-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde (dissolved in 5 ml of tetrahydrofuran), the mixture is stirred at -70°C for 60 min and then at room temperature for 12 h. 10 ml of water are added, the mixture is 5 extracted with ethyl acetate (3 x 10 ml) and the combined organic phases are washed with saturated sodium chloroide solution (10 ml). The solvent is removed under reduced pressure and the residue is purified by HPLC. This gives 0.32 g of ethyl 2-ethyl-4-{(1R,3S)-3-[2-(4-fluorophenyl)-5-methyl-oxazol-4-ylmethoxy]cyclohexyloxy}but-2-enoate C25H32FN05 (445.54) 10 MS(ESI): 446 (M + H+) 2-Ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-cyclohexyloxy}but-2-enoic acid F
N O O / 0~ NaOH
O O
F
0 o i o 0.5 g of ethyl 2-ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxy}but-2-enoate is dissolved in 5 ml of methanol, and 2.5 ml of 1 N aqueous sodium hydroxide solution are added. After 12 h of stirring at room temperature, the mixture is acidified with 3 ml of 1 N
hydrochloroic acid and the resulting precipitate is taken up in ethyl acetate.
The solvent is removed under reduced pressure and the residue of the ester hydrolysis, 2-ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxy}but-2-enoic acid, is obtained as 0.45 g of a white solid. C23HZ8FN05 (417.48) MS(ESI): 418 (M + H+) 2-Ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyloxy}butanoic acid F \ ~ N / O HZ~Pd(C) ' ~O O
O O
F
O
' ~O O
O O
0.3 g of 2-ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl-methoxy]cyclohexyloxy}but-2-enoic acid is dissolved in a solvent mixture of 2 ml of ethyl acetate and 1 ml of methanol, and 0.05 g of palladium (10%
on carbon) is added. The mixture is then hydrogenated at a hydrogen pressure of 1 bar for 3 h.
The palladium is filtered off and the solvent mixture is then removed under reduced pressure and the residue is recrystallized from acetonitrile. This gives 0.25 g of 2-ethyl-4-~(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyloxy}butanoic acid as a white solid. C23H3oFN05 (419.49), MS(ESI): 420 (M + H+) Example 2:
Using reaction conditions similar to those of example 1, 2-((1 R,3S)-[3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde and ethyl 2-(diethoxyphosphoryl)pentanoate give 2-propyl-4-[3-(2-(4-fluoro-phenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]butanoic acid.
F N ~ O
/ ~ O O
O O
C24H32FNO5 (433.52) MS(ESI): 434 (M+H+) Example 3:
Using reaction conditions similar to those of example 1, 2-((1R,3S)-[3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde and ethyl 2-(diethoxyphosphoryl)acetate give 4-{3-[2-(4-fluorophenyl)-5-methyl-oxazol-4-yimethoxy]cyclohexyloxy}butanoic acid F N ~ p O O II
O O
C2~H26FN05 (391.44) MS(ESI): 392 (M + H+) Example 4:
Using reaction conditions similar to those of example 1, 2-((1 R,3S)-[3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde and ethyl 2-(diethoxyphosphoryl)propionate give 4-{3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxy}-2-methylbutanoic acid F N ~ O
O O
° o C22H28FN05 (405.47) MS(ESI): 406 (M + H+) Example 5:
Ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy-methyl]acrylate NaH, DMF
O O O~
B~O~' 200 mg of a 60% strength sodium hydride suspension are added at room temperature to a solution of 754 mg of 3-((1 R,3S)-cis-5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol in 10 ml of dimethylformamide/5 ml of tetrahydrofuran, and the mixture is stirred at room temperature for 20 minutes. At 0°C, 1 g of ethyl 2-bromomethylacrylate is then added, and the mixture is stirred at this temperature for 2 h. 100 ml of ethyl acetate and 150 ml of saturated NaCI solution are added. The organic phase is dried over sodium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 2:1). This gives 1.18 g of ethyl ((1R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate as a colorless oil. C24H3~NO5 (413.52), MS (ESI): 414 (M + H+).
Ethyl ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy-methyl]cyclopropanecarboxylate 0 ~ 0 o \ I~ o l--' w '~o~o o~ --~ ~ N o 0 0 N
NaH /
At room temperature, 12 mg of a 60% strength sodium hydride suspension are. added to a suspension of 55 mg of trimethylsulfonium iodide in 2 ml of DMSO, and the mixture is stirred at room temperature for 20 min. At 10°C, 100 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclo-hexyloxymethyl]acrylate, dissolved in 2 ml of DMSO, are then added, and the mixture is stirred at room temperature for 90 min. The mixture is poured into ice-water and extracted with methyl tert-butyl ether. The organic phase is dried over sodium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 2:1 ). This gives ethyl ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]cyclopropanecar-boxylate as a colorless oil. C25H33NO5 (427.55), MS (ESI): 428 (M + H+).
((1 R,3S)-1-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]-cyclopropanecarboxylic acid 0 0 0~ o NaOH
\ /\ \
~N O O O ~ I ~N O O O
/ /
56 mg of ethyl ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclo-hexyloxymethyl]cyclopropanecarboxylate are dissolved in 3 ml of methanol, 0.5 ml of 5 N NaOH are added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid and purified by RP-HPLC.
This gives ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyl-oxymethyl]cyclopropane carboxylic acid as a colorless oil. C23H29N05 (399.49), MS (ESI): 400 (M + H+).
Example 6:
Ethyl 2R/S-((1 R',3S')-2-[(methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate o~ o ~ ~0 ~
N O~O O~
N O O~O
/ + N
/N I
I/
50 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclo-hexyloxymethyl]acrylate are dissolved in 5 ml of ethanol, 95 mg of N-methylhomobenzylamine are added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 1:1 + 3% NEt3). This gives ethyl 2R/S-((1 R',3S')-2-[(methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmeth-oxy)cyclohexyloxy]propionate as a colorless oil. C33Hq.4N2O5 (548.73), MS
(ESI): 549 (M + H+).
((1 R',3S')-2R/S-[(Methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid \ N o 0 0~
N \
~LiOH
O \ O
~N O 0 ~ 'O
N \ /
5 65 mg of ethyl 2R/S-((1 R',3S')-2-[(methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate are dissolved in 3 ml of tetrahydrofuran/methanol 3:1, 0.6 ml of 1 N LiOH is added and the mixture is stirred at room temperature for 6 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid 10 and purified by RP-HPLC. This gives 2R/S-((1R',3S')-[(methylphenethyl-amino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propionic acid as a colorless oil. C3~H4pN2O5 (520.67), MS (ESI): 521 (M+H+) 15 Example 7:
O \ O
~N O O ~O
N
(1 R',3S')-2R/S-[(Benzylmethylamino)methyl]-3-[3-(5-methyl-2-m-tolyl-20 oxazol-4-ylmethoxy)cyclohexyloxy]propionic acid Using reaction conditions similar to those of example 100, ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate and N-methylbenzylamine give (1 R',3S')-2R/S-[(benzylmethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid of molecular weight 506.65 (C3oH38N205), MS(ESI): 507.20 (M + H+).
Example 8:
((1 R',3S')-2R/S-Methoxymethyl-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmeth-oxy)cyclohexyloxy)propionic acid o \ o 0 0 NaCN ~
., NaQH ~ N O' v 'O O
N O O O -O
56 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4.-ylmethoxy)cyclo-hexyloxymethyl]acrylate are dissolved in 3 ml of methanol, 49 mg of sodium cyanide and 0.25 ml of 2N NaOH are added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid and purified by RP-HPLC. This gives ((1 R',3S')-2R/S-methoxymethyl-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid as a colorless oil.
Cz3H3~N06 (417.51), MS (ESI): 418.15 (M + H+).
Example 9:
Ethyl Z-((1 R',3S')-3-(4-fluoro-3-methylphenyl)-2-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxymethyl)acrylate 0 0~
F
O O ' F
220 mg of tetrabutylammonium chloroide and 332 mg of potassium carbonate are suspended in 4 ml of dimethylformamide and stirred intimately for 20 min. 400 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate, 25 mg of triphenylphos-phine and 212 mg of 4-fluoro-3-methyliodobenzene are added, the mixture is degassed and flushed with argon and 10 mg of palladium acetate and 0.2 mol of water are added. The mixture is heated at 60°C for 4 h.
After cooling, 20 ml of ethyl acetate and 50 ml of saturated NaCI solution are added. The organic phase is dried over sodium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptanelethyl acetate = 4:1 ). This gives ethyl Z-((1 R',3S')-3-(4-fluoro-3-methylphenyl)-2-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate as a colorless oil.
C3~H3aFN05 (523.65), MS (ESI): 524 (M + H+).
Ethyl 2R/S-(4-fluoro-3-methylbenzyl)-(1 R',3S')-3-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxy]propionate O
O O~O~
\ Pd/C ~' /~
H2 ~F
O
O O
80 mg of ethyl Z-((1 R',3S')-3-(4-fluoro-3-methylphenyl)-2-(3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate are dissolved in 15 ml of ethyl acetate and, after addition of 30 mg of Pd/C 10%, stirred under 1 bar of H2 for 24 h. The catalyst is filtered off and the solvent is evaporated. This gives ethyl 2RIS-(4-fluoro-3-methylbenzyl)-(1R',3S')-3-(3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate as a colorless oil. C3~H38FN05 (521.63), MS (ESI): 522 (M + H+).
(2R/S)-(4-Fluoro-3-methylbenzyl)-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid o ~
w i uoi Me( O
70 mg of ethyl 2R/S-(4-fluoro-3-methylbenzyl)-(1 R',3S')-3-(3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate are dissolved in 3 ml of tetrahydrofuranlmethanol 3:1, 0.1 ml of 1 N LiOH is added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid and purified by RP-HPLC. This gives 2R/S-(4-fluoro-3-methylbenzyl)-(1 R~,3S~)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyJ-propionic acid as a colorless oil. Cz9H34FN05 (495.60), MS (ESI): 496.20 (M + H+).
Example 10:
rac-3-(cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol o BuZSnO, CsF ~ ~N \ O O
O O
cis/racemate 21.7 g of 1,3-Cyclohexanediol and 30.3 g of dibutyltin oxide are dissolved in 450 ml of toluene and, under reflux on a water separator, heated to the boil. During the reaction, the volume of the mixture is reduced to half of the original volume. After 3 hours, the reaction mixture is cooled to room temperature and 300 ml of dimethylformamide, 29 g of 4-iodomethyl-5-methyl-2-m-tolyloxazole 1 and 23.5 g of cesium fluoride are added. The mixture is stirred at room temperature for 18 hours. The reaction mixture is diluted by addition of ethyl acetate and washed with saturated NaCI
solution. The organic phase is dried over magnesium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 10:1 --~ 1:4). This gives 58 g of rac-3-(cis-5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol as a yellowish solid which is recrystallized from n-heptane/ethyl acetate.
C18H23N03 (301.39), MS (ESI): 302 (M + H+).
3-((1 R,3S)-cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol 4 Chirazyme L-2 ~N O O vinyl acetate O O
cis/racemate NaOH
MeOH
O \
~N O O
25 g of rac-3-(cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol are 5 dissolved in 320 ml of vinyl acetate and 1.3 g of Chirazyme L-2 Lyo (Boehringer Mannheim) are added. The mixture is stirred at room temperature for about 3 hours (LC-MS control for 40-45% conversion), the enzyme is then filtered off and washed with ethyl acetate and the solvent is removed under reduced pressure. The residue is purified by flash 10 chromatography on silica gel (n-heptane/ethyl acetate = 3:1 ). This gives 8 g of acetate 3 as a colorless oil. C20H25N04 (343.43), MS (ESI): 344 (M + H+). The acetate is taken up in 170 ml of methanol and, after addition of 27 ml of 2N NaOH, stirred at room temperature for 1 hour. Most of the solvent is removed under reduced pressure. After addition of in each case 15 150 ml of water and ethyl acetate, the org. phase is washed with NaCI
solution. The organic phase is dried over magnesium sulfate and the solvent is removed under reduced pressure. This gives 6.7 g of 3-((1 R,3S)-cis-5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol as a yellowish solid.
C18H23N03 (301.39), MS (ESI): 302 (M + H+).
4-((1 R,3S)-3-Allyloxycyclohexyloxymethyl)-5-methyl-2-m-tolyloxazole 5 NaH, DMF
ally) bromide O -~- O O~
At room temperature, 470 mg of 60% strength sodium hydride suspension are added to a solution of 2.2 g of 3-((1 R,3S)-cis-5-methyl-2-m-tolyloxazol-j 4-ylmethoxy)cyclohexanol in 30 ml of dimethylformamide, and the mixture =- ' is stirred at room temperature for ~0 min. 1.36 ml of allyl bromide are then added and the mixture is stirred at 40°C until the conversion is complete; if required, further sodium hydride and allyl bromide are added. After complete conversion (LC-MS control), 100 ml of ethyl acetate and 150 ml of saturated NaCI solution are added. The organic phase is dried over magnesium sulfate, the solvents are removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 3:1). This gives 2.3 g of 4-((1 R,3S)-3-allyloxycyclo-hexyloxymethyl)-5-methyl-2-m-tolyloxazole 5 as a colorless oil.
C21 H27N03 (341.45), MS (ESI): 342 (M + H+).
(1 R',3S')-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]pro-pane-1,2-diol o \ osoa ~ \
Na~ \ N O O O
O
N O O ~ /
At 0°C, 225 mg of DABCO, 1.4 g of anhydrous N-methylmorpholine N-oxide and 350 pl of osmium tetroxide, 2.5% in tert-butanol, were added to 2.8 g of 4-((1 R,3S)-3-allyloxycyclohexyloxymethyl)-5-methyl-2-m-tolyl-oxazole in 9 ml of acetone/water 10:1. After 24 h of stirring at room temperature, 2.4 g of sodium metabisulfite were added, and after 10 min, the mixture was diluted with 25 ml of CH2C12. The mixture was filtered and the solvent was removed under reduced pressure. The residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 1:3). This gives 2.5 g of 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propane-1,2-diol as a colorless oil. C2~H2gNO5 (375.47), MS
(ESI): 376 (M + H+).
2S-(1 S',3R')-1-(tert-Butyldimethylsilanyloxy)-3-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxy]propan-2-of O TBDMSCI
\ \~O~O O imid~zoVe \ N O O O-Si N
/ o \
At 0°C, 500 mg of imidazole, 1.02 g of tert-butyldimethylsilyl chloride and 50 mg of tetrabutylammonium iodide are added to 2.5 g of 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyfoxazol-4-ylmethoxy)cyclohexyfoxy]propane-1,2-diol in 30 ml of dichloromethane. Over a period of 18 h, the mixture is allowed to warm to room temperature and then poured onto ice. The mixture is extracted with dichloromethane, the extract is dried over sodium sulfate and filtered and the solvent is removed under reduced pressure. The residue is purified by flash chromatography on silica gel (n-heptane/
ethyl acetate = 2:1 -~ 1:2). This gives 2S-(1S',3R')-1-(tert-butyldimethyl-silanyloxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propan-2-of as a colorless oil. C27H43NO5S1 (489.73), MS (ESI): 490 (M + H+).
2S'-(1 S,3R)4-{3-[3-(tert-Butyldimethylsilanyloxy)-2-prop-2-ynyloxypropoxy]-cyclohexyloxymethyl}-5-methyl-2-m-tolyloxazole o ~~ o \ ~
. ~\ -.~ ~ ! ~ ~o~o o-si \ ~O~O O-Si ---~ N
N
\~ NaH 4 / O
1~
25 mg of 60% strength sodium hydride suspension are added to 245 mg of 2S-(1 S',3R')-1-(tert-butyldimethylsilanyloxy)-3-(3-(5-methyl-2-m-tolyloxazol-ylmethoxy)cyclohexyloxy]propan-2-of in 3 ml of dimethylformamide, and the mixture is stirred at room temperature for 20 min. 200 mg of propargyl bromide are then added, and the mixture is stirred at room temperature until the conversion is complete. The mixture is taken up in saturated NaCI
solution/ethyl acetate, the organic phase is dried over sodium sulfate and filtered and the solvent is removed under reduced pressure. This gives 2S'-(1 S,3R)4-{3-[3-(tert-butyldimethxlsilanyfoxy)-2-prop-2-ynyloxypropoxy]cyclohexyloxymethyl}-5-methyl-2-m-tolyloxazole as a colorless oil. C3oHa5NO~Si (527.78), MS (ESI): 528 (M + H+).
(1 R',3S')-2R-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-prop-2-ynyloxypropan-1-of O TBAF
/ THF \ N 0 O~0 \ N O O O-Si / ~ ~~ ~ / 0 2 ml of tetrabutylammonium fluoride, 1 M in tetrahydrofuran, are added to 200 mg of 2S'-(1 S,3R)4-{3-[3-(tert-butyldimethylsilanyloxy)-2-prop-2-ynyl-oxypropoxy]cyclohexyloxymethyl~-5-methyl-2-m-tolyloxazole in 2 ml of tetrahydrofuran, and the mixture is stirred at room temperature for 2 h. The mixture is taken up in saturated NaCI solution/ethyl acetate, the organic phase is dried over sodium sulfate and filtered and the solvent is removed under reduced pressure. This gives (1 R',3S')-2R-3-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxyJ-2-prop-2-ynyloxypropan-1-of as a colorless oil. C24H3~NO5 (413.53), MS (ESI): 414 (M + H+).
2R-(1 R',3S')-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropan-1-of O PdlC ~
~ H2 \ - v _O O
w ~ N O
\ ~O O
N O ~ I / O
O
50 mg of PdIC 10% are added to crude (1 R',3S')-2R-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-prop-2-ynyloxypropan-1-of dissolved in 20 ml of methanol, and the mixture is stirred under a hydrogen pressure of 1 bar for 3 h. The catalyst is filtered off and the solvent is removed under reduced pressure. This gives 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropan-1-of as a colorless oil. The residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 1:1). C24H35NO5 (417.55), MS (ESI): 418 (M + H+}.
2R-(1 R',3S')-2-(2-Propoxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid 1. Dess-Martin periodinane \ ~ 2. NaC102 ~O O O O
O ~ 11N Y 'p ~ O
'O ~O
180 mg of Dess-Martin periodinane are added to 90 mg of 2R-(1 R',3S')-2-propoxy-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propan-1-0l in 1.5 ml of dichloromethane, and the mixture is stirred at room temperature for 2 h. 41 mg of Na2S203 in 3 ml of 5% strength NaHC03 solution are then added, and the mixture is stirred at room temperature for 10 min. The organic phase is separated off, dried over MgS04 and concentrated. The residue is taken up in 2 ml of acetonitrile, and 1.5 ml of 0.65 M NaH2P04 solution and 48 Nl of 35°l° strength H202 solution are added. At 0°C, 30 mg of NaCl02 in 2 ml of water are added dropwise over a period of 1 h. The mixture is stirred at this temperature for 3 h. Na2S03 solution, 10°l° strength HCI and 10 ml of CH2C12 are then added, the phases are separated and the organic phase is dried over MgS04 and concentrated. Purification of the residue by HPLC gives 1.2 mg of 28-(1 R',3S')-2-(2-methylpropoxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid.
Example 11:
2R-( 1 R',3S')-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propanoic acid O
O O ~ -O
O
i F F F
Using reaction conditions similar to those of example 10, 2S-(1R',3S')-1-(tert-butyldimethylsilanyloxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-trifluoromethylbenzyl bromide give 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-5 trifluoromethylbenzyloxy)propionic acid.
Example 12:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-methoxypropionic acid O
O O ~ ~OH
H3C~0 Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and methyl iodide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-methoxypropionic acid.
Example 13:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-tri-fluoromethylbenzyloxy)propanoic acid O
/ \ N ~ O OOH
O
O CHs F
F F
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-trifluoromethylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propanoic acid.
Example 14:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-tri-fluoromethylbenzyloxy)propanoic acid / \ i ° °~oH
O CHa \ ( F
F
Using reaction conditions similar to those of example 10, 1-(tert-butyldimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmeth-oxy)cyclohexyloxy]propan-2-of and 3-trifluoromethylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-tri-fluoromethylbenzyloxy)propanoic acid.
Example 15:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-methoxybenzyloxy)propanoic acid / \ i ° O~oH
O CHa \I
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 3-methoxybenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-methoxy-benzyloxy)propanoic acid.
Example 16:
3-[(1 R,3S)-3-(5-Methyl-2-m-tofyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2,5-dimethylbenzyloxy)propanoic acid O
O O' Y 'OH
'O
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2,5-dimethylbenzyl bromide give 3-[(1R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2,5-dimethylbenzyloxy)propanoic acid.
Example 17:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-methylbenzyloxy)propanoic acid 0 o~pH
o O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-methylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-methylbenzyloxy)propanoic acid.
Example 18:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-tert-butylbenzyloxy)propanoic acid $$
0 o~oH
O
O CHs Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-tert-butylbenzyl bromide give 3-[(1R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-tert-butyl-benzyloxy)propanoic acid.
Example 19:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-trifluoromethylbenzyloxy)propanoic acid 0 o~oH
o CH3 F
F~ F
Using reaction conditions similar to those. of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-trifluoromethylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-trifluoromethylbenzyloxy)propanoic acid.
Example 20:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-chlorothien-5-ylmethoxy)propionic acid 0 o~oH
O CHs / ~S
CI
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-chlorothien-5-ylmethyl chloride give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-chlorothien-5-ylmethoxy)propionic acid.
Example 21:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-butynoxy)propionic acid 0 o~oH
O CHa cH3 Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-butynyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-butynoxy)propionic acid.
Example 22:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-propynoxy)propionic acid O OI Y 'OH
IO
cH
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-propynyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-propynoxy)-propionic acid.
Example 23:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-pentynoxy)propionic acid / O OOH
O
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-pentynyl bromide give 3-[(1 R,3S)-3-(5-5 methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-pentynoxy)-propionic acid.
Example 24:
3-[( 1 R, 3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-10 propenoxy)propionic acid OH
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and allyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-15 m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-propenoxy)propionic acid.
Example 25:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-20 phenyl-2-propenoxy)propionic acid 0 o~oH
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[( 1 R, 3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 3-phenyl-2-propenyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-phenyl-2-propenoxy)propionic acid.
Example 26:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-methyl-2-propenoxy)propionic acid j O OOH
O
O CHs Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and isobutenyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazoi-4-ylmethoxy)cyclohexyloxy]-2-(2-methyl-2-propen-oxy)propionic acid.
Example 27;
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-benzyloxypropionic acid 0 o~oH
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and benzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-benzyloxypropionic acid.
Example 28:
Benzyl [(1 S,3R)-3-aliyloxycyclohex-1-yl] ether 0 o I ~ o o~
/ i Under an atmosphere of argon, 12 g of sodium hydride (55-65%) are initially charged in 200 ml of abs DMF and stirred at RT for 10 min. With ice cooling, 54 g of benzyl [(1S,3R)-3-hydroxycyclohex-1-y1] ether in 70 ml of DMF are added dropwise. The mixture is stirred at RT for 90 min. With ice cooling, 50 g of allyl bromide are slowly added dropwise. After the addition is complete, the mixture is stirred at 45°C for 1 h. According to TLC, the reaction has gone to completion. The reaction solution is quenched with 15 ml of iPrOH, diluted with water and saturated NaCI solution and extracted with MTBE. The combined organic phases are washed with water and NaCI solution, dried over MgS04 and concentrated. This gives 60 g of benzyl [(1S,3R)-3-allyloxycyclohex-1-yl] ether as a light-beige oil.
C16H2202 (246.35), MS (ESI): 247 (M + H+).
(1S,3R)-3-Allyloxycyclohex-1-yl benzoate O
O O
Analogously to benzyl (1S,3R)-3-allyloxycyclohex-1-yl ether, (1S,3R)-3-hydroxycyclohex-1-yl benzoate and allyl bromide give (1 S,3R)-3-allyloxycyclohex-1-yl benzoate. C16H2003 (260.37), MS (ESI): 261 (M + H+).
Allyl (1 R,3S)-3-trityloxymethylcyclohex-1-yl ether /
Analogously to benzyl (1S,3R)-3-allyloxycyclohex-1-yl ether, (1R,3S)-3-trityloxymethyicyclohexanol and allyl bromide give allyl (1 R,3S)-3-trityioxymethylcyclohex-1-yl ether.
(2R/2S)-3-[(1S,3R)-3-Benzyloxycyclohexyloxy]propane-1,2-diol DABCO
NMO
Os04 acetone water O O~ ~ ~ O O~O
/ O
At 0°C, 6.8 g of DABCO, 42.8 g of NMO and 8.0 mt of osmium tetroxide solution (2.5% in tert-butanoi) are added successively to 60 g of benzyl (1S,3R)-3-allyloxycyclohex-1-yl ether in 200 ml of acetonelwater (10:1).
The solution is stirred at RT overnight. After 24 h, another 5 ml of osmium tetroxide solution are added, and the solution is stirred at RT overnight. The reaction is then complete. Sodium sulfite solution and water are added, and the mixture is extracted with dichloromethane. The organic phase is dried over Na2S04 and concentrated, which gives 65 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol as a brown oil. C16H24O4 (280.37), MS (ESI): 281 (M + H+).
(2R/2S)-3-[(1 R,3S)-1-Benzoyloxycyclohex-3-yloxy]propane-1,2-diol O
O O~O
~ O
Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol, (1S,3R)-3-hydoxycyclohex-1-yl benzoate, NMO, DABCO and osmium tetroxide give (2R/2S)-3-[(1 R,3S)-1-benzoyloxycyclohex-3-yloxy]propane-1,2-diol. C16H2205 (294.35), MS (ESI): 295 (M + H+).
(2R/2S)-3-[(1 R,3S)-3-Trityloxymethylcyclohexyloxy]propane-1,2-diol O
O
o Analogously to (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol, allyl (1R,3S)-3-trityloxymethylcyclohex-1-yl ether, NMO, DABCO and osmium tetroxide give ((2R/2S)-3-[(1 R,3S)-3-trityloxymethylcyclohexyloxy]-propane-1,2-diol.
(2R/2S)-3-[(1 S,3R)-3-Benzyloxycyclohexyloxy]-2-hydroxypropyl tert-butyl-diphenylsilyl ether imidazole TBDPSCI
~ DMF
o' V 'o 0 ~
o' v 'o o' \ /
i o 20 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol are dissolved in 100 ml of DMF, 12 g of imidazole and then 20.6 g of TBDPSCI
are added and the mixture is stirred at RT. After 3 h, the reaction is complete. The solution is diluted with water/saturated NaCI solution and extracted with MTBE and the organic phase is dried over MgS04 and concentrated, which gives 35 g of (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether as a yellow oil. C32H42O4Si (518.78), MS (ESI): 519 (M + H+).
(2R/2S)-3-[(1 R,3S)-1-Benzoyloxycyclohex-1-yloxy]-2-hydroxypropyl tert-butyldimethylsilyl ether O
~ O O~p.Si-O
Analogously to (2R/2S)-3-[(1S,3R)-3-benzoyloxycyclohex-1-yloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1R,3S)-1-benzoyloxycyclohex-3-yloxy]propane-1,2-diol, imidazole and TBDMSCI
give (2R/2S)-3-[(1 S,3R)-1-benzoyloxycyclohex-1-yloxy]-2-hydroxypropyl tert-butyldimethylsilyl ether. C22H36O5Si (408.62), MS (ESI): 409 (M + H+).
(2R/2S)-3-[(1 R,3S)-3-Trityloxymethylcyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether i 0 0 o.s~ \ /
w o i U
Analogously to (2RI2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-hydroxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 R,3S)-3-trityloxymethyl-cyclohexyloxy]propane-1,2-diol, imidazole and TBDPSCI give (2R/2S)-3-5 [(1 R,3S)-3-trityloxymethylcyclohexyloxy]-2-hydroxypropyl tert-butyldiphenyl-silyl ether.
(2R/2S)-3-[(1S,3R)-3-Benzyloxycyclohexyloxy]-2-methoxypropyl tert-butyl-diphenylsilyl ether I
I \ Mel KOtBu THF
~ si --~ \ O O O~Si \ O_ v 'O O' ~ ~ I
I, 10 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and 8.5 g of iodomethane are dissolved in 100 ml of THF. At RT, 3.3 g of KOtBu are added, and the suspension is stirred at RT
for 1 h. Saturated NH4C1 solution and water are then added, and the solution is extracted with MTBE. The combined organic phases are dried over MgS04 and concentrated. The residue is chromatographed on silica gel (heptane/ethyl acetate 5:1 -~ 1:1 ), which gives 7.2 g of (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether as a light-yellow oil.
(2R/2S)-3-[(1 S,3R)-3-Benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldi-phenylsilyl ether i 0 0 o.s~ \ /
i Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1S,3R)-3-benzyloxy-cyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and iodoethane give (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether.
(2RI2S)-3-[(1 S,3R)-3-Benzyloxycyclohexyloxy]-2-allyloxypropyl tert-butyl-diphenylsilyl ether i w 0 0 o,s~ ~ /
i Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilylether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-hydroxypropyl tert-butyldiphenylsilylether and allyl bromide give (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-allyloxypropyl tert-butyl-diphenylsilyl ether.
(2R/2S)-3-[( 1 S, 3R)-3-Benzyloxycyclohexyloxy]-2-(2-methyl-2-propenloxy)-propyl tert-butyldiphenylsilyl ether i 0 0 o,s~
i Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and isobutenyl bromide give (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-(2-methyl-2-propenloxy)propyl tert-butyldiphenylsilyl ether.
(2R/2S)-3-[(1 R,3S)-3-Benzoyloxycyclohex-1-yloxy]-2-(4-trifluoromethyl-benzyloxy)propyl tert-butyldimethylsilyl ether O O~O~Si-O
F
F F
Analogously to (2R/2S)-3-[(1S,3R)-3-benzoyloxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether, (2R/2S)-3-[(1R,3S)-1-benzoyloxycyclohex-3-yloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and 4-trifluoromethylbenzyl bromide give (2R/2S)-3-[(1 R,3S)-3-benzoyl-oxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy)propyl tert-butyldi-methylsilyl ether.
(2R/2S)-3-[(1 R,3S)-3-Trityloxymethylcyclohexyloxy]-2-(4-trifluoromethyl-benzyloxy}propyl tert-butyldiphenylsilyl ether i O O O.Si O
F
F F
Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1R,3S)-3-trityloxymethyl-cyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and 4-trifluoro-methylbenzyl bromide give (2R/2S)-3-[(1 R,3S)-3-trityloxymethylcyclohexyl oxy]-2-(4-trifluoromethylbenzyloxy)propyl tert-butyldiphenylsilyl ether.
(2R/2S)-3-[(1S,3R)-3-Hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldi-phenylsilyl ether Hz / Pd/C /
MeOH
0 0 o's~ ~ ~ ' s.
0 0 0' ow 7.2 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether are dissolved in 40 ml of methanol, 4 g of Pd/C
(10%) are added and the mixture is hydrogenated at RT and a super-atmospheric pressure of 5 bar for 15 h. The catalyst is filtered off, the residue is washed with dichloromethane and the filtrate is concentrated, which gives 6.0 g of (2RI2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-meth-oxypropyl tert-butyldiphenylsilyl ether as a colorless oil. C26H3804Si (442.68), MS (ESI): 443 (M + H+).
(2R/2S)-3-[(1S,3R)-3-Hydroxycyclohexyloxy]-2-ethoxypropyl tent-butyldi-phenylsilyl ether i 0 0 o.s~ ~
Analogously to (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether gives (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether. C27H4004Si (456.70), MS (ESI): 457 (M + H+).
(2R/2S)-3-[(1 R,3S)-3-Hydroxymethylcyclohexyloxy]-2-(4-trifluoromethyl-benzyloxy)propyl tert-butyldiphenylsilyl ether \ HCOOH, MTBE
--~ O
/ /
3.5 g of (2R/2S)-3-[(1 R,3S)-3-trityloxymethylcyclohexyloxy]-2-(4-trifluoro-methylbenzyloxy)propyl tert-butyldiphenylsilyl ether are dissolved in 100 ml of MTBE, 58 g of formic acid are added and the mixture is stirred at RT.
The solution is concentrated and the residue is chromatographed on silica gel, which gives 170 mg of (2R/2S)-3-[(1 R,3S)-3-hydroxymethylcyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propyl tert-butyldi-phenylsilyl ether as a colorless oil.
(2R/2S)-3-((1 S,3R)-3-Hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldi-phenylsilyl ether 0 0 o'S~ \ /
Analogously to (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1S,3R)-3-benzyl-oxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether gives (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldi-phenylsilyl ether.
C28H4204Si (470.73), MS (ESI): 471 (M + H+) (2R/2S)-3-[(1S,3R)-3-Hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldi-phenylsilyl ether i 0 0 o.s~ \ /
Analogously to (2R/2S)-3-((1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether gives (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether. C29H4404Si (484.76), MS (ESI): 485 (M + H+).
(2R/2S)-3-[(1 R,3S)-1-Hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyl-oxy) tert-butyldimethylsilyl ether MeOH
O O~O.Si- ~ O O~ ~O.Si-/ O
/ ( /
F F
F F F F
4.6 g of (2R/2S)-3-[(1S,3R)-1-benzoyloxycyclohex-3-yloxy]-2-(4-trifluoro-methoxybenzyloxy) tert-butyldimethylsilyl ether are dissolved in 20 ml of methanol, 2.2 g of K2C03 are added and the mixture is stirred at RT for 72 h. The K2C03 is filtered off, the residue is washed with methanol and the filtrate is concentrated, which gives 0.85 g of (2R/2S)-3-[(1 R,3S)-3-hydroxycyclohexyloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether as a colorless oil. C23H37F304Si (462.63), MS (ESI): 463 (M + H+).
2-Methoxy-3-[(1 R,3S)-3-(5-methyl-2-phenyloxazol-4-ylmethoxy)cyclohexyl-oxy]propanoic acid ~ci o i O O~O
+ Si O _ N
O O~O~ ~ ~ ,O
O
i 100 mg of (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether are dissolved in 2 ml of THF, and 83 mg of 2-phenyl-5-methyloxazol-4-ylmethyl chloride and 51 mg of KOtBu are added successively. At RT, the reaction mixture is shaken overnight.
214 mg of TBAF are added, and the suspension is allowed to stand overnight. After addition of water and MBTE, the organic phase is separated off and concentrated. The residue is taken up in acetone, and 1 ml of 1.92 M Jones reagent is added. The reaction solution is shaken overnight. The solution is diluted with 3 ml of water and poured onto an extraction cartridge (kieselguhr, for 20 ml aqueous phases). The product is then eluted with ethyl acetate and the solution obtained is concentrated and purified by HPLC. This gives 5 mg of 2-methoxy-3-[(1 R,3S)-3-(5-methyl-2 phenyloxazol-4-ylmethoxy)cyclohexyloxy]propanoic acid as a yellow oil.
Example 29:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid HsC O
O~ O O OH
N H3C~0 F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 30:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid HsC O
O~O O OH
'N H3C~0 F
O~F
F
Using reaction conditions similar to those of example 28, (2R12S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid Example 31:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid O~O O OH
N H3C~0 F \
F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 32:
2-Methoxy-3-{( 1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid O~O O OH
'N
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid Example 33:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,6-dimethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O O ~ ~OH
H3C ~ N
HsC O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,6-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 34:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O
O O ~ ~OH
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 35:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-naphthyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid O =~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-naphthyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-naphthyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 36:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid O~O O OH
'N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 37:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid O~O O_ Y 'OH
'N
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-biphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 38:
2-Methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid HsC O
~O O ~ ~OH
N ,O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 39:
2-Methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid HsC O
O ~~ ~O O ~ ~OH
'N H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 40:
2-Methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O
O O ~ ~OH
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 41:
2-Methoxy-3-f (1 R,3S)-3-[5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid HsC O
~O O ~ ~OH
H3C ~ N ,O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2,6-methylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 42:
3-[(1 R,3S)-3-(5-Methyl-2-phenyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-phenyloxazol-4-ylmethyl iodide give 3-[(1 R,3S)-3-(5-methyl-2-phenyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid.
Example 43:
3-[(1 R,3S)-3-(5-Methyl-2-(3-tolyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid HsC O
~O O ~ ~OH
~N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-tolyl)oxazol-4-ylmethyl iodide give 3-[(1 R,3S)-3-(5-methyl-2-(3-tolyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid.
Example 44:
3-{(1 R,3S)-3-[5-Methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether 2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 45:
3-{(1 R,3S)-3-[5-Methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid O ~~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy~-2-pro-poxypropionic acid.
Example 46:
3-{(1 R,3S)-3-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid O~O O OH
'N O
/ HsC
F
F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-~(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 47:
3-f (1 R,3S)-3-[5-Methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid O~O O OH
'' N O
Using reaction conditions similar to those of example 28, (2RI2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-propoxy-propionic acid.
Example 48:
3-{(1 R,3S)-3-[5-Methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid O~O OI Y 'OH
'N 'O
F F ~ ~ H3C
~O
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 3-~(1 R,3S)-3-[5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 49:
3-{(1 R,3S)-3-[5-Methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid O~O O' Y 'OH
-N fO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 3-f (1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxyJcyclohexyloxy~-2-propoxypropionic acid.
Example 50:
3-{(1 R,3S)-3-[5-Methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxyJ-cyclohexyloxy}-2-propoxypropionic acid OH
r Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-((1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 51:
3-{(1 R,3S)-3-[5-Methyl-2-(2-naphthylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid ~O O ~ 'OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyi tert-butyldiphenylsilyl ether and 2-(2-naphthyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(2-naphthylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-propoxy-propionic acid.
Example 52:
3-{(1R,3S)-3-[5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid O~O O OH
'N O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 53:
3-{(1 R,3S)-3-[5-Ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid HsC O
O ~~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 54:
3-{(1 R,3S)-3-[5-Ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid HsC O
O O ~ ~OH
'N O
Using reaction conditions similar to those of example 28, (2RI2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 55:
3-{(1 R,3S)-3-[5-Ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid O \ OH
rN
F
hl3L
F F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid.
Example 56:
3-{(1 R,3S)-3-[5-Ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid HsC 1 ~ O
'O' v -O' ~ 'OH
H3C ~ N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 57:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O ~~ ~O O ~ ~OH
'N /O
C(H3 F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 58:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O~O O OH
'N /O
CrH3 F
O~F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 59:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O~O O OH
'N /O
F
F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 60:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O~O O' Y 'OH
N ~'O
F F
~O
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-~(1 R,3S)-3-[5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 61:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid ~O OOH
'O
CrH3 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 62:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O f~ ~O O ~ ~OH
F
FF
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 63:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid HsC O
O~O O OH
'N 'O
CrH3 Using reaction conditions similar to those of example 28, (2R12S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 64:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-biphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 65:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-tolyl)oxazol-4-ylmethoxy)cyclohexyl-oxy]propionic acid O O ~ ~OH
~N ~O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-tolyl)oxazol-4-ylmethoxy)cyclohexyl-oxy]propionic acid.
Example 66:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid HaC O
O ~ O OI Y 'OH
~N ~IO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)cyclohexyloxy]propionic acid.
Example 67:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy)cyclohexyloxy]propionic acid HsC O
~O O ~ ~OH
'N 'O
F ICrH3 F F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]propionic acid.
Example 68:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid HsC~ O
O ~~ ~O O ~ ~OH
H3C ~ N /O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid.
Example 69:
3-f (1 R,3S)-3-[5-Ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy~-2-propoxypropionic acid HaC O
O ~ O OI Y 'OH
'_ N IO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 70:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-phenyloxazol-4-ylmethoxy]cyclohexyl-oxy}propionic acid HsC O
p ~~ ~O O ~ OOH
O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxyJ-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-phenyloxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-phenyloxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 71:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid HsC O
~O O ~ ~OH
'N /O
ICrH3 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-methylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methylphenyl)oxazol-4-ylmethoxyJ-cyclohexyloxy}propionic acid.
Example 72:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 73:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid O~O O OH
'N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-~(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 74:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-naphthyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tent-butyldiphenylsilyl ether and 5-methyl-2-(2-naphthyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-naphthyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 75:
3-((1 R,3S)-3-[5-Ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid HsC O
~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2RI2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxyjcyclohexyl-oxy}-2-propoxypropionic acid.
Example 76:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyj-2-(4-trifluoromethylbenzyloxy)propionic acid O chiral / \ N ~ O OOH
O
O CHs i F
F F
Separation of 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyj-2-(4-trifluoromethylbenzyloxy)propanoic acid (example 13) by chiral HPLC affords, in addition to enantiomerically pure (S)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyj-2-(4-trifluoromethylbenzyloxy)propionic acid (example 10), (R)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyioxyj-2-(4-trifluoromethyl-benzyloxy)propionic acid.
Example 77:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-yl-methoxy)cyclohexyloxyj-2-(4-trifluoromethyibenzyloxy)propionic acid O OOH
F O~ O
F
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(3-trifluoromethylphenyl)-oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 78:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid O O' Y 'OH
O~ 'O
O CHs F~--F
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4.-ylmethyl iodide give (R)-3-((1 R,3S)-3-(5-methyl-2-(4-trifluoromethoxy-phenyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-frifluoromethylbenzyloxy)-propionic acid.
Example 79:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid H3C ~ ~ j I O O' Y 'OH
H3C O~ 'O
~3 F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give (R)-3-((1 R,3S)-3-(5-methyl-2-(4-isopropylphenyl)-oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 80:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(2-naphthyl)oxazol-4-ylmethoxy)cyclohexyl-oxy]-2-(4-trifluoromethylbenzyloxy)propionic acid I O OOH
O~ O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(2-naphthyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(2-naphthyl)oxazol-4-ylmethoxy)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 81:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid H3C ~ ~ / ~ O O' Y 'OH
~O IO
CHs F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give (R)-3-((1 R,3S)-3-(5-methyl-2-(4-methylphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 82:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid 'F O
F
F, 'p ~ ~ N ~ O OOH
O~ O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(4-trifluoromethoxy-phenyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)-propionic acid.
Example 83:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid F F
O OOH
F O~ O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(3-trifluoromethylphenyl)-oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 84:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid O OOH
F p~ O
F CHa F
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(3-methoxyphenyl)oxazol-4-yl-methoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 85:
3-{(1 R,3S)-3-[5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-isobutoxypropionic acid ~O O ~ ~OH
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether and 2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxyJ-cyclohexyloxy}-2-isobutoxypropionic acid.
Example 86:
3-{(1 R,3S)-3-[5-Methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxyJcyclohexyl-oxy}-2-isobutoxypropionic acid O ~~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether and 2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-isobut-oxypropionic acid.
Example 87:
3-{(1 R,3S)-3-[5-Methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-isobutoxypropionic acid O~O O OH
'N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsiiyl ether and 2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-isobut-oxypropionic acid.
Example 88:
3-{(1 R,3S)-3-[5-Methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-isobutoxypropionic acid O~O O' Y 'OH
-N IO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether and 2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-iso-butoxypropionic acid.
Example 89:
(2R12S)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid o~ ,s. \ ~ °
o~o i F
F F
333 mg of (2R/2S)-3-[(1 R,3S)-3-hydroxymethylcyclohexyloxy]-2-(4-trifluoro-methylbenzyloxy)propyl tert-butyldiphenylsilyl ether are dissolved in MTBE, 125 mg of potassium tert-butoxide and 347 mg of 5-methyl-2-(3-methylphenyl)oxazol-4-ylmethyl iodide are added successively and the mixture is stirred at RT. After the reaction has gone to completion, water and MTBE are added and the organic phase is separated off, dried over MgS04 and concentrated. The residue is chromatographed on silica gel (Flash-Master, heptane/ethyl acetate 1:0 ~ 1:1 -~ 0:1). The product-containing fractions are concentrated, the residue (420 mg) is dissolved in 10 ml of THF and 174 mg of TBAF are added. The mixture is stirred for 72 h, water and MTBE are then added and the organic phase is separated off, washed with NaCI solution, dried over MgS04 and concentrated. The residue is dissolved in 2 ml of acetone, 0.5 ml of 1.9M Jones reagent is added and the mixture is stirred at RT overnight. Water and MTBE are added, and the organic phase is then separated off, dried over MgS04 and concentrated. The residue is purified by HPLC, which gives 200 mg of (2R/2S)-3-((1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclo-hexyloxyJ-2-(4-trifluoromethylbenzyloxy)propionic acid. C30H34F3N06 (561.6), MS (ESI): 562 (M + H+).
(S)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclohexyl-oxy]-2-(4-trifluoromethylbenzyloxy)propionic acid OH
Separation of (2R/2S)-3-((1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid by chiral HPLC affords (2S)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
C30H34F3N06 (561.6), MS (ESI): 562 (M + H+).
Example 90:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclohexyl-oxy]-2-(4-trifluoromethylbenzyloxy)propionic acid o~oH
i F
1o F F
Separation of (2R/2S)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid by chiral HPLC gives (2R)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
C30H34F3N06 (561.6), MS (ESI): 562 (M + H+).
Example 91:
2-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]-3-(3-trifluoromethylphenyl)propionic acid o ~
Analogously to example 9, ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate and 3-bromobenzotrifluoride give 2-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]-3-(3-trifluoromethylphenyl)propionic acid.
Characterization of the examples by mass spectroscopy:
Example Empirical formula Monoisotope Found by MS
mass ESI as (M + H+) 1 C23H30FN05 419.49 420 2 C24H32FN05 433.52 434 3 C21 H26FN05 391.44 392 4 C22H28FN05 405.47 406 C23H29N05 399.49 400 6 C31 H40N2O5 520.67 521 7 C30H38N2O5 506.65 507 8 C23H31 N06 417.51 418 9 C29H34FN05 495.60 496 C24H33N06 431.53 432 11 C29H32F3N06 547.58 548 12 C22H29N06 403.48 404 13 C29H32F3N06 547.58 548 14 C29H32F3N06 547.58 548 C29H35N07 509.61 510 16 C30H37N06 507.63 508 17 C29H35N06 493.61 494 18 C32H41 N06 535.69 536 19 C29H32F3N06 547.58 548 C26H30CIN06S 520.05 521 21 C25H31 N06 441.53 442 22 C24H29NO6 427.50 428 23 C26H33N06 455.56 456 24 C24H31 N06 429.52 430 C30H35N06 505.62 506 26 C25H33N06 443.55 444 27 C28H33N06 479.58 480 28 C21 H27N06 389.45 390 29 C22H26F3N06 457.45 458 C22H26F3N07 473.45 474 31 C22H26F3N06 457.45 458 32 C22H29N06 403.48 404 33 C23H31 N06 417.51 418 34 C22H26F3N06 457.45 458 C25H29N06 439.51 440 36 C23H31 N06 417.51 418 37 C27H31 N06 465.55 466 38 C23H31 N07 433.51 434 39 C23H31 N06 417.51 418 40 C23H28F3N06 471.48 472 41 C24H33N06 431.53 432 42 C23H31 N06 417.51 418 43 C24H33N06 431.53 432 44 C24H30F3N07 501.50 502 45 C24H33N07 447.53 448 46 C24H30F3N06 485.51 486 47 C24H33N06 431.53 432 48 C24H30F3N07 501.50 502 49 C26H37N06 459.59 460 50 C24H30F3N06 485.51 486 51 C27H33N06 467.57 468 52 C24H30F3N06 485.51 486 53 C25H35N07 461.56 462 54 C25H35N06 445.56 446 55 C25H32F3N06 499.53 500 56 C26H37N06 459.59 460 57 C23H28F3N06 471.48 472 58 C23H28F3N07 487.48 488 59 C23H28F3N06 471.48 472 60 C23H28F3N07 487.48 488 61 C25H35N06 445.56 446 62 C23H28F3N06 471.48 472 63 C24H33N06 431.53 432 64 C28H33N06 479.58 480 65 C24H33N06 431.53 432 66 C26H37N06 459.59 460 67 C24H30F3N06 485.51 486 68 C25H35N06 445.56 446 69 C27H39N06 473.62 474 70 C22H29N06 403.48 404 71 C23H31 N06 417.51 418 72 C23H31 N07 433.51 434 73 C23H31 N06 417.51 418 74 C26H31 N06 453.54 454 75 C24H33N07 447.53 448 76 C29H32F3N06 547.58 548 77 C29H29F6N06 601.55 602 78 C29H29F6N07 617.55 618 79 C31 H36F3N06 575.63 576 80 C32H32F3N06 583.61 584 81 C29H32F3N06 547.58 548 82 C29H29F6N07 617.55 618 83 C29H29F6N06 601.55 602 84 C29H32F3N07 563.58 564 85 C25H32F3N06 499.53 500 86 C25H35N07 461.56 462 87 C25H35N06 445.56 446 88 C27H39N06 473.62 474 89 C30H34F3N06 561.60 562 90 C30H34F3N06 561.60 562 91 C29H32F3N05 531.58 532
R3 is (C1-C6)-alkyl;
W is CHifo=1;
X is (CH2)O, CH2-O-CH2;
Y1 is O;
Y2 is CH2;
n is 0, 1;
R4 is H;
R5 is H;
R6 is H;
R7 is H, (C1-C6)-alkyl, O-(C1-C6)-alkyl, (C1-C6)-alkyl-O-(C1-C6)-alkyl, O-(C2-C6)-aikenyl, O-(C2-C6)-alkynyl, CH2NR10R11, where alkyl, O-alkyl and alkenyl may be substituted by phenyl or (C5-C6)-heteroaryl, which in turn may be substituted by (C1 C6)-alkyl, O-(C1-C6)-alkyl, CF3;
R6 and R7 together with the carbon atom that carries them are (C3-C6)cycloalkyl;
R8 is H;
R 10 is (C 1-C6)-alkyl;
R11 is (C1-C6)-alkyl which is substituted by phenyl;
and their physiologically acceptable salts.
The alkyl, alkenyl and alkynyl radicals in the substituents R1, R2, R3, R4, R5 , R6, R7, R8, R9, R10, R11, R12 and R13 may be either straight-chain or branched.
Aryl means an aromatic carbocyclic mono- or bicyclic ring system which comprises 6 to 10 atoms in the ring or rings.
Heteroaryl is a mono- or bicyclic aromatic ring system having 4 to 11 ring members, in which at least one atom in the ring system is a heteroatom from the series N, O and S.
The compounds of the formula I comprise at least two centers of asymmetry and may comprise more in addition. The compounds of the formula I may therefore exist in the form of their racemates, racemic mixtures, pure enantiomers, diastereomers and mixtures of diastereomers.
The present invention encompasses all these isomeric forms of the compounds of the formula I. These isomeric forms can be obtained by known methods even if not specifically described in some cases.
Pharmaceutically acceptable salts are, because their solubility in water is greater than that of the initial or basic compounds, particularly suitable for medical applications. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloroic acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid, and of organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, malefic, malic, methanesulfonic, succinic, p-toluenesulfonic and tartaric acid. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as magnesium and calcium salts), and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediof), diethanolamine, lysine or ethyfenediamine.
Salts with a pharmaceutically unacceptable anion such as, for example, trifluoroacetate likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.
The term "physiologically functional derivative" used herein refers to any physiologically tolerated derivative of a compound of the formula I of the invention, for example an ester, which on administration to a mammal such as, for example, a human is able to form (directly or indirectly) a compound of the formula I or an active metabolite thereof.
Physiologically functional derivatives also include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be active or not.
The compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.
All references to "compound(s) of formula l" hereinafter refer to compounds) of the formula I as described above, and their salts, solvates and physiologically functional derivatives as described herein.
Use This invention relates further to the use of compounds of the formula I and their pharmaceutical compositions as PPAR ligands. The PPAR ligands of the invention are suitable as modulators of PPAR activity.
Peroxisome proliferator-activated receptors (PPAR) are transcription factors which can be activated by ligands and belong to the class of nuclear hormone receptors. There are three PPAR isoforms, PPARalpha, PPARgamma and PPARdelta, which are encoded by different genes (Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions: Motojima K, Cell Struct Funct. 1993 Oct; 18(5): 267-77).
Two variants of PPARgamma exist, PPARgamma~ and gamma2, which are the result of alternative use of promoters and differential mRNA splicing (Vidal-Puig et al. J. Clin. Invest., 97:2553-2561, 1996). Different PPARs have different tissue distribution and modulate different physiological functions. The PPARs play a key role in various aspects of the regulation of a large number of genes, the products of which genes are directly or indirectly crucially involved in lipid and carbohydrate metabolism. Thus, for example, PPARalpha receptors play an important part in the regulation of fatty acid catabolism or lipoprotein metabolism in the liver, while PPARgamma is crucially involved for example in regulating adipose cell differentiation. In addition, however, PPARs are also involved in the regulation of many other physiological processes, including those which are not directly connected with carbohydrate or lipid metabolism. The activity of different PPARs can be modulated by various fatty acids, fatty acid derivatives and synthetic compounds to varying extents. For relevant reviews about functions, physiological effect and pathophysiology, see:
Joel Berger et al., Annu. Rev. Med. 2002, 53, 409 - 435; Timothy Wilson et al. J. Med. Chem., 2000, Vol. 43, No. 4, 527-550; Steven Kliewer et al., Recent Prog Horm Res. 2001; 56: 239-63.
The present invention relates to compounds of the formula I suitable for modulating the activity of PPARs, especially the activity of PPARalpha and PPARgamma. Depending on the modulation profile, the compounds of the formula I are suitable for the treatment, control and prophylaxis of the indications described hereinafter, and for a number of other pharmaceutical applications connected thereto (see, for example, Joel Berger et al., Annu.
Rev. Med. 2002, 53, 409 - 435; Timothy Wilson et al. J. Med. Chem., 2000, Vol. 43, No. 4, 527-550; Steven Kliewer et al., Recent Prog Horm Res.
2001; 56: 239-63; Jean-Charles Fruchart, Bart Staels and Patrick Duriez:
PPARS, Metabolic Disease and Arteriosclerosis, Pharmacological Research, Vol. 44, No. 5, 345-52; 2001; Sander Kersten, Beatrice Desvergne & Walter Wahli: Roles of PPARs in health and disease, NATURE, VOL 405, 25 MAY 2000; 421-4; Ines Pineda Torra, Giulia 5 Chinetti, Caroline Duval, Jean-Charles Fruchart and Bart Staels:
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice, Curr Opin Lipidol 12: 2001, 245-254).
Compounds of this type are particularly suitable for the treatment and/or prevention of 10 1. - disorders of fatty acid metabolism and glucose utilization disorders - disorders in which insulin resistance is involved 2. Diabetes mellitus, especially type 2 diabetes, including the prevention of the sequelae associated therewith.
Particular aspects in this connection are - hyperglycemia, - improvement in insulin resistance, - improvement in glucose tolerance, - protection of the pancreatic 13 cells - prevention of macro- and microvascular disorders 3. Dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary heart disease, cerebrovascular disorders etc, especially those (but not restricted thereto) which are characterized by one or more of the following factors:
- high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, - low HDL cholesterol concentrations - low ApoA lipoprotein concentrations - high LDL cholesterol concentrations - small dense LDL cholesterol particles high ApoB lipoprotein concentrations 4. Various other conditions which may be associated with the metabolic syndrome, such as:
- obesity (excess weight), including central obesity - thromboses, hypercoagulable and prothrombotic states (arterial and venous) - high blood pressure - heart failure such as, for example (but not restricted thereto), following myocardial infarction, hypertensive heart disease or cardiomyopathy 5. Other disorders or conditions in which inflammatory reactions or cell differentiation may for example be involved are:
- atherosclerosis such as, for example (but not restricted thereto), coronary sclerosis including angina pectoris or myocardial infarction, stroke vascular restenosis or reocclusion - chronic inflammatory bowel diseases such as, for example, Crohn's disease and ulcerative colitis - pancreatitis - other inflammatory states - retinopathy - adipose cell tumors - lipomatous carcinomas such as, for example, liposarcomas - solid tumors and neoplasms such as, for example (but not restricted thereto), carcinomas of the gastrointestinal tract, of the liver, of the biliary tract and of the pancreas, endocrine tumors, carcinomas of the lungs, of the kidneys and the urinary tract, of the genital tract, prostate carcinomas etc - acute and chronic myeloproliferative disorders and lymphomas angiogenesis - neurodegenerative disorders - Alzheimer's disease - multiple sclerosis - Parkinson's disease - erythemato-squamous dermatoses such as, for example, psoriasis - acne vulgaris - other skin disorders and dermatological conditions which are modulated by PPAR
- eczemas and neurodermitis - dermatitis such as, for example, seborrheic dermatitis or photodermatitis - keratitis and keratoses such as, for example, seborrheic keratoses, senile keratoses, actinic keratosis, photo-induced keratoses or keratosis follicularis - keloids and keloid prophylaxis - warts, including condylomata or condylomata acuminata human papilloma viral (HP~ infections such as, for example, venereal papillomata, viral warts such as, for example, molluscum contagiosum, leukoplakia - papular dermatoses such as, for example, Lichen planus - skin cancer such as, for example, basal-cell carcinomas, melanomas or cutaneous T-cell lymphomas - localized benign epidermal tumors such as, for example, keratoderma, epidermal naevi - chilblains - high blood pressure - syndrome X
- polycystic ovary syndrome (PCOS) - asthma - osteoarthritis - lupus erythematosus (LE) or inflammatory rheumatic disorders such as, for example, rheumatoid arthritis - vasculitis - wasting (cachexia) - gout - ischemia/reperfusion syndrome - acute respiratory distress syndrome CARDS) Formulations The amount of a compound of formula 1 necessary to achieve the desired biological effect depends on a number of factors, for example the specific compound chosen, the intended use, the mode of administration and the clinical condition of the patient. The daily dose is generally in the range from 0.001 mg to 100 mg (typically from 0.01 mg to 50 mg) per day and per kilogram of bodyweight, for example 0.1-10 mglkg/day. An intravenous dose may be, for example, in the range from 0.001 mg to 1.0 mglkg, which can suitably be administered as infusion of 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Thus, ampules for injections may contain, for example, from 1 mg to 100 mg, and single-dose formulations which can be administered orally, such as, for example, capsules or tablets, may contain, for example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg. For the therapy of the abovementioned conditions, the compounds of formula I may be used as the compound itself, but they are preferably in the form of a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not harmful for the patient's health.
The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient. Other pharmaceutically active substances may likewise be present, including other compounds of formula I. The pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which essentially consist of mixing the ingredients with pharmacologically acceptable carriers andlor excipients.
Pharmaceutical compositions of the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be treated and on the nature of the compound of formula I used in each case. Coated formulations and coated slow-release formulations also belong within the framework of the invention. Preference is given to acid- and gastric juice-resistant formulations. Suitable coatings resistant to gastric juice comprise cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
Suitable pharmaceutical preparations for oral administration may be in the form of separate units such as, for example, capsules, cachets, suckable tablets or tablets, each of which contain a defined amount of the compound of formula J; as powders or granules, as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. The compositions are generally produced by uniform and homogeneous mixing of the active ingredient with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients.
Compressed tablets can be produced by tableting the compound in free-flowing form such as, for example, a powder or granules, where appropriate mixed with a binder, glidant, inert diluent and/or one (or more) surface-active/dispersing agents) in a suitable machine. Molded tablets can be produced by molding the compound, which is in powder form and is moistened with an inert liquid diluent, in a suitable machine.
Pharmaceutical compositions which are suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula I with a flavoring, normally sucrose and gum arabic or tragacanth, and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
Pharmaceutical compositions suitable for parenteral administration comprise preferably sterile aqueous preparations of a compound of formula 1, which are preferably isotonic with the blood of the intended recipient.
These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from 0.1 to 5% by weight of the active compound.
Pharmaceutical compositions suitable for rectal administration are preferably in the form of single-dose suppositories. These can be produced by mixing a compound of the formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
Pharmaceutical compositions suitable for topical use on the skin are preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances.
The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an aqueous solution which is buffered where appropriate, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 5 1 % to 35%, preferably about 3% to 15%. A particular possibility is for the active ingredient to be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
The compounds of the formula I are distinguished by favorable effects on 10 metabolic disorders. They beneficially influence lipid and sugar metabolism, in particular they lower the triglyceride level and are suitable for the prevention and treatment of type II diabetes and arteriosclerosis and the diverse sequalae thereof.
15 Combinations with other medicaments The compounds of the invention can be administered alone or in combination with one or more further pharmacologically active substances which have, for example, favorable effects on metabolic disturbances or disorders frequently associated therewith. Examples of such medicaments are 1. medicaments which lower blood glucose, antidiabetics, 2. active ingredients for the treatment of dyslipidemias, 3. antiatherosclerotic medicaments, 4. antiobesity agents, 5. antiinflammatory active ingredients 6. active ingredients for the treatment of malignant tumors 7. antithrombotic active ingredients 8. active ingredients for the treatment of high blood pressure 9. active ingredients for the treatment of heart failure and 10. active ingredients for the treatment and/or prevention of complications caused by diabetes or associated with diabetes.
They can be combined with the compounds of the invention of the formula I
in particular for a synergistic improvement in the effect. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
Examples which may be mentioned are:
Antidiabetics Suitable antidiabetics are disclosed for example in the Rote Liste 2001, chapter 12 or in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001. Antidiabetics include all insulins and insulin derivatives such as, for example, Lantus~ (see www.lantus.com) or Apidra~, and other fast-acting insulins (see US 6,221,633), GLP-1 receptor modulators as described in WO 01/04146 or else, for example, those disclosed in WO 98108871 of Novo Nordisk A/S.
The orally effective hypoglycemic active ingredients include, preferably, sulfonylureas, biguanides, meglitinides, oxadiazolidinediones', thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, DPP-IV inhibitors, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO 99/03861, insulin sensitizers, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds which alter lipid metabolism and lead to a change in the blood lipid composition, compounds which reduce food intake, PPAR and PXR
modulators and active ingredients which act on the ATP-dependent potassium channel of the beta cells.
In one embodiment of the invention, the compounds of the formula I are administered in combination with insulin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with substances which influence hepatic glucose production such as, for example, glycogen phosphorylase inhibitors (see: WO 01194300, WO 02/096864, WO 03/084923, WO
03/084922, WO 03/104188).
In one embodiment, the compounds of the formula I are administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
In one embodiment, the compounds of the formula I are administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a biguanide such as, for example, metformin.
In a further embodiment, the compounds of the formula I are administered in combination with a meglitinide such as, for example, repaglinide.
In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione such as, for example, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione.
In one embodiment, the compounds of the formula I are administered in combination with a DPPIV inhibitor as described, for example, in W098/19998, W099/61431, W099/67278, W099/67279, W001 /72290, WO 02/38541, W003/040174, in particular P 93/01 (1-cyclopentyl-3-methyl-1-oxo-2-pentanammonium chloroide), P-31/98, LAF237 (1-[2-[3-hydroxyadamant-1-ylamino)acetyl]pyrrolidine-2-(S)-carbonitrile), TS021 ((2S, 4S)-4-fluoro-1-[[(2-hydroxy-1,1-dimethylethyl)amino]-acetyl]pyrrolidine-2-carbonitrile monobenzenesulfonate).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARgamma agonist such as, for example, rosiglitazone, pioglitazone.
In one embodiment, the compounds of the formula I are administered in combination with compounds with an inhibitory effect on SGLT-1 and/or 2, as disclosed directly or indirectly for example in PCT/EP03/06841, PCTIEP03/13454 and PCT/EP03/13455.
In one embodiment, the compounds of the formula I are administered in combination with an o-glucosidase inhibitor such as, for example, miglitol or acarbose.
In one embodiment, the compounds of the formula I are administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
Lipid modulators In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor such as lovastatin, fluvastatin, pravastatin, simvastatin, ivastatin, itavastatin, atorvastatin, rosuvastatin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid reabsorption inhibitor (see, for example, US 6,245,744, US 6,221,897, US 6,277,831, EP 0683 773, EP
0683 774).
In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine, colesevelam.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor as described for example in WO 0250027, or ezetimibe, tiqueside, pamaqueside.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an LDL receptor inducer (see, for example, US 6,342,512).
In one embodiment, the compounds of the formula I are administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, carob/Caromax~ (Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES 1N THERAPY (2001 Sep-Oct), 18(5), 230-6.) Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, (ndustriepark Hoechst, 65926 Frankfurt/Main)). Combination with Caromax~ is possible in one preparation or by separate administration of compounds of the formula I and Caromax~. Caromax~ can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPARalpha agonist.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a mixed PPAR alpha/gamma agonist such as, for example, AZ 242 (Tesaglitazar, (S)-3-(4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl)-2-ethoxypropionic acid), BMS
298585 (N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine) or as described in WO 99/62872, WO 99/62871, WO 01 /40171, WO 01 /40169, W096/38428, WO 01 /81327, WO 01 /21602, WO 03/020269, WO 00/64888 or WO 00/64876.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate such as, for example, fenofibrate, gemfibrozil, clofibrate, bezafibrate.
In one embodiment of the invention, the compounds of the formula I are administered in combination with nicotinic acid or niacin.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, e.g. CP- 529, 414 (torcetrapib).
In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor such as, for example, implitapide.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP citrate lyase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor.
In one embodiment of the invention, the compounds of the formula I are administered in combination with a iipoprotein(a) antagonist.
Antiobesity agents In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor such as, for example, orlistat.
10 In one embodiment, the further active ingredient is fenfluramine or dexfentluramine.
In another embodiment, the further active ingredient is sibutramine.
In a further embodiment, the compounds of the formula I are administered 15 in combination with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A, et al., M.: Hormone and Metabolic Research (2001 ), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1-sulfonic acid {4-[(4-aminoquinazolin-2-ylamino)methyl]-20 cyclohexylmethyl}amide hydrochloroide (CGP 71683A)), MC4 agonists (e.g. 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4, 3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-amide; (WO 01/91752)), orexin antagonists (e.g. 1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea hydrochloroide (SB-334867-A)), H3 agonists (3-cyclohexyl-1-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropylamine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), urocortin agonists, (33 agonists (e.g. 1-(4-chloro-3-methanesulfonylmethy!phenyl)-2-[2-(2,3-dimethyl-1 H-indol-6-yloxy)ethylamino]-ethanol hydrochloroide (WO 01 /83451 )), MSH
(melanocyte-stimulating hormone) agonists, CCK-A agonists (e.g. ~2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525)), serotonin reuptake inhibitors (e.g. dexfenfluramine), mixed serotoninergic and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01 /09111 ), bombesin agonists, galanin antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing compounds (6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1 H-isoquinoline-2-carboxylic acid tertiary butyl ester (WO 01/85695)), TRH agonists (see, for example, EP 0 462 884), uncoupling protein 2 or 3 modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001 ), 26(9), 873-881 ), DA
agonists (bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO
00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or TR-~i agonists.
In one embodiment of the invention, the further active ingredient is leptin.
In one embodiment, the further active ingredient is dexamphetamine, amphetamine, mazindole or phentermine.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having effects on the coronary circulation and the vascular system, such as, for example, ACE inhibitors (e.g.
ramipril), medicaments which act on the angiotensin-renine system, calcium antagonists, beta blockers etc.
In one embodiment, the compounds of the formula I are administered in combination with medicaments having an antiinflammatory effect.
In one embodiment, the compounds of the formula I are administered in combination with medicaments which are employed for cancer therapy and cancer prevention.
It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is regarded as falling within the protection conferred by the present invention.
The activity of the compounds was tested as follows:
Determination of EC50 values of PPAR agonists in the cellular PPARalpha assay Principle The potency of substances which bind to human PPAR~ and activate in an agonistic manner is analyzed using a stably transfected HEK cell line (HEK= human embryo kidney} which is referred to here as PPARalpha reporter cell line. It contains two genetic elements, a luciferase reporter element (pOM-GAL4-Luc-Zeo) and a PPARalpha fusion protein (GR-GAL4-humanPPARo-LBD) which mediates expression of the luciferase reporter element depending on a PPARalpha ligand. The stably and constitutively expressed fusion protein GR-GAL4-humanPPARalpha-LBD binds in the cell nucleus of the PPARalpha reporter cell line via the GAL4 protein portion to the GAL4 DNA binding motifs 5'-upstream of the luciferase reporter element which is integrated in the genome of the cell line. There is only little expression of the luciferase reporter gene without addition of a PPARalpha ligand if fatty acid-depleted fetal calf serum (cs-FCS) is used in the assay. PPARD ligands bind and activate the PPAR~ fusion protein and thereby bring about expression of the luciferase reporter gene. The luciferase which is formed can be detected by means of chemiluminescence via an appropriate substrate.
Construction of the cell line The PPARalpha reporter cell line was prepared in 2 stages. Firstly, the luciferase reporter element was constructed and stably transfected into HEK cells. For this purpose, five binding sites of the yeast transcription factor GAL4 (each .5'-CGGAGTACTGTCCTCCGAG-3') were cloned in 5'-upstream of a 68 bp-long minimal MMTV promoter (Genbank Accession #
V01175). The minimal MMTV promoter section contains a CCAAT box and a TATA element in order to enable efficient transcription by RNA
polymerase I1. The cloning and sequencing of the GAL4-MMTV construct took place in analogy to the description of Sambraok J. et. al. (Molecular cloning, Cold Spring Harbor Laboratory Press, 1989). Then the complete Photinus pyralis gene (Genbank Accession # M15077) was cloned in 3'-downstream of the GAL4-MMTV element. After sequencing, the luceriferase reporter element consisting of five GAL4 binding sites, MMTV
promoter and luciferase gene was recloned into a plasmid which confers zeocin resistance in order to obtain the plasmid pOM-GAL4-Luc-Zeo. This vector was transfected into HEK cells in accordance with the statements in Ausubel, F.M. et al. (Current protocols in molecular biology, Vol. 1-3, John Wiley & Sons, Inc., 1995). Then zeocin-containing medium (0.5 mg/ml) was used to select a suitable stable cell clone which showed very low basal expression of the luceriferase gene.
In a second step, the PPARalpha fusion protein (GR-GAL4-humanPPARalpha-LBD was introduced into the stable cell clone described.
For this purpose, initially the cDNA coding for the N-terminal 76 amino acids of the glucocorticoid receptor (Genbank Accession # P04150) was linked to the cDNA section coding for amino acids 1-147 of the yeast transcription factor GAL4 (Genbank Accession # P04386). The cDNA of the ligand-binding domain of the human PPARalpha receptor (amino acids S167-Y468; Genbank Accession # S74349) was cloned in at the 3'-end of this GR-GAL4 construct. The fusion construct prepared in this way (GR-GAL4-humanPPARalpha-LBD) was recloned into the plasmid pcDNA3 (from Invitrogen) in order to enable constitutive expression therein by the cytomegalovirus promoter. This plasmid was linearized with a restriction endonuclease and stably transfected into the previously described cell clone containing the luciferase reporter element. The finished PPARalpha reporter cell line which contains a luciferase reporter element and constitutively expresses the PPARalpha fusion protein (GR-GAL4-human PPARalpha-LBD) was isolated by selection with zeocin (0.5 mg/ml) and 6418 (0.5 mglml).
Assay procedure The activity of PPARalpha agonists is determined in a 3-day assay which is described below:
Day 1 The PPAR~reporter cell line is cultivated to 80% confluence in DMEM
(# 41965-039, Invitrogen) which is mixed with the following additions: 10%
cs-FCS (fetal calf serum; #SH-30068.03, Hyclone), 0.5 mg/ml zeocin (#R250-01, Invitrogen), 0.5 mg/ml 6418 (#10131-027, Invitrogen), 1%
penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen). The cultivation takes place in standard cell culture bottles (# 353112, Becton Dickinson) in a cell culture incubator at 37°C in the presence of 5% C02. The 80%-confluent cells are washed once with 15 ml of PBS (#14190-094, Invitrogen), treated with 3 ml of trypsin solution (#25300-054, Invitrogen) at 37°C for 2 min, taken up in 5 ml of the DMEM described and counted in a cell counter. After dilution to 500.000 cells/ml, 35,000 cells are seeded in each well of a 96 well microtiter plate with a clear plastic base (#3610, Corning Costar). The plates are incubated in the cell culture incubator at 37°C and 5% C02 for 24 h.
Day 2 PPARalpha agonists to be tested are dissolved in DMSO in a concentration of 10 mM. This stock solution is diluted in DMEM (#41965-039, Invitrogen) which is mixed with 5% cs-FCS (#SH-30068.03, Hyclone), 2 mM L-glutamine (#25030-024, Invitrogen) and the previously described antibiotics (zeocin, 6418, penicillin and streptomycin).
Test substances are tested in 11 different concentrations in the range from 10 NM to 100 pM. More potent compounds are tested in concentration ranges from 1 NM to 10 pM or between 100 nM and 1 pM.
The medium of the PPARaipha reporter cell line seeded on day 1 is completely removed by aspiration, and the test substances diluted in medium are immediately added to the cells. The dilution and addition of the substances is carried out by a robot (Beckman FX). The final volume of the test substances diluted in medium is 100 NI per well of a 96 well microtiter plate. The DMSO concentration in the assay is less than 0.1 % v/v in order to avoid cytotoxic effects of the solvent.
Each plate was charged with a standard PPARalpha agonist, which was likewise diluted in 11 different concentrations, in order to demonstrate the functioning of the assay in each individual plate. The assay plates are incubated in an incubator at 37°C and 5% C02 for 24 h.
Day 3 The PPARalpha reporter cells treated with the test substances are removed from the incubator, and the medium is aspirated off. The cells are lyzed by pipetting 50 pl of Bright Glo reagent (from Promega) into each well of a 96 well microtiter plate. After incubation at room temperature in the dark for 10 minutes, the microtiter plates are measured in the luminometer (Trilux from Wallac). The measuring time for each well of a microtiter plate is 1 sec.
Evaluation The raw data from the luminometer are transferred into a Microsoft Excel file. Dose-effect plots and EC50 values of PPAR agonists are calculated using the XL.Fit program as specified by the manufacturer (IDBS).
The PPARalpha EC50 values for the compounds of Examples 1 to 91 in this assay are in the range from 0.6 nM to >10 NM.
5 The results for the activity of some compounds of the invention of the formula I are indicated in Table I below:
T~F,Ic 1 Example No. EC50 PPARalpha [nM~
18 1.5 25 6.2 47 0.8 81 0.6 10 It is evident from Table I that the compounds of the invention of the formula I activate the PPARalpha receptor and thus bring about for example in analogy to fibrates in clinical use a lowering of triglycerides in the body (see, for example, J.-Ch. Fruchard et al.: PPARS, Metabolic Disease and Atherosclerosis, Pharmacological Research, Vol. 44, No. 5, 345-52, 2001;
15 S. Kersten et al.: Roles of PPARs in health and disease, NATURE, VOL
405, 25 MAY 2000, 421-4; I. Pineda et al.: Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice, Curr Opin Lipidol 12: 2001, 245-254).
Determination of EC50 values of PPAR agonists in the cellular PPARgamma assay Principle A transient transfection system is employed to determine the cellular PPARgamma activity of PPAR agonists. It is based on the use of a luciferase reporter plasmid (pGL3basic-SxGAL4-TK} and of a PPARgamma expression plasmid (pcDNA3-GAL4-humanPPARgammaLBD). Both plasmids are transiently transfected into human embryonic kidney cells (HEK cells). There is then expression in these cells of the fusion protein GAL4-humanPPARgammaLBD which binds to the GAL4 binding sites of the reporter plasmid. In the presence of a PPARgamma-active ligand, the activated fusion protein GAL4-humanPPARgammaLBD induces expression of the luciferase reporter gene, which can be detected in the form of a chemiluminescence signal after addition of a luciferase substrate. As a difference from the stably transfected PPARalpha reporter cell line, in the cellular PPARy assay the two components (luciferase reporter plasmid and PPARgamma expression plasmid) are transiently transfected into HEK
cells because stable and permanent expression of the PPARgamma fusion protein is cytotoxic.
Construction of the plasmids The luciferase reporter plasmid pGL3basic-SxGAL4-TK is based on the vector pGL3basic from Promega. The reporter plasmid is prepared by cloning five binding sites of the yeast transcription factor GAL4 (each binding site with the sequence 5'-CTCGGAGGACAGTACTCCG-3'), together with a 160 bp-long thymidine kinase promoter section (Genbank Accession # AF027128) 5'-upstream into pGL3basic. 3'-downstream of the thymidine kinase promoter is the complete luciferase gene from Photinus pyralis (Genbank Accession # M15077) which is already a constituent of the plasmid pGL3basic used. The cloning and sequencing of the reporter plasmid pGL3basic-5xGAL4-TK took place in analogy to the description in Sambrook J. ef. al. (Molecular cloning, Cold Spring Harbor Laboratory Press, 1989).
The PPARgamma expression plasmid pcDNA3-GAL4-humanPPARyLBD
was prepared by first cloning the cDNA coding for amino acids 1-147 of the yeast transcription factor GAL4 (Genbank Accession # P04386) into the plasmid pcDNA3 (from Invitrogen) 3'-downstream of the cytomegalovirus promoter. Subsequently, the cDNA of the ligand-binding domain (LBD) of the human PPARy receptor (amino acids 1152-Y475; Accession #
81480099) 3'-downstream of the GAL4 DNA binding domain. Cloning and sequencing of the PPARgamma expression plasmid pcDNA3-GAL4-humanPPARgammaLBD again took place in analogy to the description in Sambrook J. et. al. (Molecular cloning, Cold Spring Harbor Laboratory Press, 1989). Besides the luciferase reporter plasmid pGL3basic-SxGAL4-TK and the PPARy expression plasmid pcDNA3-GAL4-humanPPARgammaLBD, also used for the cellular PPARgamma assay are the reference plasmid pRL-CMV (from Promega) and the plasmid pBluescript SK(+) from Stratagene. All four plasmids were prepared using a plasmid preparation kit from Qiagen, which ensured a plasmid quality with a minimal endotoxin content, before transfection into HEK cells.
Assay procedure The activity of PPARgamma agonists is determined in a 4-day assay which is described below. Before the transfection, HEK cells are cultivated in DMEM (# 41965-039, Invitrogen) which is mixed with the following additions: 10% FCS (#16000-044, Invitrogen), 1 % penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen).
Day 1 Firstly, solution A, a transfection mixture which contains all four plasmids previously described in addition to DMEM, is prepared. The following amounts are used to make up 3 ml of solution A for each 96 well microtiter plate for an assay: 2622 Nl of antibiotic- and serum-free DMEM (# 41965 039, Invitrogen), 100 NI of reference plasmid pRL-CMV (1 ng/NI), 100 NI of luciferase reporter plasmid pGL3basic-SxGAL4-TK (10 ng/Nl), 100 NI of PPARy expression plasmid pcDNA3-GAL4-humanPPARyLBD (100 ngJtrl) and 78 NI of plasmid pBluescript SK(+) (500 ng/Nl). Then 2 ml of solution B
are prepared by mixing 1.9 ml of DMEM (# 41965-039, Invitrogen) with 100 pl of PolyFect transfection reagent (from Qiagen) for each 96 well microtiter plate. Subsequently, 3 ml of solution A are mixed with 2 m! of solution B to give 5 ml of solution C, which is thoroughly mixed by multiple pipetting and incubated at room temperature for 10 min.
80°lo-confluent HEK cells from a cell culture bottle with a capacity of cm2 are washed once with 15 ml of PBS (#14190-094, Invitrogen) and treated with 3 ml of trypsin solution (#25300-054, Invitrogen) at 37°C
for 2 min. The cells are then taken up in 15 ml of DMEM (# 41965-039, Invitrogen) which is mixed with 10% FCS (# 16000-044, Invitrogen), 1%
penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM L
glutamine (#25030-024, lnvitrogen). After the cell suspension has been counted in a cell counter, the suspension is diluted to 250,000 cells/ml. 15 ml of this cell suspension are mixed with 5 ml of solution C for one microtiter plate. 200 NI of the suspension are seeded in each well of a 96 well microtiter plate with a clear plastic base (#3610, Corning Costar). The plates are incubated in a cell culture incubator at 37°C and 5% C02 for h.
Day 2 PPAR agonists to be tested are dissolved in DMSO in a concentration of 10 mM. This stock solution is diluted in DMEM (# 41965-039, Invitrogen) which is mixed with 2% Ultroser (#12039-012, Biosepra), 1 % penicillin streptomycin solution (#15140-122, Invitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen). Test substances are tested in a total of 11 different concentrations in the range from 10 pM to 100 pM. More potent compounds are tested in concentration ranges from 1 NM to 10 pM.
The medium of the HEK cells transfected and seeded on day 1 is completely removed by aspiration, and the test substances diluted in medium are immediately added to the cells. The dilution and addition of the substances is carried out by a robot (Beckman FX). The final volume of the test substances diluted in medium is 100 NI per well of a 96 well microtiter plate. Each plate is charged with a standard PPARy agonist, which is likewise diluted in 11 different concentrations, in order to demonstrate the functioning of the assay in each individual plate. The assay plates are incubated in an incubator at 37°C and 5% C02.
Day 4 After removal of the medium by aspiration, 50 NI of Dual-GIoT"" reagent (Dual-GIoT"" Luciferase Assay System; Promega) are added to each well in accordance with the manufacturer's instructions in order to lyze the cells and provide the substrate for the firefly luciferase (Photinus pyralis) formed in the cells. After incubation at room temperature in the dark for 10 minutes, the firefly luciferase-mediated chemiluminescence is measured in a measuring instrument (measuring timelwell 1 sec; Trilux from Wallac).
Then 50 NI of the Dual-GIoT"" Stop & Glo reagent (Dual-GIoT"" Luciferase Assay System; Promega) is added to each well in order to stop the activity of the firefly luciferase and provide the substrate for the Renilla luciferase expressed by the reference plasmid pRL-CMV. After incubation at room temperature in the dark for a further 10 minutes, a chemiluminescence mediated by the Renilla luciferase is again measured for 1 sec/well in the measuring instrument.
Evaluation The crude data from the luminometer are transferred into a Microsoft Excel file. The firefly/Renilla luciferase activity ratio is determined for each measurement derived from one well of the microtiter plate. The dose-effect plots and EC50 values of PPAR agonists are calculated from the ratios by the XL.Fit program as specified by the manufacturer (IDBS).
PPARgamma EC50 values in the range from 6 nM to >10 NM were measured for the PPAR agonists described in this application.
i _ i i ~ I i ~I
G ; ; ~i ~" II il ~I iC ~~ I~ I1 i I II
I i , i ~ id ~ i~
' ~ 0.I ~
e Z
Z
I
I
I
U
U
I
U
~I iT_ ~2 ._ , I
O
Z I C C~ O O
il I
i t w oo n -i / ~ ~ iI S II I I ~I I
o II (U U U U U .U U
° ~ ~ ~ r 10 0 .0 0 ~0 !0 0 c 'c_ ' ~
U j X 0 0 0 0~0~0~0 ao ~ n U U I I 2 tI (I
c>s ~ ~ UUUUIU
i ., o M
~ i ; I
I II II I ~I tI 'I
I!
O L I
° / Z >, t r IlL iL ~~ ~~ ~~
°' ~ ~ ~ !~ i~ ~' i~ ~~i c~ m v I I ~
- i~ ~ Q i ~ t i X W i N c7 E d' ~'7 ;p I;~
a~ ~ ~ v '~ ~ ; ~ I I ~ ! ~ , I
z I I j , I I
i i i I ~ i I ~ I
! j , 1 1 ~ I i I ~ i ~ I I ~ I ' ! I i i I I
I~ ~ , ' ~ I
i _ i I I I i I I
f I ~ t ; I ~ , ~ ! I 1 i l;l ;
i ' .I I I ' f I .o . , i ;
~o o o ~N I~ o ~o o . i i I ~= Z j= I= j= = IT T ~ ':
I N U U IU ~V fo U U UU I O ;
L~ .=.. ~ .~ U ~ --, ' I j ~ U ~ O l,= p = _ ~~ ~a~ ~ _ = I
cQ c~ g I o cs~ cD
m / ~ (_) ~ U U U ~ U p U U
' ' ' ~ _ i tL >i ~- ~ ~ Z m ~ _ t,.~ U C? g , , U
I ~' d' !'~ ~.;~ N d' .t N ~
i I I
2 Z I2 I I = I = Z 2 Z I2 Z
i i I
f ( 0 0 0 ~ 0 0 o c o o to o . o I
CV ~ N N N N N N N N !N N N C' 2 2 Z Z 2 Z Z Z = 'Z 2 2 U ~-~ IU U U 'U U U iU IU U U
I I I
j 10 ~ O O O IO O O IO I O 10 10 O O
f I i ~0 0 0 0 !o 'o to 'o o ~0 0 0 0 x ~= z = z I= z I= z z I= z s z IU U U U IU U ~U U U U U U U
I
' c~ m m m m m m im m m m 'm 'm m 2 I Z I2 'Z = I= (_ _ = 2 Z j=
I~ I i ~ ; ~ i I
I
i m , v Im m m m ~a~ m m (m m Im I m ~ ~ , ~ ~ ~I~~~~~ ~ ~ ~ ~i~i ~ i ' , , ' , I , , ' , , ; , ' ;
M M r~ r7 ro ! c~7 I M M :~ M c~ ; c~
i ~ i !
I ~ jr~ ? ~ Q T IN M Ict L~ I :~ ~f~ M IG:
iT IT If Ir ~T IT I C~ T' IT : N
I I t I i I
__ i I ~ I I
i I I I 1 l I ~ i I, ~
I ~ i I I I
I I ! I
I
t i ~ 1 ~ I f I 1 I ~ ; ~ I
I I I i I I
I ~ ~ I I
I
' I i I
O p O
I ~ O O O O O
ry ~ i i ~' I
i Z T I Z Z I I ~T
.Z~ 2 Z
N ' = 0 0 o c ~ c o 0 o c o 0 Z = = I Z 1 Z = T
U U U U U U IU C? U U U
I
j O ~ O ~ O O O O 10O O
O O
I
' O O O O O O IO O O O O
N N N N N N N N N N _N
U U U U U U ~ lU U U U v U
I Z Z Z ~ I z = T 1=~ !_ l r .
l v ~ ~ a~ a~ a~ , t''~t'~7 M
I~ ~ = I c~
~ ~ M ~ M I U ' ~ fir;, ~
r N l L1J l N M V' 4~ ~U 1~ ~ i , M
N i N N ~ N CO ~ M
~N .N i i i I -j, f j , I ~ I ~ y ~ ~ s y i i i ~ r ~ ' i ' ~I
! I
I s ~ ! a I I I
I I 1 ' ' ~ ; ~ I
! I 1 ~ I,~ y 1 I ~ ~ I
. I ! ~
I
I ' ~ i n ' I ~ i I I
~ 1 I O O ~ ( O Q
! O o i I o a I O O O I
I ~ o ~
I I
~
i ! C I C C
i I ~ I 1 I
I ~ ~ T I I
; ~ ,=I i I I
~ , ! I ~ ~
I ~
j M I I
M
O C~ I0 0 1 O c o 0 0 0 0 l o ! ; I 0 I o ~
N N ,N N IN ~N N N N N ! N
I I N
I N I I INZ T Z Z Z Is.
I I Z
i U U U ,UU U U U U U U U U IU
, IO O O O ~O ~O O O IO~O ~OIO O O
I I I
~
O O !0 0 0 ! 0 0 0 ,0 ~OO LO O
~ ~
N N N N N N N N N j N N N N
x z z = z z ~= z ~ i=N z z ~ z z z U U ~ U U IU IU~U IUU U U i U
IU U
M m N i ~ ~ ' .......-.r. ~ N
N Q7 i t N
i I c~ = ~ ~~ ~= I I I ~ s Z .1.
g ~,~ ~ ~ !
~
I
~r I
y O- ~ M I
' ~ ~ 1 M
( ~~ ~
r ~~ ~ ~ ~ ~ ~ ~ U ~ -ri U O
Iv N N N N O '~ (VIN 1c~O I
I i f I
i i ; i N M I~t(l~rU t~ ~CJ''v7O ~ N M V
i C~ ('~ M I i c~7('~~ C"e- d'tt'd' I
I ~7M C'~ '~ I ~ ~
i ! 1 j ~ ~ ~ I ~ I ! , ~ ~
j ~ j f ~ I I i I ~ f ~ ~ t n !
I ! I ~ i ~ i ~ i , ~ ~ r ~ ~ ~ ~ s ~ : 1 ~ ~
~
j ~ ~ 1 1, ~ i ; 1 i ( t i i i ; ; ~ 1 ~ ~
i ~ ~ ~ ~ ~ ~ ~ ( I ~ i m y s y s s s y s n y s s ~ i c I ;
I ~ ~ I y i I
I I ' I ~ I i I i l ~ I I I
i i 0 0~ a t a.o 0 0 0 o o) 0 f I
i L L L 1 0 o L. L L.L L L ~I~ l , 4 a.a a a a il c~d 4. a W
~ , , ~ , ~ , ~ ~ n. u~u~
~
~
I
c c c c c c c ~ ~ G c ~ I
i j ~
I
I I ~ i I=iz z z z z ~z ~z z ~= z z z ~ = z . I ~ ~ ~ ~
I
M
o ~ 0 0 0 0 0 o Io c c c o . o , N N N N N N N N iNN N N N !NN
I S I i Z i= I z ~ ~_~ Z 2 2 IUCJ U ~U U (U~U C? U U I U I U IUU
U
"-' 0 0 0 0 0 0 0 0 0 0 O ~O~O O ~O
!
t I
to0 0 0 0 0 0 0 0 0 o io~ 0 0 0 N N N N N N N N N N N N N N N
z 2 Z z Z z 2 2 I Z z ~=f I Z z ~UU U U U U U U U U U IU~ U U U
I , M v fl7N N ~ a~m fr +.....r ~ N 47N
' W 'W !1J , I !
_ ~ I 4 , ~zI =
-r (~ I L (~'~ (~ ~ ~ ,~ (I~ ('~
r.. I C~ t j ~ f !L~ ~ LL ~ L ~ ~ M ~ (~'~, !1. U-, L1.
U ! lL~ U C L O , LL , i.Lo~ U ~ U
d'~ C.~, I s U ~,j~ U N U U ~ i J , V'I N N :~ CV :'~; O O
~ ~' I
~
I i I
~C ' I~.100~ I I N I ~tlt7cJ !~a? I I O
w COI~ ~ O O r~I~ c'~li~>n O
~~ !~ >n iL~ ~ ~ I f I t i I f ;
' ; i ~ ~ I i ' ~ I i f ~ I ~ , n ~ ~ i , I y y ! ' I I
~ I a i l I l n ~ I j I I I I ; I ; I ~ i I
I I i I
I ~ I I i I I ~ i ~ ~ ~ f i ~ I
I ~ I ! ~ I I ~ , y I i y ; I i ~ ; ; I ; I
i l I i ! ; n ~ ! i ~ I j i i ~ ~ i j I
I I i o ~ I
) ! i I ~ ; U
I I o j o o 0 0 o o 0 o , o 0 0 0 o.o ~
~ ' j i s ...... '' ~
.
,~ ..,w ~....~.,w.,. ~ ,~ w u~U! W uJ U
u~ uJU! u~W u~ u~uJ I
.
I
I ~ c~
L
C~1 I
I I
~D ~= I I I Z = Z = I Z Z =
I= I ~ 1 ~ G , I
r i i I j ~ t _ o 0 0 0 0 0 0 0 o 0 0 0 0 o I !
_ N N N N N N N N N N N N N N N N
i=~ = I I2= T = Z I
Z
~ ~= Z I Z I I= U U ~ U C.~ U ~ IU U
U U U U U IU U IU U
I I
~o '00 0 0 0 0 0 0 0 0 0 0 ~oo Io ~
i 'o ~oo ,00 0 0 0 0 0 0 ,o'o .00 0 N N I N N N iNN N N N N N N
X N 2 I Z 2 I Z 2 2 I 2 I Z I=
I I T U U U U i U U U U U U U !U
U U U U I ~
I
M Q? N av N .~-.-~.~.-. +.Q7 ~ N I ~
!lllIuJuJ~ W ~ ~ ~~N '~W ~~
uJ ~ ~
I I
I I
I I
1- t3~ m C ~ i I ~ ~ N
I
V ~ ~ ;~_; ,~~ .;z ~ p ~ I p ~
~ I I I
' N ~ ~ ~ ' IN d- M I~d' N
I 'NI N M M
I
I ~ ~
I I ~ I
' ' I
w i ! , d'lf7CO I 00 ! ~ r 1 , I ~ 'U
r N C~7 L I~ rnO N ('~~t i ~
,~ ~ I~ ~ ~ ~ ,~;~ ~ ,~ ~ i~~ ~ ~ ,~, i v 1 i ~ j ! I ~ 1 a i i ;
O I ~ ~ I ~ I i I
~ I I ;
I I
I I I I ~ 1 I ~ I I I
I I I f ~ i I ~ I
I I
1 ~ I I I i ~
I
' I
i ~ I i i , ~ ! 1 l I I I l ; i I ~ I
I I 1 I I 1 i i f i I
i NOON iONSON~ ~ ~~iON ~ I O
I I Z Z I I Z ~ ~ Z 2 IUU U U U U U U ~ U U
~
i ~ i v v a ~ v z z z z z z z ~ o o z z t U U U U U U U IU m m ~' U U
m m ~,r~r v v ~r w ~ ~r 'r 1 1 1 1 1 1 1 1 ~ I
I M
~ U V Cue.)I U ~ Cue) U C~.a U ~ d~ ~ U d~ ~ ~ I 1 ~t~t ~
'I~ Z _ ~_ _ ,2_ ~=I= = 2 Z I ~ Z
I I
M
I
= 0 0 o i r, r, o o 0 0 0 0 r-, 0 0 I .
I
N N N N N N ~ N N INN N N N
I I ~=i= N Z _ = 2 N I I 2 U U U U IU T ~ U U C> T U U
U U I Z
U
U
I
I
~ 'o o Io0 0 0 o '00 I o ~ o o l t 0 ~ 'o ' ( I X ce'. N i N N N N N ~ IO N O N
I Z N 2 N ~ I _ ~' = N N ON N
U T U 2 = I U U U Z 'N Z 'r I U U U ~ I U Z
U I
I U
U
i I ~ U
M v a7 N ~ N ~ N N 07~ ~ m m I N
i _ ~,= _ 'r= S Z I
I I
_ *.
C~c'~ y 0 N M M ~ M ~ L
I I U ~''U c~ ~ ~~ c'U U ~ U( 1 1 cr3O W N ~ O ~.~ ~ ~ ' I I ~ f ~ M ~I M , M
I i ;~ , ~ ~ I
i i i ~f i L h ~ ~ 00c0 b ~ ~ CO~ 0~0 ~ ~ O
I J ~ ; ~ I ~ I s ~ap0 ' C7 ~ ~ i I
I
a I
' i ~ l I
~
_ i I
I
i I
'N
1~
i i J
i I .
. ~r l Z
V
i I
~t C.~
i I
' ~ T
M
t r (_ ' t C' I
i I C'! =
'~
I T~ ~ s N
l t I U
i i 1 i ? x ~2 O
lU
c ( 'o a~
i a~
i N ~ U
i.T j ~
i .
I N
Q? I
i Y
!~
I
, i , I
X Ir i U
LLl v L
The,compounds of the formula I according to the invention can be obtained according to the reaction schemes below:
Process A:
This process serves for the synthesis of the building block A-A where R1, R2, W and R3 are as defined above.
NaN02 O O H2/Pd O O
R3 O~ R3~0~ ~ R3~'O~
O~N N HCI
X41 ~4 2 I~ 3 Ri\WYcoci O O R3 O \ O
t )o ~\
R2 _ W~N COzEt POCI3 WY 'N O LiAIH4 X44 R1~~ )o R1~t )o R2 R''~~2 X45 ~6 O ~ 12, PPh3, ImH O
w W
R1 W~N O R1 ~N I
~/~ )o ~7 ,4g The ester A-1 in which R3 is as defined above is reacted with sodium nitrite and hydrochloroic acid to give the oxime A-2 which is reduced by hydrogenation with hydrogen over palladium/carbon to give the amine A-3.
The compound A-3 is reacted with acid chloroides of the formula A-4 in which R1, W and R2 are as defined above and base (for example triethylamine) to give the compound A-5.
The compound A-5 is converted by heating in phosphoryl chloroide into the compound A-6.
The ester A-6 is reduced with lithium aluminum hydride in diethyl ether to give the alcohol A-7. This is converted with iodine, imidazole (ImH) and triphenylphosphine into the iodide A-8.
Process B:
This process serves for the synthesis of the building block A-8 in which R1, R2, W and R3 are as defined above.
W CHO HCI O~ pOCl3 O
W . _ ~R3 + R1~
O~N ( )o ~R2 R1 ~W p- R1 W N CI
( )o~R2 )o R2 Nal O
acetone ~W~ ~N I
R1~ , R2 The compound B-1 is reacted with the aldehyde B-2 in which R1, R2, W
and R3 are as defined above in ethanol with hydrogen chloroide to give the compound B-3.
The compound B-3 is heated to the boil in phosphoryl chloroide, which gives the compound B-4. This is heated with sodium iodide in acetone to the boil. This gives the compound A-8.
Process C:
O Bu2Sn0 R3 R3 O O
CsF ~O O Chirazyme L-2 vinyl acetate O ,N - O iN
O ~ W, W
O / N ~ R2 ~ R2 C-1 R1 "( )o C-2 Rl v( )~ C-$
W ~~
~( )o A-8 NaH
NaOH R3 ~ allyl bromide ~O O
O ~_ IN
W
~ R2 R1 "( )o C.d R.' C-5 O O~
Os04 R3 O p ~ R3 Na104 ~ R6 P(O)(OEt)Z ~_ O
O iN O iN
O O
W, _ ~ ~ R2 ~ ~ R2 R1 "( )o R1 "( )o R3 ~ H2 R3 NaOH 0,.,_ /10 O PdlC O~O O
~ i~N I / i~N
O O
R6 W ~ R6 ~~, R2 O ~ ~ R2 p R1~( )o R1 "( )o The compound C-1 is boiled with dibutyltin oxide in toluene under reflux on a water separator. After addition of dimethylformamide, cesium fluoride and 5 the compound A-8 (see process A), the suspension is stirred at room temperature. This gives the compound C-2. This is converted with Chirazyme L-2 in vinyl acetate into the enantiomerically enriched acetate C-3. Using sodium hydroxide in methanol, the acetate C-3 is converted into the alcohol C-4.
10 At room temperature, the compound C-4 is reacted with sodium hydride and allyl bromide and dimethylformamide to give the compound C-5.
The compound C-5 is reacted with osmium tetroxide and sodium periodate in diethyl ether to give the compound C-6. In a Horner-Emmons-Wadsworth reaction, this is converted with sodium hydride and the compound C-7 into the compound C-8.
The compound C-8 is hydrolyzed to the free acid by stirring for a number of hours with sodium hydroxide in methanol at room temperature. The resulting compound C-9 is hydrogenated with hydrogen over palladium/
carbon to give the compound C-10.
Using this process, it is possible to synthesize examples 1 to 4.
Process D:
NaH ~
--..~ _ O~O O
, ~_ O O
O I B~ O
~N ~N
,1 ~ o ,1 R1~( )o O y )o R2 C-2 R1' '~ D-1 Me3S01 NR10R11 aryl halide NaH Pd(0) R3 ~ ~ R3 ~
O~O p~0 ~O
O ~N O O O
W~ O O ~ R10~N
I ~ W , I
( )o ~( )o R11 R1 R2 R1 ~ R
D-2 D-3 (~,-~e)a"".",, , , ,., 3, .....,., ,Z D-4 NaOH NaOH H2 PdIC
NaOH
O ~N
W' l R1~( )o (C~-C6)alkoxy, F, CF;
The compound C-2 is reacted with sodium hydride and ethyl 2-bromo-methylacrylate in dimethylformamide at 0°C, to give the compound D-1.
The compound D-1 is then reacted either with trimethylsulfonium iodide and sodium hydride in dimethyl sulfoxide to give the compound D-2, or with a secondary amine NR10R11, where R10 and R11 are as defined above, to give the compound D-3, or with an aryl halide and a palladium(0) catalyst in a Heck reaction to give the compound D-4. The compound D-4 is then hydrogenated using hydrogen over palladium-on-carbon to give the compound D-5.
Using sodium hydroxide, the compounds D-2, D-3 and D-5 are converted into compounds of the formula D-6, where R6 and R7 are as defined above.
Using this process, it is possible to synthesize examples 5 to 9.
Process E:
Os04 ~ O v O TBDMSCI
---~ O / N HO -w~ HO
R~ - R1~'~)0 G5 ~1 R3 ~ NaH R3 o ~ alkyl-I TBAF
O HO ~ O~ R7 ~N
W~ O_Si~ W, ~ ~ R2 ~ R2 R1~~ )o R1~~ )°
&2 ~3 1. DMP
R3 2. NaCIOz R3 HzOz ~_ O O
O iN R7 ~ O ~N R7 W~~ W~ HO O
R1W )°
R1W )°
&4 ~5 Using osmium tetroxide, 1,5-diazabicyclo[2.2.2]octane (DABCO) and N-methylmorpholine-N-oxide, the compound C-5 is dihydroxylated to the compound E-1. The primary hydroxyl group is then protected as trialkylsilyl ether E-2 by stirring the compound E-1 with a trialkylchlorosilane (for example tert-butyldimethylsilyl chloroide) and imidazole as base in dimethylformamide at room temperature. The compound E-2 is then reacted with a strong base (for example sodium hydride or potassium tert-butoxide) and an alkyl halide to give the compound E-3 where R7 is as defined above. Using tetrabutylammonium fluoride in tetrahydrofuran, the silyl protective group is removed, giving the compound E-4.
The compound E-4 is stirred at room temperature with Dess-Martin Periodinane (DMP) in dichloromethane for a number of hours, worked up and then reacted with sodium chloroite and hydrogen peroxide in acetonitrile to give the compound E-5. Alternatively, E-5 can be synthesized from E-4 by direct oxidation of E-4 using a chromium(VI) compound (for example Cr03 in sulfuric acid).
Using this process, it is possible to synthesize examples 10 to 27.
Process F:
This process serves as an alternative preparation of intermediates E-3 (see process E) PG
Os04 p (Alk)3SiCl O
( )n p ( )n ( )n HO HO
F-1 ~ F-2 HO F-3 O-Sid base PG
alkyl O~ O~ O
halide ( ) H2, Pd/C for PG=Bn, n=0 ( )n K2C03, MeOH for PG=Bz, n=0 HCOOOH, MeOH for PG=Tr, n=1 /S~'O
base ( )n p O ~ N R7 I
W
O i N R2 O
o ~Si~
W, R1~
The racemic or enantiomerically pure compound F-1 in which PG is as defined in the scheme is dihydroxylated to the compound F-2 using osmium tetroxide, 1,5-diazabicyclo[2.2.2]octane (DABCO) and N-methyl-morpholine-N-oxide.
The primary hydroxyl group is then protected as trialkylsilyl ether F-3 by stirring the compound F-2 at room temperature with a trialkylchlorosilane (for example tert-butyldimethylsilyl chloroide) and imidazole as base in dimethylformamide. The compound F-3 is then reacted with a strong base (for example sodium hydride or potassium tert-butoxide) and an alkyl halide to give the compound F-4 in which R7 is as defined above. The benzyl protective group is removed hydrolytically using hydrogen over Pd (10% on carbon), the benzoyl protective group is cleaved using potassium carbonate in methanol and the trityl group is removed using formic acid in methanol, which gives the compound F-5.
The compound F-5 is reacted with the alkyl iodide A-8 in the presence of a strong base (for example sodium hydride or potassium tert-butoxide) in an inert solvent (for example MTBE, chlorobenzene) to give the compound E-3 in which R1, R2, R3, R7 and W are as defined above.
The subsequent conversions of E-3 to E-5 are carried out as described under process E.
Using this process, it is possible to synthesize examples 28 to 90.
Process G:
I Pt02 O R8-OH
O \ N HOAc N R8 O NH3CI
O p O
cis racemate cis racemate / I /
BnBr LiAIH4 = R8~0 N O N
O \
cis racemate cis racemate R3 ~ H2 ~O N
base ~O N PdIC O ~ ~N
O iN
R~ I \
I
/ ('' R2 O ~ N R2 R1~( )o cis racemate R1~( )o cis racemate ~ G-7 W i \ G-6 R~~~
O O
1. coupling Ra R6 2. if required R3 ~ R8 R7 ester hydrolysis ~p /'~~ N O
O ORB O ~ N
R4 R~ R7 w' cis racemate ~(- R2 HO O R1 V ( )~ G-9 The compound G-1 (3-aminobenzoic acid) is hydrogenated in acetic acid using hydrogen over platinum dioxide under elevated pressure, which gives 10 the compound G-2. Using thionyl chloroide in an alcohol R80H in which R8 is as defined above (except for R8 = H), this is converted into an ester, which gives the compound G-3. The compound G-3 is then reacted with benzyl bromide and potassium carbonate to give the dibenzylamine G-4.
Reduction of G-4 with LiAIH4 affords the alcohol G-5.
Using an alkyl iodide A-8, the compound G-5 is converted into the compound G-6 in which R1, R2, W and R3 are as defined above. The compound G-6 is hydrogenated using hydrogen over palladium to give the compound G-7 in which R1, R2, W and R3 are as defined above.
The compound G-7 is coupled with carboxylic acid derivatives G-8 in which R4, R5, R6 and R7 are as defined above. If dicarboxylic acid monoesters G-8 are used, the coupling is followed by ester hydrolysis (using, for example, LiOH in THF/methanol/water for R8 = methyl or ethyl). This gives the compound G-9 in which R1, R2, W, R3, R4, R5, R6 and R7 are as defined above.
Using this process, it is possible to synthesize examples 28 to 90.
The abbreviations used denote:
Ac Acetyl Bn Benzyl 'Bu Isobutyl tBu tert-Butyl BuLi n=Butyllithium Bz Benzoyl Cy Cyclohexyl TLC Thin-layer chromatography DCI Direct chemical ionization (in MS) DCM Dichloromethane DMAP 4-N,N-Dimethylaminopyridine DMF N, N-Dimethylformamide DMSO Dimethyl sulfoxide EA Ethyl acetate EDC N'-(3-Dimethylaminopropyl)-N-ethylcarbodiimide x HCI
EI Electron impact ionization (in MS) eq Equivalent ESI Electrospray ionization (in MS) Et Ethyl sat. Saturated h Hour HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HOBt 1-Hydroxy-1 H-benzotriazole x H20 HPLC High pressure, high performance liquid chromatography LC-MS Liquid chromatography-coupled mass spectroscopy Me Methyl MS Mass spectroscopy MsCI Methanesulfonyl chloroide NMR Nuclear magnetic resonance spectroscopy Pd/C Palladium on carbon 'Pr Isopropyl "Pr n-Propyl Rf Retention time (in TLC) RT Room temperature TBAF Tetrabutylammonium fluoride TBAI Tetrabutylammonium iodide TBDPSCI tert-Butyldiphenylsilyl chloroide TBDMSCI tert-Butyldimethylsilyl chloroide THF Tetrahydrofuran Tr Trityl It is possible to prepare other compounds by the processes mentioned above.
Building block synthesis according to process A:
O O NaN02 H2lPd O O
O~ --~ ( 0~ ---~. O
O'N N HCI
w coca I i O O POCI3 O ~ O LiAIH4 --.-w \ N COzEt I \ N O
/
12, PPh3. ImH
\ ~N 0 \ ~N
5 Ethyl2-hydroxyimino-4-methyl-3-oxopentanoate NaN02 o~ ~ I o~
,N
O
42.4 g of ethyl 4-methyl-3-oxopentanoate are dissolved in 100 ml of glacial 10 acetic acid, and 21 g of sodium nitrite, dissolved in 100 ml of water, are' added at 5°C. Over a period of one hour, the mixture is allowed to warm to room temperature, 100 ml of water are added and the mixture is stirred at room temperature for another hour. The mixture is extracted three times with in each case 150 ml of methyl tert-butyl ether, 200 ml of water are 15 added to the combined organic phases and the mixture is neutralized by addition of solid NaHC03. The organic phase is removed, washed with saturated NaCI solution and dried over MgS04, and the solvent is removed under reduced pressure. This gives 46 g of ethyl 2-hydroxyimino-4-methyl-3-oxopentanoate as an oil. C8H13N04 (187.20), MS (ESI) = 188 (M+H+).
Ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide o~ -.~ o~
HCI
10 g of HCI are introduced into 200 ml of ethanol. 46 g of ethyl 2-hydroxy-imino-4-methyl-3-oxopentanoate are dissolved in this mixture, 5 g of Pd (10% on carbon) are added and the mixture is stirred under atmosphere of hydrogen (5 bar) for 8 hours. The reaction mixture is filtered through Celite and the solvent is removed under reduced pressure. This gives 45 g of ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide as a white solid.
C8H15N03*HCI (209.5), MS(ESI) = 188 (M+H+) Ethyl 4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate Coct o N + ' ~ ~ N O
HCt 10 g of ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide and 7.4 g of 4-methylbenzoyl chloroide are dissolved in 250 ml of dichloromethane, and 13.3 ml of triethylamine are slowly added dropwise at 0°C. The mixture is stirred at room temperature for one hour and then washed with water, the organic phase is separated off and dried over MgS04 and the solvent is then removed under reduced pressure. This gives 13 g of ethyl 4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate as an oil.
C16H21 N04 (291.35), MS(ESI) = 292 (M+H+).
Ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate o~ o ~ o N O -' \ \N
O
13 g of ethyl 4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate in 80 ml of phosphorus oxychloroide are heated to the boil under reflux for 2 h. The phosphorus oxychloroide is removed under reduced pressure and the resulting residue is dissolved in 200 ml of dichloromethane, washed three times with saturated NaHC03 solution and dried over MgS04, and the solvent is then removed under reduced pressure. This gives 11 g of ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate as a brownish sold. C16H19N03 (273.33), MS(ESI) = 292 (M+H+), Rf(n-heptane:ethyl acetate) = 2:1 ) = 0.43.
(5-Isopropyl-2-p-tolyloxazol-4-yl)methanol 11 g of ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate are dissolved in 100 ml of tetrahydrofuran, and 40 ml of a 1 molar solution of lithium aluminum hydride in tetrahydrofuran are added at 0°C. After 30 min, 1 N
of HCI are added to the reaction mixture, and the mixture is extracted five times with ethyl acetate. The combined organic phases are dried over MgS04 and the solvent is then removed under reduced pressure. The residue is purified on silica gel using the mobile phase n-heptane:ethyl acetate = 6:1 => 1:1. This gives 4.3 g of (5-isopropyl-2-p-tolyloxazol-4-yl)methanol as a light-yellow solid.
C14H17N02 (231.30), MS(ESI) - 232 (M+H+), Rf(n-heptane:ethyl acetate) = 1:1 ) = 0.17.
4-lodomethyl-5-isopropyl-2-p-tolyloxazole 500 mg of (5-isopropyl-2-p-tolyloxazol-4-yl)methanol, together with 690 mg of triphenylphosphine and 600 mg of imidazole, are dissolved in 20 ml of toluene. 715 mg of iodine are added, and the mixture is stirred at room temperature for 1 hour. 10 ml of saturated sodium carbonate solution and 500 mg of iodine are then added. After 10 minutes, the organic phase is separated off, washed twice with saturated Na2S2O3 solution and dried over MgS04, and the solvents are then removed under reduced pressure.
The residue is purified on silica gel using the mobile phase n-heptane:ethyl acetate = 10:1. This gives 400 mg of 4-iodomethyl-5-isopropyl-2-p-tolyl-oxazole as a white solid. C14H161N0 (341.19), MS(ESI): 342 (M+H+), Rf(n-heptane:ethyl acetate = 1:1 ) = 0.75.
Analogously to the building block synthesis according to process K, ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloroide and 3-methoxybenzoyl chloroide gave 4-iodomethyl-2-(3-methoxyphenyl)-5-isopropyloxazole.
O
C14H161N02 (357.19), MS(ESI): 358 (M+H+), Rf(n-heptane:ethyl acetate =
1:1) = 0.60.
Analogously to the building block synthesis of 4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl 4,4,4-trifluoro-3-oxobutyrate and 3-methoxybenzoyl chloroide gave 4-iodomethyl-2-(3-methoxyphenyl)-5-trifluoromethyloxazole.
F F
F
O
I
,O
C12H9F31N02 (383.11), MS(ESI): 384 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl 4,4,4-trifluoro-3-oxobutyrate and 3-trifluoromethyl-benzoyl chloroide gave 4-iodomethyl-2-(3-trifluoromethylphenyl)-5-trifluoro-methyloxazole.
F
C12H6F61N0 (421.08), MS(ESI): 422 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl 4,4,4-trifluoro-3-oxobutyrate and 4-methylbenzoyl chloroide gave 4-iodomethyl-5-trifluoromethyl-2-p-tolyloxazole.
C12H9F31N0 (367.11), MS(ESI): 368 (M+H+).
Building block synthesis according to process B:
O --' \ + \ CHO~ O
~N J / ~ / \ wN+
O I 1_ / O
j POC13 Nal, acetone O
---~. O \ _---> w \ ~N \ N I
w CI ~ /
4-Methyl-5-phenyl-2-p-tolyloxazole 3-oxide CHO HC~ O
w.
o,N ~ ~ ~ ~ ~ ~ o_ 12.5 g of 1-phenyl-1,2-propanedione-2-oxime and 10 ml of p-tolualdehyde are added to 50 ml of glacial acetic acid, and HCI gas is introduced for 30 minutes, with ice-cooling. The product is precipitated as the hydrochloroide by addition of methyl tert-butyl ether and filtered off with suction, and the precipitate is washed with methyl tert-butyl ether. The precipitate is suspended in water and the pH is made alkaline using ammonia. The mixture is extracted three times with in each case 200 ml of dichloromethane, the combined organic phases are dried over MgS04 and the solvent is then removed under reduced pressure. This gives 6.4 g of 4-methyl-5-phenyl-2-p-tolyloxazole 3-oxide as a white solid. C17H15N02 (265.31), MS(ESI) = 266 (M+H+).
4-Chloromethyl-5-phenyl-2-p-tolyloxazole / \
/ \
O \ POCI3 O
O I ~ N CI
6.4 g of 4-methyl-5-phenyl-2-p-tolyloxazole 3-oxide are dissolved in 50 ml of chloroform, 2.4 ml of phosphorus oxychloroide are added and the mixture is, under reflux, heated at the boil for 30 minutes. The reaction mixture is cooled to 0°C, the pH is made slightly alkaline using ammonia and the mixture is extracted three times with in each case 100 ml of ethyl acetate. The combined organic phases are washed with water and dried over MgS04, and the solvent then removed under reduced pressure. This gives 5.4 g of 4-chloromethyl-5-phenyl-2-p-tolyloxazole as a yellow solid.
C17H14CIN0 (283.76), MS(ESI) = 284 (M+H+), Rf(n-heptane:ethyl acetate) = 7:1) = 0.41 4-lodomethyl-5-phenyl-2-p-tolyloxazole Together with 3 g of sodium iodide, 1.8 g of 4-chloromethyl-5-phenyl-2-p-tolyloxazole are, in 150 ml of acetone, heated at the boil under reflux for 2 hours. After cooling of the reaction mixture, 300 ml of methyl tert-butyl ether are added, the mixture is washed three times with saturated Na2S203 solution and dried over MgS04 and the solvents are then removed under reduced pressure. This gives 2.7 g of 4-iodomethyl-5-phenyl-2-p-tolyloxazole as a light-yellow solid.
C17H141N0 (375.21), MS(ESI): 376 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-phenyl-1,2-propanedione-2-oxime and m-anisaldehyde gave 4-iodomethyl-2-(3-methoxyphenyl)-5-phenyloxazole.
C17H141N02 (391.21), MS(ESI): 392 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and m-anisaldehyde gave 4-iodomethyl-5-ethyl-2-(3-methoxyphenyl)oxazole.
,O
C13H141N02 (343.17), MS(ESI): 344 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and p-tolualdehyde gave 4-iodomethyl-5-ethyl-2-p-tolylazole.
O
i i C13H141N0 (327.17), MS(ESI): 328 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and 2,6-dimethyl-benzaldehyde gave 4-iodomethyl-5-ethyl-2-(2,6-dimethylphenyl)oxazole.
O
N I
C14H161N0 (341.19), MS(ESI): 342 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-ethyl-1,2-propanedione-2-oxime and 2-trifluoromethyl-benzaldehyde gave 4-iodomethyl-5-ethyl-2-(2-trifluoromethylphenyl)-oxazole.
F F
FO
N I
C13H11F31N0 (381.14), MS(ESI): 382 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-cyclohexyl-1,2-propanedione-2-oxime and m-anis-aldehyde gave 4-iodomethyl-5-cyclohexyl-2-(3-methoxyphenyl)oxazole.
O
N I
,O
C17H201N02 (397.26), MS(ESI): 398 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, 1-cyclohexyl-1,2-propanedione-2-oxime and p-toluene-aldehyde gave 4-iodomethyl-5-cyclohexyl-2-p-tolyloxazole.
O
w ~ N !
C17H201N0 (381.26), MS(ESI): 382 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and p-toluenealdehyde gave 4-iodo-methyl-5-methyl-2-p-tolyloxazole.
O
N I
C12H121N0 (313.14), MS(ES1): 314 (M+H+) Analogously to the building block synthesis of 4-chloromethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and benzaldehyde gave 4-chloro-methyl-5-methyl-2-phenyloxazole.
O
\ 'N CI
5 C11H101N0 (207.66), MS(ESI): 208 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-biphenyloxazole, diacetylmonoxime and p-biphenylcarbaldehyde gave 10 4-iodomethyl-5-methyl-2-p-biphenyloxazole.
O
\ N I
\ /
/
C12H121N0 (375.21), MS(ESI): 376 (M+H+) 15 Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2-naphthalenecarbaldehyde gave 4-iodomethyl-5-methyl-2-naphthyloxazole.
O
N I
C12H121N0 (349.17), MS(ESI): 350 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2,4-dimethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(2,4-dimethylphenyl)oxazole.
C13H141N0 (327.17), MS(ESI): 328 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2,6-dimethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(2,6-dimethylphenyl)oxazole.
O
I \ ,N I
C13H141N0 (327.17), MS(ESI): 328 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and m-anisaldehyde gave 4-iodo-methyl-2-(3-methoxyphenyl)-5-methyloxazole.
,O
C12H121N02 (329.14), MS(ESI): 330 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 3-trifluoromethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(3-trifluoromethylphenyl)oxazole.
O
w N I
F F
F
C12H9F31N0 (367.11), MS(ESI): 368 (M+H+) Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 4-fluorobenzaldehyde gave 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole.
O
I
F
C11H9FIN0 (317.10), MS(ESI):318 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyfoxazole, diacetylmonoxime and 4-methoxybenzaldehyde gave 4-iodomethyl-2-(4-methoxyphenyl)-5-methyloxazole.
O
N I
O
C12H121N02 (329.14), MS(ESI):330 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 4-trifluoromethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole.
F
F
C12H9F31N0 (367.11), MS(ESI):368 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 2-trifluoromethylbenzaldehyde gave 4-iodomethyl-5-methyl-2-(2-trifluoromethylphenyl)oxazole.
F F
F O
N I
C12H9F31N0 (367.11), MS(ESI):368 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl 2-p-tolyloxazole, diacetylmonoxime and m-toluenealdehyde gave 4-iodo methyl-5-methyl-2-m-tolyloxazole.
C12H121N0 (313.14), MS(ESI):314 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 3-trifluoromethoxybenzaldehyde gave 4-iodomethyl-5-methyl-2-(3-trifluoromethoxyphenyl)oxazole.
O
N I
F\ /O
~F
F
C12H9F31N02 (383.11), MS(ESI):384 (M+H+), Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 5-methylfuran-2-carbaldehyde gave 4-iodomethyl-5-methyl-2-(5-methylfuran-2-yl)oxazole.
O
O ~N
I
C10H101N02 (303.11), MS(ESl):304 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and thiophene-2-carbaldehyde gave 4-iodomethyl-5-methyl-2-thiophen-2-yloxazole.
O
S \N
I
C9H81NOS (305.14), MS(ESI):306 (M+H+).
Analogously to the building block synthesis of 4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and 4-isopropylbenzaldehyde gave 4-iodomethyl-2-(4-isopropylphenyl)-5-methyloxazole.
O
N I
5 C14H161N0 (341.19), MS(ESI):342 (M+H+).
Example 1:
2-Ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyloxy}butanoic acid Bu2Sn0 1. Chirazy CsF O OH v'snyl acet<
HO OH ~ 2. NaOH
N~ O
N~
/
F F
Os04 allyl bromide O O~ Na104 O OHO
NaH
N' O~ N1 / O
F F
NaH / O~ NaOH
O O
/-- O
O
O-P=O N\ \
O
o f F
/ O H~/Pd(C;
O O
O
N\ y-F F
rac-3-(cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol a~zsno O
O~ CsF \
~ ~N ~~----~~ I + O ~O ~ I ~ \N O O
F~
F
cislracemate 21.7 g of 1,3-cyclohexanediol and 30.3 g of dibutyltin oxide are dissolved in 450 ml of toluene and, under reflux on a water separator, heated to the boil.
During the duration of the reaction, the reaction volume is reduced to half of the original volume. After 3 hours, the reaction mixture is cooled to room temperature, and 300 ml of dimethylformamide, 29 g of 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole and 23.5 g of cesium fluoride are added.
The mixture is stirred at room temperature for another 18 hours. The reaction mixture is diluted by addition of ethyl acetate and washed with saturated sodium chloroide solution. The organic phase is dried over magnesium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptanel ethyl acetate = 10:1 ~ 1:4). This gives 58 g of rac-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol as a yellowish solid which is recrystallized from n-heptane/ethyl acetate. C17H20FN03 (305.35), MS
(ESI): 306 (M + H+).
3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol O~ ~ Chirazyme L-2 \ O
O O vinyl acetate I ~N O O
N
F ~ F
cislracemate NaOH
MeOH
O
~N O O
F
g of rac-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol are dissolved in 320 ml of vinyl acetate, and 1.3 g of Chirazyme L-2 Lyo 25 (Boehringer Mannheim) are added. After about three hours of stirring at room temperature (LC-MS control for 40-45% conversion), the enzyme is filtered off and rinsed with ethyl acetate, and the solvent is removed under reduced pressure. The residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 3:1 ). This gives 8 g of the acetate as a colorless oil. C19H22FN04 (347.39), MS (ESI): 348 (M + H+). The acetate is taken up in 170 ml of methanol and, after addition of 27 ml of 2N NaOH, stirred at room temperature for one hour. Most of the solvent is removed under reduced pressure. After addition of in each case 150 ml of water and ethyl acetate, the organic phase is washed with sodium chloroide solution.
The organic phase is dried over magnesium sulfate and the solvent is removed under reduced pressure. This gives 6.7 g of 3-((1R,3S)-cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol as a yellowish solid. C17H20FN03 (305.35), MS (ESI): 306 (M + H+).
4-(3-Allyloxycyclohexyloxymethyl)-2-(4-fluorophenyl)-5-methyloxazole NaH, DMF
O '~ O O
O ~ O O Br ,N ~ 'N
F F
2 g of the 3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol are dissolved in 15 ml of dimethylformamide, and 0.3 g of sodium hydride is added. After 30 minutes, 2.4 g of allyl bromide are added dropwise. The mixture is stirred at room temperature for 5 hours. 15 ml of 1 N HCI are then added to the reaction mixture, and the mixture is washed three times with 15 ml of ethyl acetate. The organic phase is dried over magnesium sulfate, and the solvent is then removed under reduced pressure. The residue is purified by RP-HPLC. This gives 2.4 g of 4-(3-allyloxycyclohexyloxymethyl)-2-(4-fluorophenyl)-5-methyloxazole as a yellowish oil. C20H24FN03 (345.42) MS(ESI): 346 (M+H+) [3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl]acet-aldehyde Os04 Na104 O O~ ~ 0 ~ 0 O~O
~N ~N
F F
2.0 g of 4-(3-allyloxycyclohexyloxymethyl)-2-(4-fluorophenyl)-5-methyloxa-zole are dissolved in 50 ml of diethyl ether, and 3.8 g of sodium periodate, dissolved in 50 ml of water, are added. At 0°C, 1 ml of an osmium tetroxide solution (2.5% by weight in tert-butanol) is added, and the mixture is stirred vigorously at room temperature. After 8 h, 100 ml of methyl tent-butyl ether are added, and the mixture is washed with a saturated sodium thiosulfate solution. The organic phase is dried over magnesium sulfate and the solvent is removed under reduced pressure. The residue is purified on silica gel (n-heptane:ethyl acetate = 1:1 --~ 1:5). This gives 1.4 g of [3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl]acetaldehyde as a yellow-brown oil. C20H25N04 (343.42), MS(ESI): 344 (M+H+), Rf(n-heptane:ethyl acetate = 1:1 ) = 0.25.
Ethyl 2-ethyl=4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-cyclohexyloxy}but-2-enoate NaH
O O~O O 0 ~ O
O
N~ O O N~ O
O
i F F
0.58 g of ethyl 2-(diethoxyphosphoryl)butanoate is dissolved in tetrahydrofuran (20 ml), and 0.06 g of sodium hydride is added at 0°C.
The suspension is stirred at 0°C for 30 min and at room temperature for 30 min and then cooled to -70°C. After addition of 0.4 g of 2-((1 R,3S)-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde (dissolved in 5 ml of tetrahydrofuran), the mixture is stirred at -70°C for 60 min and then at room temperature for 12 h. 10 ml of water are added, the mixture is 5 extracted with ethyl acetate (3 x 10 ml) and the combined organic phases are washed with saturated sodium chloroide solution (10 ml). The solvent is removed under reduced pressure and the residue is purified by HPLC. This gives 0.32 g of ethyl 2-ethyl-4-{(1R,3S)-3-[2-(4-fluorophenyl)-5-methyl-oxazol-4-ylmethoxy]cyclohexyloxy}but-2-enoate C25H32FN05 (445.54) 10 MS(ESI): 446 (M + H+) 2-Ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-cyclohexyloxy}but-2-enoic acid F
N O O / 0~ NaOH
O O
F
0 o i o 0.5 g of ethyl 2-ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxy}but-2-enoate is dissolved in 5 ml of methanol, and 2.5 ml of 1 N aqueous sodium hydroxide solution are added. After 12 h of stirring at room temperature, the mixture is acidified with 3 ml of 1 N
hydrochloroic acid and the resulting precipitate is taken up in ethyl acetate.
The solvent is removed under reduced pressure and the residue of the ester hydrolysis, 2-ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxy}but-2-enoic acid, is obtained as 0.45 g of a white solid. C23HZ8FN05 (417.48) MS(ESI): 418 (M + H+) 2-Ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyloxy}butanoic acid F \ ~ N / O HZ~Pd(C) ' ~O O
O O
F
O
' ~O O
O O
0.3 g of 2-ethyl-4-{(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl-methoxy]cyclohexyloxy}but-2-enoic acid is dissolved in a solvent mixture of 2 ml of ethyl acetate and 1 ml of methanol, and 0.05 g of palladium (10%
on carbon) is added. The mixture is then hydrogenated at a hydrogen pressure of 1 bar for 3 h.
The palladium is filtered off and the solvent mixture is then removed under reduced pressure and the residue is recrystallized from acetonitrile. This gives 0.25 g of 2-ethyl-4-~(1 R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4 ylmethoxy]cyclohexyloxy}butanoic acid as a white solid. C23H3oFN05 (419.49), MS(ESI): 420 (M + H+) Example 2:
Using reaction conditions similar to those of example 1, 2-((1 R,3S)-[3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde and ethyl 2-(diethoxyphosphoryl)pentanoate give 2-propyl-4-[3-(2-(4-fluoro-phenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]butanoic acid.
F N ~ O
/ ~ O O
O O
C24H32FNO5 (433.52) MS(ESI): 434 (M+H+) Example 3:
Using reaction conditions similar to those of example 1, 2-((1R,3S)-[3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde and ethyl 2-(diethoxyphosphoryl)acetate give 4-{3-[2-(4-fluorophenyl)-5-methyl-oxazol-4-yimethoxy]cyclohexyloxy}butanoic acid F N ~ p O O II
O O
C2~H26FN05 (391.44) MS(ESI): 392 (M + H+) Example 4:
Using reaction conditions similar to those of example 1, 2-((1 R,3S)-[3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]acetaldehyde and ethyl 2-(diethoxyphosphoryl)propionate give 4-{3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxy}-2-methylbutanoic acid F N ~ O
O O
° o C22H28FN05 (405.47) MS(ESI): 406 (M + H+) Example 5:
Ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy-methyl]acrylate NaH, DMF
O O O~
B~O~' 200 mg of a 60% strength sodium hydride suspension are added at room temperature to a solution of 754 mg of 3-((1 R,3S)-cis-5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol in 10 ml of dimethylformamide/5 ml of tetrahydrofuran, and the mixture is stirred at room temperature for 20 minutes. At 0°C, 1 g of ethyl 2-bromomethylacrylate is then added, and the mixture is stirred at this temperature for 2 h. 100 ml of ethyl acetate and 150 ml of saturated NaCI solution are added. The organic phase is dried over sodium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 2:1). This gives 1.18 g of ethyl ((1R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate as a colorless oil. C24H3~NO5 (413.52), MS (ESI): 414 (M + H+).
Ethyl ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy-methyl]cyclopropanecarboxylate 0 ~ 0 o \ I~ o l--' w '~o~o o~ --~ ~ N o 0 0 N
NaH /
At room temperature, 12 mg of a 60% strength sodium hydride suspension are. added to a suspension of 55 mg of trimethylsulfonium iodide in 2 ml of DMSO, and the mixture is stirred at room temperature for 20 min. At 10°C, 100 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclo-hexyloxymethyl]acrylate, dissolved in 2 ml of DMSO, are then added, and the mixture is stirred at room temperature for 90 min. The mixture is poured into ice-water and extracted with methyl tert-butyl ether. The organic phase is dried over sodium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 2:1 ). This gives ethyl ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]cyclopropanecar-boxylate as a colorless oil. C25H33NO5 (427.55), MS (ESI): 428 (M + H+).
((1 R,3S)-1-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]-cyclopropanecarboxylic acid 0 0 0~ o NaOH
\ /\ \
~N O O O ~ I ~N O O O
/ /
56 mg of ethyl ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclo-hexyloxymethyl]cyclopropanecarboxylate are dissolved in 3 ml of methanol, 0.5 ml of 5 N NaOH are added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid and purified by RP-HPLC.
This gives ((1 R,3S)-1-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyl-oxymethyl]cyclopropane carboxylic acid as a colorless oil. C23H29N05 (399.49), MS (ESI): 400 (M + H+).
Example 6:
Ethyl 2R/S-((1 R',3S')-2-[(methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate o~ o ~ ~0 ~
N O~O O~
N O O~O
/ + N
/N I
I/
50 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclo-hexyloxymethyl]acrylate are dissolved in 5 ml of ethanol, 95 mg of N-methylhomobenzylamine are added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 1:1 + 3% NEt3). This gives ethyl 2R/S-((1 R',3S')-2-[(methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmeth-oxy)cyclohexyloxy]propionate as a colorless oil. C33Hq.4N2O5 (548.73), MS
(ESI): 549 (M + H+).
((1 R',3S')-2R/S-[(Methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid \ N o 0 0~
N \
~LiOH
O \ O
~N O 0 ~ 'O
N \ /
5 65 mg of ethyl 2R/S-((1 R',3S')-2-[(methylphenethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate are dissolved in 3 ml of tetrahydrofuran/methanol 3:1, 0.6 ml of 1 N LiOH is added and the mixture is stirred at room temperature for 6 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid 10 and purified by RP-HPLC. This gives 2R/S-((1R',3S')-[(methylphenethyl-amino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propionic acid as a colorless oil. C3~H4pN2O5 (520.67), MS (ESI): 521 (M+H+) 15 Example 7:
O \ O
~N O O ~O
N
(1 R',3S')-2R/S-[(Benzylmethylamino)methyl]-3-[3-(5-methyl-2-m-tolyl-20 oxazol-4-ylmethoxy)cyclohexyloxy]propionic acid Using reaction conditions similar to those of example 100, ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate and N-methylbenzylamine give (1 R',3S')-2R/S-[(benzylmethylamino)methyl]-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid of molecular weight 506.65 (C3oH38N205), MS(ESI): 507.20 (M + H+).
Example 8:
((1 R',3S')-2R/S-Methoxymethyl-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmeth-oxy)cyclohexyloxy)propionic acid o \ o 0 0 NaCN ~
., NaQH ~ N O' v 'O O
N O O O -O
56 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4.-ylmethoxy)cyclo-hexyloxymethyl]acrylate are dissolved in 3 ml of methanol, 49 mg of sodium cyanide and 0.25 ml of 2N NaOH are added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid and purified by RP-HPLC. This gives ((1 R',3S')-2R/S-methoxymethyl-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid as a colorless oil.
Cz3H3~N06 (417.51), MS (ESI): 418.15 (M + H+).
Example 9:
Ethyl Z-((1 R',3S')-3-(4-fluoro-3-methylphenyl)-2-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxymethyl)acrylate 0 0~
F
O O ' F
220 mg of tetrabutylammonium chloroide and 332 mg of potassium carbonate are suspended in 4 ml of dimethylformamide and stirred intimately for 20 min. 400 mg of ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate, 25 mg of triphenylphos-phine and 212 mg of 4-fluoro-3-methyliodobenzene are added, the mixture is degassed and flushed with argon and 10 mg of palladium acetate and 0.2 mol of water are added. The mixture is heated at 60°C for 4 h.
After cooling, 20 ml of ethyl acetate and 50 ml of saturated NaCI solution are added. The organic phase is dried over sodium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptanelethyl acetate = 4:1 ). This gives ethyl Z-((1 R',3S')-3-(4-fluoro-3-methylphenyl)-2-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate as a colorless oil.
C3~H3aFN05 (523.65), MS (ESI): 524 (M + H+).
Ethyl 2R/S-(4-fluoro-3-methylbenzyl)-(1 R',3S')-3-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxy]propionate O
O O~O~
\ Pd/C ~' /~
H2 ~F
O
O O
80 mg of ethyl Z-((1 R',3S')-3-(4-fluoro-3-methylphenyl)-2-(3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate are dissolved in 15 ml of ethyl acetate and, after addition of 30 mg of Pd/C 10%, stirred under 1 bar of H2 for 24 h. The catalyst is filtered off and the solvent is evaporated. This gives ethyl 2RIS-(4-fluoro-3-methylbenzyl)-(1R',3S')-3-(3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate as a colorless oil. C3~H38FN05 (521.63), MS (ESI): 522 (M + H+).
(2R/S)-(4-Fluoro-3-methylbenzyl)-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionic acid o ~
w i uoi Me( O
70 mg of ethyl 2R/S-(4-fluoro-3-methylbenzyl)-(1 R',3S')-3-(3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propionate are dissolved in 3 ml of tetrahydrofuranlmethanol 3:1, 0.1 ml of 1 N LiOH is added and the mixture is stirred at room temperature for 18 h. The solvent is removed under reduced pressure and the residue is acidified with trifluoroacetic acid and purified by RP-HPLC. This gives 2R/S-(4-fluoro-3-methylbenzyl)-(1 R~,3S~)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyJ-propionic acid as a colorless oil. Cz9H34FN05 (495.60), MS (ESI): 496.20 (M + H+).
Example 10:
rac-3-(cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol o BuZSnO, CsF ~ ~N \ O O
O O
cis/racemate 21.7 g of 1,3-Cyclohexanediol and 30.3 g of dibutyltin oxide are dissolved in 450 ml of toluene and, under reflux on a water separator, heated to the boil. During the reaction, the volume of the mixture is reduced to half of the original volume. After 3 hours, the reaction mixture is cooled to room temperature and 300 ml of dimethylformamide, 29 g of 4-iodomethyl-5-methyl-2-m-tolyloxazole 1 and 23.5 g of cesium fluoride are added. The mixture is stirred at room temperature for 18 hours. The reaction mixture is diluted by addition of ethyl acetate and washed with saturated NaCI
solution. The organic phase is dried over magnesium sulfate, the solvent is removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 10:1 --~ 1:4). This gives 58 g of rac-3-(cis-5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol as a yellowish solid which is recrystallized from n-heptane/ethyl acetate.
C18H23N03 (301.39), MS (ESI): 302 (M + H+).
3-((1 R,3S)-cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol 4 Chirazyme L-2 ~N O O vinyl acetate O O
cis/racemate NaOH
MeOH
O \
~N O O
25 g of rac-3-(cis-5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol are 5 dissolved in 320 ml of vinyl acetate and 1.3 g of Chirazyme L-2 Lyo (Boehringer Mannheim) are added. The mixture is stirred at room temperature for about 3 hours (LC-MS control for 40-45% conversion), the enzyme is then filtered off and washed with ethyl acetate and the solvent is removed under reduced pressure. The residue is purified by flash 10 chromatography on silica gel (n-heptane/ethyl acetate = 3:1 ). This gives 8 g of acetate 3 as a colorless oil. C20H25N04 (343.43), MS (ESI): 344 (M + H+). The acetate is taken up in 170 ml of methanol and, after addition of 27 ml of 2N NaOH, stirred at room temperature for 1 hour. Most of the solvent is removed under reduced pressure. After addition of in each case 15 150 ml of water and ethyl acetate, the org. phase is washed with NaCI
solution. The organic phase is dried over magnesium sulfate and the solvent is removed under reduced pressure. This gives 6.7 g of 3-((1 R,3S)-cis-5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexanol as a yellowish solid.
C18H23N03 (301.39), MS (ESI): 302 (M + H+).
4-((1 R,3S)-3-Allyloxycyclohexyloxymethyl)-5-methyl-2-m-tolyloxazole 5 NaH, DMF
ally) bromide O -~- O O~
At room temperature, 470 mg of 60% strength sodium hydride suspension are added to a solution of 2.2 g of 3-((1 R,3S)-cis-5-methyl-2-m-tolyloxazol-j 4-ylmethoxy)cyclohexanol in 30 ml of dimethylformamide, and the mixture =- ' is stirred at room temperature for ~0 min. 1.36 ml of allyl bromide are then added and the mixture is stirred at 40°C until the conversion is complete; if required, further sodium hydride and allyl bromide are added. After complete conversion (LC-MS control), 100 ml of ethyl acetate and 150 ml of saturated NaCI solution are added. The organic phase is dried over magnesium sulfate, the solvents are removed under reduced pressure and the residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 3:1). This gives 2.3 g of 4-((1 R,3S)-3-allyloxycyclo-hexyloxymethyl)-5-methyl-2-m-tolyloxazole 5 as a colorless oil.
C21 H27N03 (341.45), MS (ESI): 342 (M + H+).
(1 R',3S')-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]pro-pane-1,2-diol o \ osoa ~ \
Na~ \ N O O O
O
N O O ~ /
At 0°C, 225 mg of DABCO, 1.4 g of anhydrous N-methylmorpholine N-oxide and 350 pl of osmium tetroxide, 2.5% in tert-butanol, were added to 2.8 g of 4-((1 R,3S)-3-allyloxycyclohexyloxymethyl)-5-methyl-2-m-tolyl-oxazole in 9 ml of acetone/water 10:1. After 24 h of stirring at room temperature, 2.4 g of sodium metabisulfite were added, and after 10 min, the mixture was diluted with 25 ml of CH2C12. The mixture was filtered and the solvent was removed under reduced pressure. The residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 1:3). This gives 2.5 g of 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propane-1,2-diol as a colorless oil. C2~H2gNO5 (375.47), MS
(ESI): 376 (M + H+).
2S-(1 S',3R')-1-(tert-Butyldimethylsilanyloxy)-3-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxy]propan-2-of O TBDMSCI
\ \~O~O O imid~zoVe \ N O O O-Si N
/ o \
At 0°C, 500 mg of imidazole, 1.02 g of tert-butyldimethylsilyl chloride and 50 mg of tetrabutylammonium iodide are added to 2.5 g of 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyfoxazol-4-ylmethoxy)cyclohexyfoxy]propane-1,2-diol in 30 ml of dichloromethane. Over a period of 18 h, the mixture is allowed to warm to room temperature and then poured onto ice. The mixture is extracted with dichloromethane, the extract is dried over sodium sulfate and filtered and the solvent is removed under reduced pressure. The residue is purified by flash chromatography on silica gel (n-heptane/
ethyl acetate = 2:1 -~ 1:2). This gives 2S-(1S',3R')-1-(tert-butyldimethyl-silanyloxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propan-2-of as a colorless oil. C27H43NO5S1 (489.73), MS (ESI): 490 (M + H+).
2S'-(1 S,3R)4-{3-[3-(tert-Butyldimethylsilanyloxy)-2-prop-2-ynyloxypropoxy]-cyclohexyloxymethyl}-5-methyl-2-m-tolyloxazole o ~~ o \ ~
. ~\ -.~ ~ ! ~ ~o~o o-si \ ~O~O O-Si ---~ N
N
\~ NaH 4 / O
1~
25 mg of 60% strength sodium hydride suspension are added to 245 mg of 2S-(1 S',3R')-1-(tert-butyldimethylsilanyloxy)-3-(3-(5-methyl-2-m-tolyloxazol-ylmethoxy)cyclohexyloxy]propan-2-of in 3 ml of dimethylformamide, and the mixture is stirred at room temperature for 20 min. 200 mg of propargyl bromide are then added, and the mixture is stirred at room temperature until the conversion is complete. The mixture is taken up in saturated NaCI
solution/ethyl acetate, the organic phase is dried over sodium sulfate and filtered and the solvent is removed under reduced pressure. This gives 2S'-(1 S,3R)4-{3-[3-(tert-butyldimethxlsilanyfoxy)-2-prop-2-ynyloxypropoxy]cyclohexyloxymethyl}-5-methyl-2-m-tolyloxazole as a colorless oil. C3oHa5NO~Si (527.78), MS (ESI): 528 (M + H+).
(1 R',3S')-2R-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-prop-2-ynyloxypropan-1-of O TBAF
/ THF \ N 0 O~0 \ N O O O-Si / ~ ~~ ~ / 0 2 ml of tetrabutylammonium fluoride, 1 M in tetrahydrofuran, are added to 200 mg of 2S'-(1 S,3R)4-{3-[3-(tert-butyldimethylsilanyloxy)-2-prop-2-ynyl-oxypropoxy]cyclohexyloxymethyl~-5-methyl-2-m-tolyloxazole in 2 ml of tetrahydrofuran, and the mixture is stirred at room temperature for 2 h. The mixture is taken up in saturated NaCI solution/ethyl acetate, the organic phase is dried over sodium sulfate and filtered and the solvent is removed under reduced pressure. This gives (1 R',3S')-2R-3-[3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclohexyloxyJ-2-prop-2-ynyloxypropan-1-of as a colorless oil. C24H3~NO5 (413.53), MS (ESI): 414 (M + H+).
2R-(1 R',3S')-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropan-1-of O PdlC ~
~ H2 \ - v _O O
w ~ N O
\ ~O O
N O ~ I / O
O
50 mg of PdIC 10% are added to crude (1 R',3S')-2R-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-prop-2-ynyloxypropan-1-of dissolved in 20 ml of methanol, and the mixture is stirred under a hydrogen pressure of 1 bar for 3 h. The catalyst is filtered off and the solvent is removed under reduced pressure. This gives 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropan-1-of as a colorless oil. The residue is purified by flash chromatography on silica gel (n-heptane/ethyl acetate = 1:1). C24H35NO5 (417.55), MS (ESI): 418 (M + H+}.
2R-(1 R',3S')-2-(2-Propoxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid 1. Dess-Martin periodinane \ ~ 2. NaC102 ~O O O O
O ~ 11N Y 'p ~ O
'O ~O
180 mg of Dess-Martin periodinane are added to 90 mg of 2R-(1 R',3S')-2-propoxy-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]propan-1-0l in 1.5 ml of dichloromethane, and the mixture is stirred at room temperature for 2 h. 41 mg of Na2S203 in 3 ml of 5% strength NaHC03 solution are then added, and the mixture is stirred at room temperature for 10 min. The organic phase is separated off, dried over MgS04 and concentrated. The residue is taken up in 2 ml of acetonitrile, and 1.5 ml of 0.65 M NaH2P04 solution and 48 Nl of 35°l° strength H202 solution are added. At 0°C, 30 mg of NaCl02 in 2 ml of water are added dropwise over a period of 1 h. The mixture is stirred at this temperature for 3 h. Na2S03 solution, 10°l° strength HCI and 10 ml of CH2C12 are then added, the phases are separated and the organic phase is dried over MgS04 and concentrated. Purification of the residue by HPLC gives 1.2 mg of 28-(1 R',3S')-2-(2-methylpropoxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid.
Example 11:
2R-( 1 R',3S')-3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propanoic acid O
O O ~ -O
O
i F F F
Using reaction conditions similar to those of example 10, 2S-(1R',3S')-1-(tert-butyldimethylsilanyloxy)-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-trifluoromethylbenzyl bromide give 2R-(1 R',3S')-3-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-5 trifluoromethylbenzyloxy)propionic acid.
Example 12:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-methoxypropionic acid O
O O ~ ~OH
H3C~0 Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and methyl iodide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-methoxypropionic acid.
Example 13:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-tri-fluoromethylbenzyloxy)propanoic acid O
/ \ N ~ O OOH
O
O CHs F
F F
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-trifluoromethylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propanoic acid.
Example 14:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-tri-fluoromethylbenzyloxy)propanoic acid / \ i ° °~oH
O CHa \ ( F
F
Using reaction conditions similar to those of example 10, 1-(tert-butyldimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmeth-oxy)cyclohexyloxy]propan-2-of and 3-trifluoromethylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-tri-fluoromethylbenzyloxy)propanoic acid.
Example 15:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-methoxybenzyloxy)propanoic acid / \ i ° O~oH
O CHa \I
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 3-methoxybenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-methoxy-benzyloxy)propanoic acid.
Example 16:
3-[(1 R,3S)-3-(5-Methyl-2-m-tofyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2,5-dimethylbenzyloxy)propanoic acid O
O O' Y 'OH
'O
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2,5-dimethylbenzyl bromide give 3-[(1R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2,5-dimethylbenzyloxy)propanoic acid.
Example 17:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-methylbenzyloxy)propanoic acid 0 o~pH
o O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-methylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-methylbenzyloxy)propanoic acid.
Example 18:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-tert-butylbenzyloxy)propanoic acid $$
0 o~oH
O
O CHs Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 4-tert-butylbenzyl bromide give 3-[(1R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-tert-butyl-benzyloxy)propanoic acid.
Example 19:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-trifluoromethylbenzyloxy)propanoic acid 0 o~oH
o CH3 F
F~ F
Using reaction conditions similar to those. of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-trifluoromethylbenzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-trifluoromethylbenzyloxy)propanoic acid.
Example 20:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-chlorothien-5-ylmethoxy)propionic acid 0 o~oH
O CHs / ~S
CI
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-chlorothien-5-ylmethyl chloride give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-chlorothien-5-ylmethoxy)propionic acid.
Example 21:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-butynoxy)propionic acid 0 o~oH
O CHa cH3 Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-butynyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-butynoxy)propionic acid.
Example 22:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-propynoxy)propionic acid O OI Y 'OH
IO
cH
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-propynyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-propynoxy)-propionic acid.
Example 23:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-pentynoxy)propionic acid / O OOH
O
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 2-pentynyl bromide give 3-[(1 R,3S)-3-(5-5 methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-pentynoxy)-propionic acid.
Example 24:
3-[( 1 R, 3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-10 propenoxy)propionic acid OH
Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and allyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-15 m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-propenoxy)propionic acid.
Example 25:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-20 phenyl-2-propenoxy)propionic acid 0 o~oH
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[( 1 R, 3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and 3-phenyl-2-propenyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(3-phenyl-2-propenoxy)propionic acid.
Example 26:
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-(2-methyl-2-propenoxy)propionic acid j O OOH
O
O CHs Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and isobutenyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazoi-4-ylmethoxy)cyclohexyloxy]-2-(2-methyl-2-propen-oxy)propionic acid.
Example 27;
3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-benzyloxypropionic acid 0 o~oH
O CHa Using reaction conditions similar to those of example 10, 1-(tert-butyl-dimethylsilanyloxy)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyloxy]propan-2-of and benzyl bromide give 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-2-benzyloxypropionic acid.
Example 28:
Benzyl [(1 S,3R)-3-aliyloxycyclohex-1-yl] ether 0 o I ~ o o~
/ i Under an atmosphere of argon, 12 g of sodium hydride (55-65%) are initially charged in 200 ml of abs DMF and stirred at RT for 10 min. With ice cooling, 54 g of benzyl [(1S,3R)-3-hydroxycyclohex-1-y1] ether in 70 ml of DMF are added dropwise. The mixture is stirred at RT for 90 min. With ice cooling, 50 g of allyl bromide are slowly added dropwise. After the addition is complete, the mixture is stirred at 45°C for 1 h. According to TLC, the reaction has gone to completion. The reaction solution is quenched with 15 ml of iPrOH, diluted with water and saturated NaCI solution and extracted with MTBE. The combined organic phases are washed with water and NaCI solution, dried over MgS04 and concentrated. This gives 60 g of benzyl [(1S,3R)-3-allyloxycyclohex-1-yl] ether as a light-beige oil.
C16H2202 (246.35), MS (ESI): 247 (M + H+).
(1S,3R)-3-Allyloxycyclohex-1-yl benzoate O
O O
Analogously to benzyl (1S,3R)-3-allyloxycyclohex-1-yl ether, (1S,3R)-3-hydroxycyclohex-1-yl benzoate and allyl bromide give (1 S,3R)-3-allyloxycyclohex-1-yl benzoate. C16H2003 (260.37), MS (ESI): 261 (M + H+).
Allyl (1 R,3S)-3-trityloxymethylcyclohex-1-yl ether /
Analogously to benzyl (1S,3R)-3-allyloxycyclohex-1-yl ether, (1R,3S)-3-trityloxymethyicyclohexanol and allyl bromide give allyl (1 R,3S)-3-trityioxymethylcyclohex-1-yl ether.
(2R/2S)-3-[(1S,3R)-3-Benzyloxycyclohexyloxy]propane-1,2-diol DABCO
NMO
Os04 acetone water O O~ ~ ~ O O~O
/ O
At 0°C, 6.8 g of DABCO, 42.8 g of NMO and 8.0 mt of osmium tetroxide solution (2.5% in tert-butanoi) are added successively to 60 g of benzyl (1S,3R)-3-allyloxycyclohex-1-yl ether in 200 ml of acetonelwater (10:1).
The solution is stirred at RT overnight. After 24 h, another 5 ml of osmium tetroxide solution are added, and the solution is stirred at RT overnight. The reaction is then complete. Sodium sulfite solution and water are added, and the mixture is extracted with dichloromethane. The organic phase is dried over Na2S04 and concentrated, which gives 65 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol as a brown oil. C16H24O4 (280.37), MS (ESI): 281 (M + H+).
(2R/2S)-3-[(1 R,3S)-1-Benzoyloxycyclohex-3-yloxy]propane-1,2-diol O
O O~O
~ O
Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol, (1S,3R)-3-hydoxycyclohex-1-yl benzoate, NMO, DABCO and osmium tetroxide give (2R/2S)-3-[(1 R,3S)-1-benzoyloxycyclohex-3-yloxy]propane-1,2-diol. C16H2205 (294.35), MS (ESI): 295 (M + H+).
(2R/2S)-3-[(1 R,3S)-3-Trityloxymethylcyclohexyloxy]propane-1,2-diol O
O
o Analogously to (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol, allyl (1R,3S)-3-trityloxymethylcyclohex-1-yl ether, NMO, DABCO and osmium tetroxide give ((2R/2S)-3-[(1 R,3S)-3-trityloxymethylcyclohexyloxy]-propane-1,2-diol.
(2R/2S)-3-[(1 S,3R)-3-Benzyloxycyclohexyloxy]-2-hydroxypropyl tert-butyl-diphenylsilyl ether imidazole TBDPSCI
~ DMF
o' V 'o 0 ~
o' v 'o o' \ /
i o 20 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]propane-1,2-diol are dissolved in 100 ml of DMF, 12 g of imidazole and then 20.6 g of TBDPSCI
are added and the mixture is stirred at RT. After 3 h, the reaction is complete. The solution is diluted with water/saturated NaCI solution and extracted with MTBE and the organic phase is dried over MgS04 and concentrated, which gives 35 g of (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether as a yellow oil. C32H42O4Si (518.78), MS (ESI): 519 (M + H+).
(2R/2S)-3-[(1 R,3S)-1-Benzoyloxycyclohex-1-yloxy]-2-hydroxypropyl tert-butyldimethylsilyl ether O
~ O O~p.Si-O
Analogously to (2R/2S)-3-[(1S,3R)-3-benzoyloxycyclohex-1-yloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1R,3S)-1-benzoyloxycyclohex-3-yloxy]propane-1,2-diol, imidazole and TBDMSCI
give (2R/2S)-3-[(1 S,3R)-1-benzoyloxycyclohex-1-yloxy]-2-hydroxypropyl tert-butyldimethylsilyl ether. C22H36O5Si (408.62), MS (ESI): 409 (M + H+).
(2R/2S)-3-[(1 R,3S)-3-Trityloxymethylcyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether i 0 0 o.s~ \ /
w o i U
Analogously to (2RI2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-hydroxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 R,3S)-3-trityloxymethyl-cyclohexyloxy]propane-1,2-diol, imidazole and TBDPSCI give (2R/2S)-3-5 [(1 R,3S)-3-trityloxymethylcyclohexyloxy]-2-hydroxypropyl tert-butyldiphenyl-silyl ether.
(2R/2S)-3-[(1S,3R)-3-Benzyloxycyclohexyloxy]-2-methoxypropyl tert-butyl-diphenylsilyl ether I
I \ Mel KOtBu THF
~ si --~ \ O O O~Si \ O_ v 'O O' ~ ~ I
I, 10 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and 8.5 g of iodomethane are dissolved in 100 ml of THF. At RT, 3.3 g of KOtBu are added, and the suspension is stirred at RT
for 1 h. Saturated NH4C1 solution and water are then added, and the solution is extracted with MTBE. The combined organic phases are dried over MgS04 and concentrated. The residue is chromatographed on silica gel (heptane/ethyl acetate 5:1 -~ 1:1 ), which gives 7.2 g of (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether as a light-yellow oil.
(2R/2S)-3-[(1 S,3R)-3-Benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldi-phenylsilyl ether i 0 0 o.s~ \ /
i Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1S,3R)-3-benzyloxy-cyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and iodoethane give (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether.
(2RI2S)-3-[(1 S,3R)-3-Benzyloxycyclohexyloxy]-2-allyloxypropyl tert-butyl-diphenylsilyl ether i w 0 0 o,s~ ~ /
i Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilylether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-hydroxypropyl tert-butyldiphenylsilylether and allyl bromide give (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-allyloxypropyl tert-butyl-diphenylsilyl ether.
(2R/2S)-3-[( 1 S, 3R)-3-Benzyloxycyclohexyloxy]-2-(2-methyl-2-propenloxy)-propyl tert-butyldiphenylsilyl ether i 0 0 o,s~
i Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and isobutenyl bromide give (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-(2-methyl-2-propenloxy)propyl tert-butyldiphenylsilyl ether.
(2R/2S)-3-[(1 R,3S)-3-Benzoyloxycyclohex-1-yloxy]-2-(4-trifluoromethyl-benzyloxy)propyl tert-butyldimethylsilyl ether O O~O~Si-O
F
F F
Analogously to (2R/2S)-3-[(1S,3R)-3-benzoyloxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether, (2R/2S)-3-[(1R,3S)-1-benzoyloxycyclohex-3-yloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and 4-trifluoromethylbenzyl bromide give (2R/2S)-3-[(1 R,3S)-3-benzoyl-oxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy)propyl tert-butyldi-methylsilyl ether.
(2R/2S)-3-[(1 R,3S)-3-Trityloxymethylcyclohexyloxy]-2-(4-trifluoromethyl-benzyloxy}propyl tert-butyldiphenylsilyl ether i O O O.Si O
F
F F
Analogously to (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1R,3S)-3-trityloxymethyl-cyclohexyloxy]-2-hydroxypropyl tert-butyldiphenylsilyl ether and 4-trifluoro-methylbenzyl bromide give (2R/2S)-3-[(1 R,3S)-3-trityloxymethylcyclohexyl oxy]-2-(4-trifluoromethylbenzyloxy)propyl tert-butyldiphenylsilyl ether.
(2R/2S)-3-[(1S,3R)-3-Hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldi-phenylsilyl ether Hz / Pd/C /
MeOH
0 0 o's~ ~ ~ ' s.
0 0 0' ow 7.2 g of (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether are dissolved in 40 ml of methanol, 4 g of Pd/C
(10%) are added and the mixture is hydrogenated at RT and a super-atmospheric pressure of 5 bar for 15 h. The catalyst is filtered off, the residue is washed with dichloromethane and the filtrate is concentrated, which gives 6.0 g of (2RI2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-meth-oxypropyl tert-butyldiphenylsilyl ether as a colorless oil. C26H3804Si (442.68), MS (ESI): 443 (M + H+).
(2R/2S)-3-[(1S,3R)-3-Hydroxycyclohexyloxy]-2-ethoxypropyl tent-butyldi-phenylsilyl ether i 0 0 o.s~ ~
Analogously to (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether gives (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether. C27H4004Si (456.70), MS (ESI): 457 (M + H+).
(2R/2S)-3-[(1 R,3S)-3-Hydroxymethylcyclohexyloxy]-2-(4-trifluoromethyl-benzyloxy)propyl tert-butyldiphenylsilyl ether \ HCOOH, MTBE
--~ O
/ /
3.5 g of (2R/2S)-3-[(1 R,3S)-3-trityloxymethylcyclohexyloxy]-2-(4-trifluoro-methylbenzyloxy)propyl tert-butyldiphenylsilyl ether are dissolved in 100 ml of MTBE, 58 g of formic acid are added and the mixture is stirred at RT.
The solution is concentrated and the residue is chromatographed on silica gel, which gives 170 mg of (2R/2S)-3-[(1 R,3S)-3-hydroxymethylcyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propyl tert-butyldi-phenylsilyl ether as a colorless oil.
(2R/2S)-3-((1 S,3R)-3-Hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldi-phenylsilyl ether 0 0 o'S~ \ /
Analogously to (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1S,3R)-3-benzyl-oxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether gives (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldi-phenylsilyl ether.
C28H4204Si (470.73), MS (ESI): 471 (M + H+) (2R/2S)-3-[(1S,3R)-3-Hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldi-phenylsilyl ether i 0 0 o.s~ \ /
Analogously to (2R/2S)-3-((1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxy-propyl tert-butyldiphenylsilyl ether, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclo-hexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether gives (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether. C29H4404Si (484.76), MS (ESI): 485 (M + H+).
(2R/2S)-3-[(1 R,3S)-1-Hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyl-oxy) tert-butyldimethylsilyl ether MeOH
O O~O.Si- ~ O O~ ~O.Si-/ O
/ ( /
F F
F F F F
4.6 g of (2R/2S)-3-[(1S,3R)-1-benzoyloxycyclohex-3-yloxy]-2-(4-trifluoro-methoxybenzyloxy) tert-butyldimethylsilyl ether are dissolved in 20 ml of methanol, 2.2 g of K2C03 are added and the mixture is stirred at RT for 72 h. The K2C03 is filtered off, the residue is washed with methanol and the filtrate is concentrated, which gives 0.85 g of (2R/2S)-3-[(1 R,3S)-3-hydroxycyclohexyloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether as a colorless oil. C23H37F304Si (462.63), MS (ESI): 463 (M + H+).
2-Methoxy-3-[(1 R,3S)-3-(5-methyl-2-phenyloxazol-4-ylmethoxy)cyclohexyl-oxy]propanoic acid ~ci o i O O~O
+ Si O _ N
O O~O~ ~ ~ ,O
O
i 100 mg of (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether are dissolved in 2 ml of THF, and 83 mg of 2-phenyl-5-methyloxazol-4-ylmethyl chloride and 51 mg of KOtBu are added successively. At RT, the reaction mixture is shaken overnight.
214 mg of TBAF are added, and the suspension is allowed to stand overnight. After addition of water and MBTE, the organic phase is separated off and concentrated. The residue is taken up in acetone, and 1 ml of 1.92 M Jones reagent is added. The reaction solution is shaken overnight. The solution is diluted with 3 ml of water and poured onto an extraction cartridge (kieselguhr, for 20 ml aqueous phases). The product is then eluted with ethyl acetate and the solution obtained is concentrated and purified by HPLC. This gives 5 mg of 2-methoxy-3-[(1 R,3S)-3-(5-methyl-2 phenyloxazol-4-ylmethoxy)cyclohexyloxy]propanoic acid as a yellow oil.
Example 29:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid HsC O
O~ O O OH
N H3C~0 F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 30:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid HsC O
O~O O OH
'N H3C~0 F
O~F
F
Using reaction conditions similar to those of example 28, (2R12S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid Example 31:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid O~O O OH
N H3C~0 F \
F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 32:
2-Methoxy-3-{( 1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid O~O O OH
'N
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid Example 33:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,6-dimethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O O ~ ~OH
H3C ~ N
HsC O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,6-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 34:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O
O O ~ ~OH
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 35:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-naphthyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid O =~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-naphthyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-naphthyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 36:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid O~O O OH
'N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 37:
2-Methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid O~O O_ Y 'OH
'N
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-biphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 38:
2-Methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid HsC O
~O O ~ ~OH
N ,O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 39:
2-Methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid HsC O
O ~~ ~O O ~ ~OH
'N H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 40:
2-Methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O
O O ~ ~OH
H3C~0 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 41:
2-Methoxy-3-f (1 R,3S)-3-[5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid HsC O
~O O ~ ~OH
H3C ~ N ,O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-methoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2,6-methylphenyl)oxazol-4-ylmethyl iodide give 2-methoxy-3-{(1 R,3S)-3-[5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 42:
3-[(1 R,3S)-3-(5-Methyl-2-phenyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-phenyloxazol-4-ylmethyl iodide give 3-[(1 R,3S)-3-(5-methyl-2-phenyloxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid.
Example 43:
3-[(1 R,3S)-3-(5-Methyl-2-(3-tolyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid HsC O
~O O ~ ~OH
~N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-tolyl)oxazol-4-ylmethyl iodide give 3-[(1 R,3S)-3-(5-methyl-2-(3-tolyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-propoxypropionic acid.
Example 44:
3-{(1 R,3S)-3-[5-Methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether 2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 45:
3-{(1 R,3S)-3-[5-Methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid O ~~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy~-2-pro-poxypropionic acid.
Example 46:
3-{(1 R,3S)-3-[5-Methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid O~O O OH
'N O
/ HsC
F
F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-~(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 47:
3-f (1 R,3S)-3-[5-Methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid O~O O OH
'' N O
Using reaction conditions similar to those of example 28, (2RI2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-propoxy-propionic acid.
Example 48:
3-{(1 R,3S)-3-[5-Methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid O~O OI Y 'OH
'N 'O
F F ~ ~ H3C
~O
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 3-~(1 R,3S)-3-[5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 49:
3-{(1 R,3S)-3-[5-Methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid O~O O' Y 'OH
-N fO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 3-f (1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxyJcyclohexyloxy~-2-propoxypropionic acid.
Example 50:
3-{(1 R,3S)-3-[5-Methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxyJ-cyclohexyloxy}-2-propoxypropionic acid OH
r Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-((1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 51:
3-{(1 R,3S)-3-[5-Methyl-2-(2-naphthylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid ~O O ~ 'OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyi tert-butyldiphenylsilyl ether and 2-(2-naphthyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(2-naphthylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-propoxy-propionic acid.
Example 52:
3-{(1R,3S)-3-[5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid O~O O OH
'N O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-propoxypropionic acid.
Example 53:
3-{(1 R,3S)-3-[5-Ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid HsC O
O ~~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 54:
3-{(1 R,3S)-3-[5-Ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid HsC O
O O ~ ~OH
'N O
Using reaction conditions similar to those of example 28, (2RI2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 55:
3-{(1 R,3S)-3-[5-Ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid O \ OH
rN
F
hl3L
F F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-propoxypropionic acid.
Example 56:
3-{(1 R,3S)-3-[5-Ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid HsC 1 ~ O
'O' v -O' ~ 'OH
H3C ~ N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(2,6-dimethylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 57:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O ~~ ~O O ~ ~OH
'N /O
C(H3 F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 58:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O~O O OH
'N /O
CrH3 F
O~F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 59:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O~O O OH
'N /O
F
F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 60:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O~O O' Y 'OH
N ~'O
F F
~O
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-~(1 R,3S)-3-[5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 61:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid ~O OOH
'O
CrH3 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 62:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid O f~ ~O O ~ ~OH
F
FF
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid.
Example 63:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-yl-methoxy]cyclohexyloxy}propionic acid HsC O
O~O O OH
'N 'O
CrH3 Using reaction conditions similar to those of example 28, (2R12S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmeth-oxy]cyclohexyloxy}propionic acid.
Example 64:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-biphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 65:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-tolyl)oxazol-4-ylmethoxy)cyclohexyl-oxy]propionic acid O O ~ ~OH
~N ~O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-tolyl)oxazol-4-ylmethoxy)cyclohexyl-oxy]propionic acid.
Example 66:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid HaC O
O ~ O OI Y 'OH
~N ~IO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)cyclohexyloxy]propionic acid.
Example 67:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-yl-methoxy)cyclohexyloxy]propionic acid HsC O
~O O ~ ~OH
'N 'O
F ICrH3 F F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]propionic acid.
Example 68:
2-Ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid HsC~ O
O ~~ ~O O ~ ~OH
H3C ~ N /O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-[(1 R,3S)-3-(5-ethyl-2-(2,4-dimethylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]propionic acid.
Example 69:
3-f (1 R,3S)-3-[5-Ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy~-2-propoxypropionic acid HaC O
O ~ O OI Y 'OH
'_ N IO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid.
Example 70:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-phenyloxazol-4-ylmethoxy]cyclohexyl-oxy}propionic acid HsC O
p ~~ ~O O ~ OOH
O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxyJ-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-phenyloxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-phenyloxazol-4-ylmethoxy]cyclohexyloxy}propionic acid.
Example 71:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid HsC O
~O O ~ ~OH
'N /O
ICrH3 Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-methylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methylphenyl)oxazol-4-ylmethoxyJ-cyclohexyloxy}propionic acid.
Example 72:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 73:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid O~O O OH
'N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tert-butyldiphenylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-~(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}propionic acid.
Example 74:
2-Ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-naphthyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}propionic acid OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1S,3R)-3-benzyloxycyclohexyloxy]-2-ethoxypropyl tent-butyldiphenylsilyl ether and 5-methyl-2-(2-naphthyl)oxazol-4-ylmethyl iodide give 2-ethoxy-3-{(1 R,3S)-3-[5-methyl-2-(2-naphthyl)oxazol-4-ylmethoxy]cyclohexyloxy}-propionic acid.
Example 75:
3-((1 R,3S)-3-[5-Ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-propoxypropionic acid HsC O
~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2RI2S)-3-[(1S,3R)-3-hydroxycyclohexyloxy]-2-propoxypropyl tert-butyldiphenylsilyl ether and 5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxyjcyclohexyl-oxy}-2-propoxypropionic acid.
Example 76:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyj-2-(4-trifluoromethylbenzyloxy)propionic acid O chiral / \ N ~ O OOH
O
O CHs i F
F F
Separation of 3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyj-2-(4-trifluoromethylbenzyloxy)propanoic acid (example 13) by chiral HPLC affords, in addition to enantiomerically pure (S)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxyj-2-(4-trifluoromethylbenzyloxy)propionic acid (example 10), (R)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyioxyj-2-(4-trifluoromethyl-benzyloxy)propionic acid.
Example 77:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-yl-methoxy)cyclohexyloxyj-2-(4-trifluoromethyibenzyloxy)propionic acid O OOH
F O~ O
F
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(3-trifluoromethylphenyl)-oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 78:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid O O' Y 'OH
O~ 'O
O CHs F~--F
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4.-ylmethyl iodide give (R)-3-((1 R,3S)-3-(5-methyl-2-(4-trifluoromethoxy-phenyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-frifluoromethylbenzyloxy)-propionic acid.
Example 79:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid H3C ~ ~ j I O O' Y 'OH
H3C O~ 'O
~3 F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give (R)-3-((1 R,3S)-3-(5-methyl-2-(4-isopropylphenyl)-oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 80:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(2-naphthyl)oxazol-4-ylmethoxy)cyclohexyl-oxy]-2-(4-trifluoromethylbenzyloxy)propionic acid I O OOH
O~ O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(2-naphthyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(2-naphthyl)oxazol-4-ylmethoxy)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 81:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid H3C ~ ~ / ~ O O' Y 'OH
~O IO
CHs F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(4-methylphenyl)oxazol-4-ylmethyl iodide give (R)-3-((1 R,3S)-3-(5-methyl-2-(4-methylphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 82:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmeth-oxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid 'F O
F
F, 'p ~ ~ N ~ O OOH
O~ O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(4-trifluoromethoxy-phenyl)oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)-propionic acid.
Example 83:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy)-cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid F F
O OOH
F O~ O
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(3-trifluoromethylphenyl)-oxazol-4-ylmethoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 84:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid O OOH
F p~ O
F CHa F
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 R,3S)-1-hydroxycyclohex-1-yloxy]-2-(4-trifluoromethylbenzyloxy) tert-butyldimethylsilyl ether and 5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give (R)-3-[(1 R,3S)-3-(5-methyl-2-(3-methoxyphenyl)oxazol-4-yl-methoxy)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
Example 85:
3-{(1 R,3S)-3-[5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]-cyclohexyloxy}-2-isobutoxypropionic acid ~O O ~ ~OH
F F
F
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether and 2-(3-trifluoromethylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxyJ-cyclohexyloxy}-2-isobutoxypropionic acid.
Example 86:
3-{(1 R,3S)-3-[5-Methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxyJcyclohexyl-oxy}-2-isobutoxypropionic acid O ~~ ~O O ~ ~OH
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether and 2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-isobut-oxypropionic acid.
Example 87:
3-{(1 R,3S)-3-[5-Methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyl-oxy}-2-isobutoxypropionic acid O~O O OH
'N O
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsiiyl ether and 2-(4-methylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(4-methylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-isobut-oxypropionic acid.
Example 88:
3-{(1 R,3S)-3-[5-Methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclo-hexyloxy}-2-isobutoxypropionic acid O~O O' Y 'OH
-N IO
Using reaction conditions similar to those of example 28, (2R/2S)-3-[(1 S,3R)-3-hydroxycyclohexyloxy]-2-isobutoxypropyl tert-butyldiphenylsilyl ether and 2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give 3-{(1 R,3S)-3-[5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-2-iso-butoxypropionic acid.
Example 89:
(2R12S)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclo-hexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid o~ ,s. \ ~ °
o~o i F
F F
333 mg of (2R/2S)-3-[(1 R,3S)-3-hydroxymethylcyclohexyloxy]-2-(4-trifluoro-methylbenzyloxy)propyl tert-butyldiphenylsilyl ether are dissolved in MTBE, 125 mg of potassium tert-butoxide and 347 mg of 5-methyl-2-(3-methylphenyl)oxazol-4-ylmethyl iodide are added successively and the mixture is stirred at RT. After the reaction has gone to completion, water and MTBE are added and the organic phase is separated off, dried over MgS04 and concentrated. The residue is chromatographed on silica gel (Flash-Master, heptane/ethyl acetate 1:0 ~ 1:1 -~ 0:1). The product-containing fractions are concentrated, the residue (420 mg) is dissolved in 10 ml of THF and 174 mg of TBAF are added. The mixture is stirred for 72 h, water and MTBE are then added and the organic phase is separated off, washed with NaCI solution, dried over MgS04 and concentrated. The residue is dissolved in 2 ml of acetone, 0.5 ml of 1.9M Jones reagent is added and the mixture is stirred at RT overnight. Water and MTBE are added, and the organic phase is then separated off, dried over MgS04 and concentrated. The residue is purified by HPLC, which gives 200 mg of (2R/2S)-3-((1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclo-hexyloxyJ-2-(4-trifluoromethylbenzyloxy)propionic acid. C30H34F3N06 (561.6), MS (ESI): 562 (M + H+).
(S)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclohexyl-oxy]-2-(4-trifluoromethylbenzyloxy)propionic acid OH
Separation of (2R/2S)-3-((1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid by chiral HPLC affords (2S)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
C30H34F3N06 (561.6), MS (ESI): 562 (M + H+).
Example 90:
(R)-3-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxymethyl)cyclohexyl-oxy]-2-(4-trifluoromethylbenzyloxy)propionic acid o~oH
i F
1o F F
Separation of (2R/2S)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid by chiral HPLC gives (2R)-3-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy-methyl)cyclohexyloxy]-2-(4-trifluoromethylbenzyloxy)propionic acid.
C30H34F3N06 (561.6), MS (ESI): 562 (M + H+).
Example 91:
2-[(1 R,3S)-3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]-3-(3-trifluoromethylphenyl)propionic acid o ~
Analogously to example 9, ethyl ((1 R,3S)-2-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]acrylate and 3-bromobenzotrifluoride give 2-[(1 R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]-3-(3-trifluoromethylphenyl)propionic acid.
Characterization of the examples by mass spectroscopy:
Example Empirical formula Monoisotope Found by MS
mass ESI as (M + H+) 1 C23H30FN05 419.49 420 2 C24H32FN05 433.52 434 3 C21 H26FN05 391.44 392 4 C22H28FN05 405.47 406 C23H29N05 399.49 400 6 C31 H40N2O5 520.67 521 7 C30H38N2O5 506.65 507 8 C23H31 N06 417.51 418 9 C29H34FN05 495.60 496 C24H33N06 431.53 432 11 C29H32F3N06 547.58 548 12 C22H29N06 403.48 404 13 C29H32F3N06 547.58 548 14 C29H32F3N06 547.58 548 C29H35N07 509.61 510 16 C30H37N06 507.63 508 17 C29H35N06 493.61 494 18 C32H41 N06 535.69 536 19 C29H32F3N06 547.58 548 C26H30CIN06S 520.05 521 21 C25H31 N06 441.53 442 22 C24H29NO6 427.50 428 23 C26H33N06 455.56 456 24 C24H31 N06 429.52 430 C30H35N06 505.62 506 26 C25H33N06 443.55 444 27 C28H33N06 479.58 480 28 C21 H27N06 389.45 390 29 C22H26F3N06 457.45 458 C22H26F3N07 473.45 474 31 C22H26F3N06 457.45 458 32 C22H29N06 403.48 404 33 C23H31 N06 417.51 418 34 C22H26F3N06 457.45 458 C25H29N06 439.51 440 36 C23H31 N06 417.51 418 37 C27H31 N06 465.55 466 38 C23H31 N07 433.51 434 39 C23H31 N06 417.51 418 40 C23H28F3N06 471.48 472 41 C24H33N06 431.53 432 42 C23H31 N06 417.51 418 43 C24H33N06 431.53 432 44 C24H30F3N07 501.50 502 45 C24H33N07 447.53 448 46 C24H30F3N06 485.51 486 47 C24H33N06 431.53 432 48 C24H30F3N07 501.50 502 49 C26H37N06 459.59 460 50 C24H30F3N06 485.51 486 51 C27H33N06 467.57 468 52 C24H30F3N06 485.51 486 53 C25H35N07 461.56 462 54 C25H35N06 445.56 446 55 C25H32F3N06 499.53 500 56 C26H37N06 459.59 460 57 C23H28F3N06 471.48 472 58 C23H28F3N07 487.48 488 59 C23H28F3N06 471.48 472 60 C23H28F3N07 487.48 488 61 C25H35N06 445.56 446 62 C23H28F3N06 471.48 472 63 C24H33N06 431.53 432 64 C28H33N06 479.58 480 65 C24H33N06 431.53 432 66 C26H37N06 459.59 460 67 C24H30F3N06 485.51 486 68 C25H35N06 445.56 446 69 C27H39N06 473.62 474 70 C22H29N06 403.48 404 71 C23H31 N06 417.51 418 72 C23H31 N07 433.51 434 73 C23H31 N06 417.51 418 74 C26H31 N06 453.54 454 75 C24H33N07 447.53 448 76 C29H32F3N06 547.58 548 77 C29H29F6N06 601.55 602 78 C29H29F6N07 617.55 618 79 C31 H36F3N06 575.63 576 80 C32H32F3N06 583.61 584 81 C29H32F3N06 547.58 548 82 C29H29F6N07 617.55 618 83 C29H29F6N06 601.55 602 84 C29H32F3N07 563.58 564 85 C25H32F3N06 499.53 500 86 C25H35N07 461.56 462 87 C25H35N06 445.56 446 88 C27H39N06 473.62 474 89 C30H34F3N06 561.60 562 90 C30H34F3N06 561.60 562 91 C29H32F3N05 531.58 532
Claims (15)
1. A compound of the formula I
in which:
Ring A is (C3-C8)cycloalkanediyl or (C3-C8)cycloalkenediyl, where in the cycloalkanediyl or cycloalkenediyl rings one or more carbon atoms may be replaced by oxygen atoms;
R1, R2 independently of one another are H, F, Cl, Br, CF3, OCF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, SCF3, SFS, OCF2-CHF2, (C6-C10)-aryl, (C6-C10)-aryloxy, OH, NO2; or R1 and R2 together with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C6-C10)-aryl, (C5-C11)-heteroaryl;
R3 is H, (C1-C6)-alkyl, (C3-C8)cycloalkyl, (C1-C3)-alkyl-(C3-C8)cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl, (C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl or (C1-C3)-alkyl which is fully or partially substituted by F;
W is CH or N if o = 1;
W is O, S or NR9 if o = 0;
X is (C1-C6)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;
Y1 is O;
Y2 is CR12R13, SO, SO2;
n is 0-2;
R4 is H, F, (C1-C6)-alkyl;
R5 is H, F, (C1-C6)-alkyl;
R6 is H, (C1-C6)-alkyl; or F if n is not 0;
R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)-cycloalkyl, phenyl, (C5-C11)-heteroaryl, O-(C3-C8)-cycloalkyl, O-phenyl, which may be substituted by OH, NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)-cycloalkyl, O-phenyl, O-(C5-C11)-heteroaryl, and where (C3-C8)-cycloalkyl, phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, Cl, Br, J, OH, NR10R11, CO-(C1-C6)-alkyl, CO-(C6-C10)-aryl, CO-(C1-C6)-alkyl-(C6-C10)-aryl, CO-(C5-C11)-heteroaryl, C(O)-O-(C1-C6)-alkyl, C(O)-O-(C1-C6)-alkyl-(C6-C10)-aryl, C(O)-O-(C6-C10)-aryl, C(O)-O-(C5-C11)-heteroaryl, SO2-(C1-C6)-alkyl, SO2-(C1-C6)-alkyl-(C6-C10)-aryl, SO2-(C1-C6)-alkyl-SO2-(C1-C6)-alkyl, SO2-(C6-C10)-aryl, SO2-(C5-C11)-heteroaryl;
R6 and R7 together with the carbon atom that carries them are (C3-C8)cycloalkyl;
R8 is H, (C1-C6)-alkyl;
R9 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R10 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R11 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R12 is H, (C1-C6)-alkyl;
R13 is H, (C1-C6)-alkyl;
and its physiologically acceptable salts.
in which:
Ring A is (C3-C8)cycloalkanediyl or (C3-C8)cycloalkenediyl, where in the cycloalkanediyl or cycloalkenediyl rings one or more carbon atoms may be replaced by oxygen atoms;
R1, R2 independently of one another are H, F, Cl, Br, CF3, OCF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, SCF3, SFS, OCF2-CHF2, (C6-C10)-aryl, (C6-C10)-aryloxy, OH, NO2; or R1 and R2 together with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C6-C10)-aryl, (C5-C11)-heteroaryl;
R3 is H, (C1-C6)-alkyl, (C3-C8)cycloalkyl, (C1-C3)-alkyl-(C3-C8)cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl, (C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl or (C1-C3)-alkyl which is fully or partially substituted by F;
W is CH or N if o = 1;
W is O, S or NR9 if o = 0;
X is (C1-C6)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;
Y1 is O;
Y2 is CR12R13, SO, SO2;
n is 0-2;
R4 is H, F, (C1-C6)-alkyl;
R5 is H, F, (C1-C6)-alkyl;
R6 is H, (C1-C6)-alkyl; or F if n is not 0;
R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)-cycloalkyl, phenyl, (C5-C11)-heteroaryl, O-(C3-C8)-cycloalkyl, O-phenyl, which may be substituted by OH, NR10R11, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)-cycloalkyl, O-phenyl, O-(C5-C11)-heteroaryl, and where (C3-C8)-cycloalkyl, phenyl, (C5-C11)-heteroaryl may additionally be substituted by (C1-C6)-alkyl, optionally fully or partially substituted by F, O-(C1-C6)-alkyl, optionally fully or partially substituted by F, Cl, Br, J, OH, NR10R11, CO-(C1-C6)-alkyl, CO-(C6-C10)-aryl, CO-(C1-C6)-alkyl-(C6-C10)-aryl, CO-(C5-C11)-heteroaryl, C(O)-O-(C1-C6)-alkyl, C(O)-O-(C1-C6)-alkyl-(C6-C10)-aryl, C(O)-O-(C6-C10)-aryl, C(O)-O-(C5-C11)-heteroaryl, SO2-(C1-C6)-alkyl, SO2-(C1-C6)-alkyl-(C6-C10)-aryl, SO2-(C1-C6)-alkyl-SO2-(C1-C6)-alkyl, SO2-(C6-C10)-aryl, SO2-(C5-C11)-heteroaryl;
R6 and R7 together with the carbon atom that carries them are (C3-C8)cycloalkyl;
R8 is H, (C1-C6)-alkyl;
R9 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R10 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R11 is H, (C1-C6)-alkyl, which is unsubstituted or substituted by phenyl;
R12 is H, (C1-C6)-alkyl;
R13 is H, (C1-C6)-alkyl;
and its physiologically acceptable salts.
2. A compound of the formula I as claimed in claim 1 in which Ring A is (C3-C8)cycloalkanediyl or (C3-C8)cycloalkenediyl, where in the cycloalkanediyl or cycloalkenediyl rings one carbon atom may be replaced by an oxygen atom;
X is (C1-C6)-alkanediyl, where in the alkanediyl group the C1 or C2 carbon atom (to Ring A) may be replaced by an oxygen atom;
and its physiologically acceptable salts.
X is (C1-C6)-alkanediyl, where in the alkanediyl group the C1 or C2 carbon atom (to Ring A) may be replaced by an oxygen atom;
and its physiologically acceptable salts.
3. A compound of the formula I as claimed in one or more of claims 1 to 2, in which Ring A is cis-cyclohexane-1,3-diyl R1, R2 independently of one another are H, F, CF3, (C1-C6)-alkyl, O-(C1-C6)-alkyl, phenyl, or R1 and R2 together with the phenyl ring = naphthyl;
R3 is (C1-C6)-alkyl;
W is CH if o = 1;
X is (CH2)O, CH2-O-CH2;
Y1 is O;
Y2 is CH2;
n is 0, 1;
R4 is H;
R5 is H;
R6 is H;
R7 is H, (C1-C6)-alkyl, O-(C1-C6)-alkyl, (C1-C6)-alkyl-O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, CH2NR10R11, where alkyl, O-alkyl and alkenyl may be substituted by phenyl or (C5-C6)-heteroaryl, which in turn may be substituted by (C1-C6)-alkyl, O-(C1-C6)-alkyl, CF3;
R6 and R7 together with the carbon atom that carries them are (C3-C6)cycloalkyl;
R8 is H;
R10 is (C1-C6)-alkyl;
R11 is (C1-C6)-alkyl which is substituted by phenyl;
and its physiologically acceptable salts.
R3 is (C1-C6)-alkyl;
W is CH if o = 1;
X is (CH2)O, CH2-O-CH2;
Y1 is O;
Y2 is CH2;
n is 0, 1;
R4 is H;
R5 is H;
R6 is H;
R7 is H, (C1-C6)-alkyl, O-(C1-C6)-alkyl, (C1-C6)-alkyl-O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, CH2NR10R11, where alkyl, O-alkyl and alkenyl may be substituted by phenyl or (C5-C6)-heteroaryl, which in turn may be substituted by (C1-C6)-alkyl, O-(C1-C6)-alkyl, CF3;
R6 and R7 together with the carbon atom that carries them are (C3-C6)cycloalkyl;
R8 is H;
R10 is (C1-C6)-alkyl;
R11 is (C1-C6)-alkyl which is substituted by phenyl;
and its physiologically acceptable salts.
4. A pharmaceutical, comprising one or more compounds of formula I
as claimed in one or more of claims 1 to 3.
as claimed in one or more of claims 1 to 3.
5. A pharmaceutical, comprising one or more compounds of the formula I as claimed in one or more of claims 1 to 3 and one or more active compounds having favorable effects on metabolic disorders or diseases associated therewith.
6. A pharmaceutical, comprising one or more compounds of the formula I as claimed in one or more of claims 1 to 3 and one or more antidiabetics.
7. A pharmaceutical, comprising one or more compounds of the formula I as claimed in one or more of claims 1 to 3 and one or more lipid modulators.
8. The use of the compounds of the formula I as claimed in one or more of claims 1 to 3 for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders.
9. The use of the compounds of the formula I as claimed in one or more of claims 1 to 3 for the treatment and/or prevention of disorders where insulin resistance is involved.
10. The use of the compounds of the formula I as claimed in one or more of claims 1 to 3 for the treatment and/or prevention of diabetes mellitus and its sequelae.
11. The use of the compounds of the formula I as claimed in one or more of claims 1 to 3 for the treatment and/or prevention of dyslipidemias and their sequelae.
12. The use of the compounds of the formula I as claimed in one or more of claims 1 to 3 for the treatment and/or prevention of states associated with metabolic syndrome.
13. The use of the compounds as claimed in one or more of claims 1 to 3 in combination with at least one further active compound for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders.
14. The use of the compounds as claimed in one or more of claims 1 to 3 in combination with at least one further active compound for the treatment and/or prevention of disorders in which insulin resistance is involved.
15. A process for preparing a pharmaceutical comprising one or more of the compounds as claimed in one or more of claims 1 to 3, which comprises mixing the active compound with a pharmaceutically acceptable carrier and bringing this mixture into a form suitable for administration.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10308355A DE10308355A1 (en) | 2003-02-27 | 2003-02-27 | Aryl-cycloalkyl-substituted alkanoic acid derivatives, process for their preparation and their use as medicaments |
DE10308355.3 | 2003-02-27 | ||
PCT/EP2004/001586 WO2004076428A1 (en) | 2003-02-27 | 2004-02-19 | 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2517386A1 true CA2517386A1 (en) | 2004-09-10 |
Family
ID=32920629
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002517381A Abandoned CA2517381A1 (en) | 2003-02-27 | 2004-02-19 | 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis |
CA002517386A Abandoned CA2517386A1 (en) | 2003-02-27 | 2004-02-19 | 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis |
CA002516620A Abandoned CA2516620A1 (en) | 2003-02-27 | 2004-02-19 | 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002517381A Abandoned CA2517381A1 (en) | 2003-02-27 | 2004-02-19 | 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002516620A Abandoned CA2516620A1 (en) | 2003-02-27 | 2004-02-19 | 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis |
Country Status (34)
Country | Link |
---|---|
US (5) | US7365084B2 (en) |
EP (3) | EP1599453B1 (en) |
JP (3) | JP2006519199A (en) |
KR (3) | KR20050106462A (en) |
CN (3) | CN100439347C (en) |
AR (3) | AR043427A1 (en) |
AT (3) | ATE365159T1 (en) |
AU (3) | AU2004215677B2 (en) |
BR (3) | BRPI0407814A (en) |
CA (3) | CA2517381A1 (en) |
CL (2) | CL2004000391A1 (en) |
CO (2) | CO5690578A2 (en) |
DE (4) | DE10308355A1 (en) |
DK (3) | DK1599452T3 (en) |
EC (2) | ECSP055985A (en) |
ES (3) | ES2326418T3 (en) |
HR (3) | HRP20050743A2 (en) |
IL (2) | IL170316A (en) |
MA (3) | MA27736A1 (en) |
MX (3) | MXPA05008995A (en) |
NO (3) | NO20054398L (en) |
OA (2) | OA13034A (en) |
PA (1) | PA8596801A1 (en) |
PE (3) | PE20050292A1 (en) |
PL (3) | PL378130A1 (en) |
PT (3) | PT1599453E (en) |
RS (1) | RS20050594A (en) |
RU (3) | RU2005129995A (en) |
SA (1) | SA04250153A (en) |
TN (2) | TNSN05204A1 (en) |
TW (3) | TW200508210A (en) |
UY (2) | UY28209A1 (en) |
WO (3) | WO2004076427A1 (en) |
ZA (2) | ZA200505768B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
US7399777B2 (en) * | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
DE10308353A1 (en) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as medicines |
DE102004038403B4 (en) * | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Process for preparing the enantiomeric forms of cis-configured 3-hydroxycyclohexanecarboxylic acid derivatives |
DE102004039533B4 (en) | 2004-08-14 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Acetic acid derivatives with cyclohexylmethoxy substituents, process for their preparation and their use as medicaments |
DE102004039532B4 (en) | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Cyclohexylmethyloxy substituted acetic acid derivatives, process for their preparation and their use as medicaments |
DE102004039509B4 (en) * | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Aryl-cycloalkyl substituted alkanoic acid derivatives, process for their preparation and their use as medicaments |
DE102004060227B3 (en) | 2004-12-15 | 2006-07-20 | Sanofi-Aventis Deutschland Gmbh | Process for the preparation of oxazoles by condensation of aromatic aldehydes with α-ketoximes to N-oxides and subsequent reaction with activated acid derivatives |
GT200600218A (en) * | 2005-06-10 | 2007-03-28 | FORMULATION AND PROCESS OF DIRECT COMPRESSION | |
CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
BRPI0621960A2 (en) | 2006-08-10 | 2011-12-27 | Wood One Co Ltd | hypoglycemic composition containing acacia bark derivative |
CN101801906A (en) | 2007-08-16 | 2010-08-11 | 索尔维公司 | The method of 3-oxo-alkanoic acid ester that preparation 4-fluorine replaces |
PL2246343T3 (en) * | 2008-02-29 | 2016-12-30 | Process for production of thiophene compound and intermediate thereof | |
US7615661B2 (en) * | 2008-03-12 | 2009-11-10 | International Flavors & Fragrances Inc. | Thioester compounds and their use in fragrance or flavor applications |
KR102499050B1 (en) | 2017-12-13 | 2023-02-14 | 캐논 가부시끼가이샤 | Cartridge |
CN109810071B (en) * | 2019-03-28 | 2023-04-21 | 中国科学院成都生物研究所 | miRNA biosynthesis inhibitor |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2663336B1 (en) | 1990-06-18 | 1992-09-04 | Adir | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
FR2663464B1 (en) * | 1990-06-19 | 1992-09-11 | Commissariat Energie Atomique | INTEGRATED CIRCUIT IN SILICON-ON-INSULATION TECHNOLOGY COMPRISING A FIELD-EFFECT TRANSISTOR AND ITS MANUFACTURING METHOD. |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | Hypolipidaemic benzothiazepine derivatives their preparation and pharmaceutical compositions containing them |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
JP3144624B2 (en) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N-benzyldioxothiazolidylbenzamide derivative and method for producing the same |
CN1158290C (en) | 1996-01-17 | 2004-07-21 | 诺沃挪第克公司 | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
ATE356830T1 (en) | 1996-08-30 | 2007-04-15 | Novo Nordisk As | GLP-1 DERIVATIVES |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
DE69723869T2 (en) | 1996-12-31 | 2004-04-22 | Dr. Reddy's Laboratories Ltd. | HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEIR AND THEIR APPLICATION IN THE TREATMENT OF DIABETIS AND RELATED DISEASES |
DE19726167B4 (en) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, process for its preparation and pharmaceutical preparation containing it |
JP2001510195A (en) | 1997-07-16 | 2001-07-31 | ノボ ノルディスク アクティーゼルスカブ | Condensed 1,2,4-thiadiazine derivatives, their preparation and use |
CO4970713A1 (en) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
EP1067109B1 (en) * | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
DE19823831A1 (en) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
SE9801992D0 (en) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
MA26634A1 (en) | 1998-06-04 | 2004-12-20 | Astra Ab | NOVEL 3-ARYL PROPIONIC ACID DERIVATIVES AND THE LIKE |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19828113A1 (en) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs of Dipeptidyl Peptidase IV Inhibitors |
DE19828114A1 (en) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs of unstable inhibitors of dipeptidyl peptidase IV |
AU5443499A (en) * | 1998-08-27 | 2000-03-21 | Ono Pharmaceutical Co. Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
DE19845405C2 (en) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Aryl-substituted propanolamine derivatives and their use |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
DE19916108C1 (en) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | 1,4-Benzothiazepine-1,1-dioxide derivatives substituted with sugar residues, process for their preparation and their use |
JP2002542245A (en) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | Substituted imidazoles, their manufacture and use |
US6908926B1 (en) * | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
YU72201A (en) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Di-aryl acid derivatives as ppar receptor ligands |
AU782404B2 (en) * | 1999-04-28 | 2005-07-28 | Sanofi-Aventis Deutschland Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
EP1175421A1 (en) | 1999-04-30 | 2002-01-30 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
ATE333448T1 (en) | 1999-06-18 | 2006-08-15 | Merck & Co Inc | ARYLTHIAZOLIDINEDIONE AND ARYLOXA ZOLIDINEDIONE DERIVATIVES |
JP2003504082A (en) | 1999-07-09 | 2003-02-04 | コヘージョン テクノロジーズ, インコーポレイテッド | Ecarin polypeptides, polynucleotides encoding ecarin, and methods for their use |
DE60004066T2 (en) | 1999-07-29 | 2004-04-15 | Eli Lilly And Co., Indianapolis | BENZOFURYLPIPERAZINE: 5-HT2C SEROTONINE RECEPTOR AGONISTS |
CN1372541A (en) * | 1999-09-01 | 2002-10-02 | 阿文蒂斯药物德国有限公司 | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
SE9904413D0 (en) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
PT1237855E (en) | 1999-12-03 | 2004-06-30 | Astrazeneca Ab | (S) -2-ETOXY-3 - [4- (2- {4-METHOSULPHONYL-OXYPHENYL} ETHOXY) PHENYL] PROPANOIC CRYSTALLINE FORM |
PT2266665T (en) | 2000-03-31 | 2016-07-07 | Royalty Pharma Collection Trust | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
AU4882801A (en) | 2000-04-25 | 2001-11-07 | Kyorin Pharmaceutical Co. Ltd. | Novel stable crystal of thiazolidinedione derivative and process for producing the same |
KR100502876B1 (en) | 2000-04-28 | 2005-07-21 | 아사히 가세이 파마 가부시키가이샤 | Novel Bicyclic Compounds |
JP2004507456A (en) | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
JP2003534377A (en) | 2000-05-30 | 2003-11-18 | メルク エンド カムパニー インコーポレーテッド | Melanocortin receptor agonist |
MXPA02011458A (en) | 2000-06-09 | 2003-04-25 | Aventis Pharma Gmbh | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament. |
DE10038709A1 (en) | 2000-08-09 | 2002-02-28 | Aventis Pharma Gmbh | Substituted and unsubstituted benzooxathiazoles and compounds derived from them |
EP1182251A1 (en) * | 2000-08-11 | 2002-02-27 | Yissum Research Development Company of the Hebrew University of Jerusalem | Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB |
AU2001284658A1 (en) | 2000-08-23 | 2002-03-13 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
EA200300286A1 (en) * | 2000-08-23 | 2003-08-28 | Эли Лилли Энд Компани | AGONISTS OF RECEPTORS ACTIVATED BY PEROXISOMAL PROLIFERATOR |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
AU2002222573A1 (en) | 2000-12-05 | 2002-06-18 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
EP1345895B1 (en) | 2000-12-21 | 2006-12-27 | Sanofi-Aventis Deutschland GmbH | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
ATE370130T1 (en) * | 2000-12-25 | 2007-09-15 | Ono Pharmaceutical Co | DIHYDRONAPHTHALINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENTS |
EP1360172A1 (en) * | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
PE20021091A1 (en) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | DERIVATIVES OF PHENYLUREA SUBSTITUTED WITH CARBONAMIDE AND PROCEDURE FOR THEIR PREPARATION |
HUP0400268A2 (en) * | 2001-06-07 | 2004-07-28 | Eli Lilly And Co. | Modulators of peroxisome proliferator activated receptors (ppar), their use and pharmaceutical compositions containing them |
DE10154689A1 (en) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituted amino ketone compounds |
WO2003004458A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | New compounds |
FR2827859B1 (en) | 2001-07-30 | 2005-09-23 | Lipha | 4- (ARYLTHIO) - OR 4- (HETEROARYLTHIO) -BUTYRIC DERIVATIVES IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DIABETES |
EP1425014B1 (en) | 2001-08-31 | 2006-12-13 | Sanofi-Aventis Deutschland GmbH | Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
DE60327922D1 (en) | 2002-02-05 | 2009-07-23 | Lilly Co Eli | UREA-LINKER COMPOUNDS AND ITS USE AS PPAR REGULATORS |
DE10215908B4 (en) | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-urea derivatives and their use as medicaments |
DE10215907A1 (en) | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-urea derivatives, processes for their preparation and their use |
DE10225635C1 (en) | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-benzoylureido-cinnamic acid derivatives, process for their preparation and their use |
WO2004004665A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
-
2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/en not_active Withdrawn
-
2004
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/en not_active Application Discontinuation
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 AT AT04712490T patent/ATE365159T1/en not_active IP Right Cessation
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/en not_active Application Discontinuation
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/en not_active Expired - Fee Related
- 2004-02-19 PL PL378130A patent/PL378130A1/en not_active Application Discontinuation
- 2004-02-19 PT PT04712494T patent/PT1599453E/en unknown
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/en not_active Application Discontinuation
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/en not_active Expired - Lifetime
- 2004-02-19 AT AT04712503T patent/ATE435217T1/en not_active IP Right Cessation
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/en not_active IP Right Cessation
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/en not_active IP Right Cessation
- 2004-02-19 PL PL377735A patent/PL377735A1/en not_active Application Discontinuation
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/en not_active Expired - Lifetime
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/en not_active Application Discontinuation
- 2004-02-19 ES ES04712494T patent/ES2326418T3/en not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/en not_active IP Right Cessation
- 2004-02-19 EP EP04712494A patent/EP1599453B1/en not_active Expired - Lifetime
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 DK DK04712490T patent/DK1599452T3/en active
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/en active IP Right Grant
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/en not_active Expired - Lifetime
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/en active Pending
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 PL PL378437A patent/PL378437A1/en not_active Application Discontinuation
- 2004-02-19 DK DK04712503T patent/DK1599455T3/en active
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/en active IP Right Grant
- 2004-02-19 ES ES04712503T patent/ES2329366T3/en not_active Expired - Lifetime
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/en not_active Application Discontinuation
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/en not_active Application Discontinuation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/en unknown
- 2004-02-19 PT PT04712503T patent/PT1599455E/en unknown
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/en active Application Filing
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/en active Pending
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/en active IP Right Grant
- 2004-02-19 DK DK04712494T patent/DK1599453T3/en active
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/en not_active Expired - Fee Related
- 2004-02-19 ES ES04712490T patent/ES2287700T3/en not_active Expired - Lifetime
- 2004-02-19 EP EP04712503A patent/EP1599455B1/en not_active Expired - Lifetime
- 2004-02-19 AT AT04712494T patent/ATE430738T1/en not_active IP Right Cessation
- 2004-02-19 PT PT04712490T patent/PT1599452E/en unknown
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/en active Pending
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/en not_active Expired - Fee Related
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/en active IP Right Grant
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/en active Application Filing
- 2004-02-19 EP EP04712490A patent/EP1599452B1/en not_active Expired - Lifetime
- 2004-02-25 TW TW093104697A patent/TW200508210A/en unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/en unknown
- 2004-02-25 TW TW093104705A patent/TW200510352A/en unknown
- 2004-02-27 UY UY28209A patent/UY28209A1/en unknown
- 2004-02-27 AR ARP040100629A patent/AR043427A1/en not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/en unknown
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 AR ARP040100636A patent/AR043433A1/en not_active Application Discontinuation
- 2004-02-27 UY UY28210A patent/UY28210A1/en unknown
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/en not_active Application Discontinuation
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/en unknown
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/en not_active Application Discontinuation
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/en unknown
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/en not_active Application Discontinuation
- 2004-02-27 US US10/789,017 patent/US7335671B2/en active Active
- 2004-02-27 AR ARP040100635A patent/AR043432A1/en not_active Application Discontinuation
- 2004-02-27 US US10/788,996 patent/US7259177B2/en active Active
- 2004-06-09 SA SA04250153A patent/SA04250153A/en unknown
-
2005
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-26 MA MA28459A patent/MA27736A1/en unknown
- 2005-08-26 MA MA28465A patent/MA27742A1/en unknown
- 2005-08-26 HR HR20050743A patent/HRP20050743A2/en not_active Application Discontinuation
- 2005-08-26 HR HR20050744A patent/HRP20050744A2/en not_active Application Discontinuation
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/en unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/en not_active Application Discontinuation
- 2005-08-26 MA MA28460A patent/MA27737A1/en unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/en unknown
- 2005-08-26 HR HR20050742A patent/HRP20050742A2/en not_active Application Discontinuation
- 2005-08-26 CO CO05085508A patent/CO5690580A2/en not_active Application Discontinuation
- 2005-09-22 NO NO20054398A patent/NO20054398L/en unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/en unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/en unknown
-
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7872034B2 (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
US7598281B2 (en) | Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | |
AU2004216520B2 (en) | Diarylcycloalkyl derivatives, method for their production and their use as medicaments | |
AU2004216519B2 (en) | 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments | |
AU2004215675A1 (en) | Arylcycloalkyl derivatives with branched side chains as PPAR receptor modulators, method for their production and their use as medicaments | |
AU2004215676B2 (en) | Cycloalkyl derivatives comprising bioisosteric carboxylic acid groups, method for the production thereof, and use thereof as a medicament | |
MX2007000913A (en) | 2 - { - 3 2 - (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes. | |
MX2007000846A (en) | 2 - {-3-`2-(phenyl) -oxazol-4 -ylmethoxymethyl!- cyclohexylmethoxy} -propionic acid derivatives used as ppar ligandes (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |